U.S. patent application number 15/210560 was filed with the patent office on 2017-01-12 for autotaxin inhibitors.
This patent application is currently assigned to NOVARTIS AG. The applicant listed for this patent is Vikki Furminger, Owen Rhys Hughes, Darren Mark Legrand, Emily Stanley, Christopher Thomson. Invention is credited to Vikki Furminger, Owen Rhys Hughes, Darren Mark Legrand, Emily Stanley, Christopher Thomson.
Application Number | 20170007614 15/210560 |
Document ID | / |
Family ID | 50931610 |
Filed Date | 2017-01-12 |
United States Patent
Application |
20170007614 |
Kind Code |
A1 |
Legrand; Darren Mark ; et
al. |
January 12, 2017 |
Autotaxin inhibitors
Abstract
The present invention relates to novel compounds that are
autotaxin inhibitors, processes for their preparation,
pharmaceutical compositions and medicaments containing them and to
their use in diseases and disorders mediated by autotaxin.
Inventors: |
Legrand; Darren Mark; (East
Grinstead, GB) ; Furminger; Vikki; (Horsham, GB)
; Thomson; Christopher; (Horsham, GB) ; Hughes;
Owen Rhys; (Derbyshire, GB) ; Stanley; Emily;
(Horsham, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Legrand; Darren Mark
Furminger; Vikki
Thomson; Christopher
Hughes; Owen Rhys
Stanley; Emily |
East Grinstead
Horsham
Horsham
Derbyshire
Horsham |
|
GB
GB
GB
GB
GB |
|
|
Assignee: |
NOVARTIS AG
Basel
CH
|
Family ID: |
50931610 |
Appl. No.: |
15/210560 |
Filed: |
July 14, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13833460 |
Mar 15, 2013 |
9409895 |
|
|
15210560 |
|
|
|
|
61739214 |
Dec 19, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/426 20130101;
A61P 25/00 20180101; C07D 413/12 20130101; A61P 9/00 20180101; A61K
31/4174 20130101; C07D 403/12 20130101; A61K 31/55 20130101; A61K
31/4174 20130101; A61K 31/337 20130101; A61K 31/4468 20130101; A61K
31/4245 20130101; C07D 295/185 20130101; A61K 31/337 20130101; A61K
31/439 20130101; A61K 31/454 20130101; A61K 31/5377 20130101; A61K
31/4192 20130101; A61K 31/4245 20130101; A61K 31/496 20130101; A61K
2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00 20130101;
A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00
20130101; A61K 31/454 20130101; A61K 2300/00 20130101; A61P 35/00
20180101; C07D 249/08 20130101; A61K 31/4192 20130101; C07D 211/34
20130101; A61K 31/55 20130101; C07D 401/12 20130101; A61K 31/426
20130101; A61K 31/445 20130101; A61K 31/5375 20130101 |
International
Class: |
A61K 31/5377 20060101
A61K031/5377; A61K 31/445 20060101 A61K031/445; A61K 31/4468
20060101 A61K031/4468; A61K 31/4192 20060101 A61K031/4192; A61K
31/496 20060101 A61K031/496; A61K 31/439 20060101 A61K031/439; A61K
31/55 20060101 A61K031/55; A61K 31/454 20060101 A61K031/454; A61K
31/5375 20060101 A61K031/5375 |
Claims
1-15. (canceled)
16. A method of treating a disease or condition mediated by
Autotaxin in a subject comprising: administering to said subject a
therapeutically effective amount of a compound of formula (I):
##STR00122## or a pharmaceutically acceptable salt thereof, wherein
A is selected from ##STR00123## Y.sup.1 is
--(CR.sup.2bR.sup.2c).sub.m-- or --CH.dbd.CH--; X is selected from
--C(.dbd.O)--, --N(R.sup.3)--C(.dbd.O)-- and
--C(.dbd.O)--N(R.sup.3)--; Y.sup.2 is
--(CR.sup.4aR.sup.4b).sub.n--; m is selected from 0, 1, 2, 3, 4 and
5; n is selected from 0, 1, 2, 3, 4 and 5; wherein when Y.sup.1 is
--(CR.sup.2bR.sup.2c).sub.m--; the sum of m and n is not less than
2 and no more than 5; or A-Y.sup.1--X-- is ##STR00124## L is
selected from ##STR00125## W is CH or N; Z is selected from
CH.sub.2, O and NR.sup.5c; Y.sup.3 is selected from
--O--(CR.sup.6aR.sup.6b)--, --(CR.sup.6cR.sup.6d)--O--,
--CH.dbd.CH--, --CR.sup.6eR.sup.6f--CR.sup.6gR.sup.6h--, and
--O--(CR.sup.6iR.sup.6j--CR.sup.6kR.sup.6l)--; R.sup.1a, R.sup.1b,
R.sup.1c, R.sup.1d and R.sup.1e are defined according to any one of
(a) R.sup.1b is halogen; R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1c
and R.sup.1e are H; (b) R.sup.1b is halogen; R.sup.1d is halogen,
CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy;
R.sup.1c is halogen; and R.sup.1a and R.sup.1e are H; (c) R.sup.1b
is C.sub.1-4alkyl; R.sup.1d is C.sub.1-4alkyl, C.sub.1-4haloalkyl,
C.sub.1-4haloalkoxy or CN; R.sup.1a, R.sup.1c and R.sup.1e are H;
(d) R.sup.1b is CN; R.sup.1d is C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1c and R.sup.1e are H; (e)
R.sup.1b is C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and
R.sup.1a, R.sup.1c and R.sup.1e are H; and R.sup.1d is H or CN; (f)
R.sup.1a is halogen; R.sup.1c is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and Rib, R.sup.1d and
R.sup.1e are H; (g) R.sup.1c is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1b
and R.sup.1e are H; and R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl, C.sub.1-4haloalkoxy, or H; R.sup.2a, R.sup.2b,
R.sup.2c, R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d,
R.sup.5a, R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c,
R.sup.6d, R.sup.6e, R.sup.6f, R.sup.6g, R.sup.6h, R.sup.6i,
R.sup.6j, R.sup.6k and R.sup.6l are independently selected from H
and C.sub.1-4alkyl.
17. The method according to claim 16 or a pharmaceutically
acceptable salt thereof, wherein R.sup.1a, R.sup.1b, R.sup.1c,
R.sup.1d and R.sup.1e are defined according to any one of (a)
R.sup.1b is fluoro, chloro or bromo; R.sup.1d is fluoro, chloro,
bromo, CN, methyl, trifluoromethyl or trifluoromethoxy; and
R.sup.1a, R.sup.1c and R.sup.1e are H; (c) R.sup.1b is methyl;
R.sup.1d is methyl, trifluoromethyl, trifluoromethoxy or CN;
R.sup.1a, R.sup.1c and R.sup.1e are H; (f) R.sup.1a is fluoro,
chloro or bromo; R.sup.1c is fluoro, chloro, bromo, CN, methyl,
trifluoromethyl or trifluoromethoxy; and R.sup.1b, R.sup.1d and
R.sup.1e are H; and (g) R.sup.1c is fluoro, chloro, bromo, CN,
methyl, trifluoromethyl or trifluoromethoxy; and R.sup.1aR.sup.1b
and R.sup.1e are H; and R.sup.1d is fluoro, chloro, bromo, CN,
methyl, trifluoromethyl, trifluoromethoxy, or H.
18. The method according to claim 16 or a pharmaceutically
acceptable salt thereof, wherein Y.sup.3 is
--O--(CR.sup.6aR.sup.6b)-- or --(CR.sup.6cR.sup.6d)--O--.
19. The method according to claim 16 or a pharmaceutically
acceptable salt thereof, wherein X is selected from
--N(R.sup.3)--C(.dbd.O)-- and --C(.dbd.O)--N(R.sup.3)--.
20. The method according to claim 16 or a pharmaceutically
acceptable salt thereof, wherein the compound is of formula (II)
##STR00126##
21. The method according to claim 16 or a pharmaceutically
acceptable salt thereof, wherein --Y.sup.1--X--Y.sup.2-- is
selected from ##STR00127##
22. The method according to claim 16 which is selected from the
group consisting of: 3,5-dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; 3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate; 3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate; 3,5-dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate; 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate; 3,5-dichlorobenzyl
4-(2-(N-methyl-2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carb-
oxylate; 3,5-dichlorobenzyl
4-(2-(2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate;
(E)-3,5-dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate; 3,5-dichlorobenzyl
2-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)morpholine-4-carboxyla-
te; 3,5-dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)
ethyl)morpholine-4-carboxylate; 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate; 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)piperidine-1-
-carboxylate; 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te; 3,5-dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e; 3,5-dichlorobenzyl
4-(3-(3-hydroxyisoxazol-5-yl)propanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)piperidine-1--
carboxylate; 3,5-dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate; 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te;
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)-N-me-
thyl-2-oxo-2,3-dihydrooxazole-5-carboxamide;
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)-2-oxo-2-
,3-dihydrooxazole-5-carboxamide; 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1--
carboxylate; 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate-
; 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate;
3,5-dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late; 3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; 3-Chloro-5-fluorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide;
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; 3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate;
N-(1-(3-(3,5-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-
-4-yl)butanamide;
N-(1-(3-(2,4-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-
-4-yl)butanamide; 3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate; 3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)azepane-1-carboxylate;
3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl)butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carb-
amate; 3,5-Dichlorobenzyl
(1-(4-(1H-1,2,3-triazol-4-yl)butanoyl)azepan-4-yl)carbamate;
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
(S)- or (R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
(S)- or (R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)azetidine-1-carboxylate;
3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4-yl)pentanoyl)piperidin-4-yl)carbamate;
4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl)phenyl)propanoyl)pi-
peridin-4-yl)butanamide;
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-4-
-yl)butanamide; 3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5-yl)propanamido)methyl)piperidine-1-carboxylate;
2,4-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate; 3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidine-1-carb-
oxylate; 3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
3-cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
3,5-dichlorobenzyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
23. The method according to claim 16, wherein the compound is
3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate.
24. The method according to claim 16, wherein the compound is
3-Cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate.
25. The method according to claim 16 wherein the disease or
condition is selected from fibrosis, pruritus, cirrhosis, cancer,
diabetes, kidney diseases and neuropathic pain.
26. The method according to claim 16, wherein the disease or
condition is idiopathic pulmonary fibrosis.
Description
TECHNICAL FIELD
[0001] The present invention relates to novel compounds that are
autotaxin inhibitors, processes for their preparation,
pharmaceutical compositions and medicaments containing them and to
their use in diseases and disorders mediated by autotaxin.
BACKGROUND
[0002] Autotaxin (ATX), also known as ectonucleotide
pyrophosphatase/phosphodiesterase (ENPP2), is a secreted ectoenzyme
known to possess lysophospholipase D activity (Umezu-Goto et al.,
2002), and is responsible for producing the bioactive lipid
mediator lysophosphatidic acid (LPA) by the hydrolysis of
lysophosphatidylcholine (LPC) (Tokumura et al., 2002). LPA is
highly implicated in the pathogenesis of a number of
physio-pathological diseases, including cancer (Liu et al., 2009;
Mills & Moolenaar, 2003), neuropathic pain (Inoue et al., 2004)
and fibrosis (Tager et al., 2008). Following the production of LPA,
the lipid binds to specific G protein-coupled receptors of which
there are seven known isoforms (Noguchi et al., 2009). Binding of
LPA activates multiple signalling pathways (Mills & Moolenaar,
2003) including cell migration (van Dijk et al., 1998),
proliferation and survival (Brindley, 2004). Other cellular
responses include smooth muscle contraction, apoptosis and platelet
aggregation (Tigyi & Parrill, 2003).
[0003] ATX was originally identified as a cell motility-stimulating
factor following isolation from human A2058 melanoma cells (Stracke
et al., 1992). Subsequent work on the enzyme was focused towards
its role as a motility factor due to its aberrant expression in
many cancer types including breast and renal cancer (Stassar et
al., 2001), Hodgkin's lymphoma (Baumforth et al., 2005), follicular
lymphoma (Masuda et al., 2008), as well as fibrosis of the lung and
kidney (Hama et al., 2004). Ten years following its discovery, ATX
was characterised as a secreted lysophospholipase (lysoPLD)
(Tokumura et al., 2002; Gesta et al., 2002). Since then ATX gene
knockout mice have shown that the ATX-LPA signalling axis plays a
vital role during embryonic development of the cardiovascular and
neural system (Tanaka et al., 2006; van Meeteren et al., 2006),
resulting in early embryonic lethality (Bachner et al., 1999).
[0004] ATX belongs to a family of proteins called nucleotide
pyrophosphatase/phosphodiesterase (NPP), encoded for by the gene
ENPP. The family consists of seven structurally related enzymes
(ENPP 1-7) conserved within vertebrates which are numbered
according to their discovery. They were originally defined by their
ability to hydrolyse pyrophosphate or phosphodiester bonds of
various nucleotides and nucleotides derivatives in vitro (Stefan et
al., 1999; Coding et al., 1998; Gijsbers et al., 2001), though
ENPP2 and choline phosphate esters (ENPP6 & 7) have specific
activity for other extracellular non-nucleotide molecules. ENPP2
(ATX) is unique within the family as it is the only secreted
protein, whereas other ENPP members are transmembrane proteins
(Stefan et al., 2005).
[0005] WO02/100352 (Merck) and WO 02/080928 (Merck) relate to
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B receptor
antagonists for the treatment or prevention of migraines.
[0006] WO2010/115491 (Merck) and WO 2009/046841 (Merck) relate to
piperidine and piperazine derivatives as ATX inhibitors.
[0007] WO2010/112116 (Merck) and WO 2010/112124 (Merck) relate to
heterocyclic compounds as ATX inhibitors and WO 2011/044978 (Merck)
relates to sulfoxide derivatives for treating tumours.
[0008] Hence, there is a need for further potent inhibitors of
ATX.
DESCRIPTION OF THE EMBODIMENTS
[0009] In an embodiment 1 of the invention, there is provided a
compound of formula (I)
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein A is
selected from
##STR00002##
A' is selected from O, S and NR.sup.2a; A'' is selected from O and
S; Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m-- or CH.dbd.CH--; X is
selected from --C(.dbd.O)--, --N(R.sup.3)--C(.dbd.O)-- and
C(.dbd.O)--N(R.sup.3)--; Y.sup.2 is --(CR.sup.4aR.sup.4b).sub.n--;
m is selected from 0, 1, 2, 3, 4 and 5; n is selected from 0, 1, 2,
3, 4 and 5; wherein when Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m--
and A is not HO--C(.dbd.O)--, the sum of m and n is not less than 2
and no more than 5; and wherein when Y.sup.1 is
--(CR.sup.2bR.sup.2c).sub.m-- and A is HO--C(.dbd.O)--, the sum of
m and n is not less than 2 and no more than 7; or
A-Y.sup.1--X-- is
##STR00003##
[0010] L is selected from
##STR00004##
W is CH or N;
[0011] Z is selected from CH.sub.2, O and NR.sup.5c; Y.sup.3 is
selected from --O--(CR.sup.6aR.sup.6b)--,
--(CR.sup.6cR.sup.6d)--O--, --CH.dbd.CH--,
--CR.sup.6eR.sup.6f--CR.sup.6gR.sup.6h-- and
--O--(CR.sup.6iR.sup.6j--CR.sup.6kR.sup.6l)--; R.sup.1a, R.sup.1b,
R.sup.1c, R.sup.1d and R.sup.1e are defined according to any one of
(a) R.sup.1b is halogen; R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1c
and R.sup.1e are H; (b) R.sup.1b is halogen; R.sup.1d is halogen,
CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy;
R.sup.1c is halogen; and R.sup.1a and R.sup.1e are H; (c) R.sup.1b
is C.sub.1-4alkyl; R.sup.1d is C.sub.1-4alkyl, C.sub.1-4haloalkyl,
C.sub.1-4haloalkoxy or CN; R.sup.1a, R.sup.1c and R.sup.1e are H;
(d) R.sup.1b is CN; R.sup.1d is C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1c and R.sup.1e are H; (e)
R.sup.1b is C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; R.sup.1a,
R.sup.1c and R.sup.1e are H; and R.sup.1d is H or CN; (f) R.sup.1a
is halogen; R.sup.1c is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1b, R.sup.1d
and R.sup.1e are H; (g) R.sup.1c is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; R.sup.1a, R.sup.1b and
R.sup.1e are H; and R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl, C.sub.1-4haloalkoxy, or H; R.sup.2 is selected
from H, C.sub.1-4alkyl and halogen; R.sup.2a, R.sup.2b, R.sup.2c,
R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.5a,
R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d,
R.sup.6e, R.sup.6f, R.sup.6g, R.sup.6h, R.sup.6i, R.sup.6j,
R.sup.6k and R.sup.6l are independently selected from H and
C.sub.1-4alkyl.
[0012] In an embodiment 1.1 of the invention, there is provided a
compound of formula (I)
##STR00005##
or a pharmaceutically acceptable salt thereof, wherein A is
selected from
##STR00006##
A' is selected from O, S and NR.sup.2a; A'' is selected from O and
S; Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m-- or --CH.dbd.CH--; X is
selected from --C(.dbd.O)--, --N(R.sup.3)--C(.dbd.O)-- and
--C(.dbd.O)--N(R.sup.3)--; Y.sup.2 is
--(CR.sup.4aR.sup.4b).sub.n--; m is selected from 0, 1, 2, 3, 4 and
5; n is selected from 0, 1, 2, 3, 4 and 5; wherein when Y.sup.1 is
--(CR.sup.2bR.sup.2c).sub.m-- and A is not HO--C(.dbd.O)--, the sum
of m and n is not less than 2 and no more than 5; and wherein when
Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m-- and A is HO--C(.dbd.O)--,
the sum of m and n is not less than 2 and no more than 7; or
A-Y.sup.1--X-- is
##STR00007##
[0013] L is selected from
##STR00008##
W is CH or N;
[0014] Z is selected from CH.sub.2, O and NR.sup.5c; Y.sup.3 is
selected from --O--(CR.sup.6aR.sup.6b)--,
--(CR.sup.6cR.sup.6d)--O--, --CH.dbd.CH--,
--CR.sup.6eR.sup.6f--CR.sup.6gR.sup.6h--, and
--O--(CR.sup.6iR.sup.6j--CR.sup.6kR.sup.6l)--; R.sup.1a, R.sup.1b,
R.sup.1c, R.sup.1d and R.sup.1e are defined according to any one of
(a) R.sup.1b is halogen; R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1c
and R.sup.1e are H; (b) R.sup.1b is halogen; R.sup.1d is halogen,
CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy;
R.sup.1c is halogen; and R.sup.1a and R.sup.1e are H; (c) R.sup.1b
is C.sub.1-4alkyl; R.sup.1d is C.sub.1-4alkyl, C.sub.1-4haloalkyl,
C.sub.1-4haloalkoxy or CN; R.sup.1a, R.sup.1c and R.sup.1e are H;
(d) R.sup.1b is CN; R.sup.1d is C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1c and R.sup.1e are H; (e)
R.sup.1b is C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and
R.sup.1a, R.sup.1c and R.sup.1e are H; and R.sup.1d is H or CN; (f)
R.sup.1a is halogen; R.sup.1c is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1b, R.sup.1d
and R.sup.1e are H; (g) R.sup.1c is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy; and R.sup.1a, R.sup.1b
and R.sup.1e are H; and R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl, C.sub.1-4haloalkoxy, or H; R.sup.2 is selected
from H, C.sub.1-4alkyl and halogen; R.sup.2a, R.sup.2b, R.sup.2c,
R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.5a,
R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d,
R.sup.6e, R.sup.6f, R.sup.6g, R.sup.6h, R.sup.6i, R.sup.6j,
R.sup.6k and R.sup.6l are independently selected from H and
C.sub.1-4alkyl; and wherein when L is
##STR00009##
n is not 1.
[0015] In an embodiment 1.2 of the invention, there is provided a
compound of formula (I)
##STR00010##
or a pharmaceutically acceptable salt thereof, wherein A is
selected from
##STR00011##
A' is selected from O, S and NR.sup.2a; A'' is selected from O and
S; Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m-- or --CH.dbd.CH--; X is
selected from --C(.dbd.O)--, --N(R.sup.3)--C(.dbd.O)-- and
--C(.dbd.O)--N(R.sup.3)--; Y.sup.2 is
--(CR.sup.4aR.sup.4b).sub.n--; m is selected from 0, 1, 2, 3, 4 and
5; n is selected from 0, 1, 2, 3, 4 and 5; wherein when Y.sup.1 is
--(CR.sup.2bR.sup.2c).sub.m-- the sum of m and n is not less than 2
and no more than 5; or
A-Y.sup.1--X-- is
##STR00012##
[0016] L is selected from
##STR00013##
W is CH or N;
[0017] Z is selected from CH.sub.2, O and NR.sup.5c; Y.sup.3 is
selected from --O--(CR.sup.6aR.sup.6b), --(CR.sup.6cR.sup.6d)--O--,
--CH.dbd.CH-- and --CR.sup.6eR.sup.6f--CR.sup.6gR.sup.6h--;
R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d and R.sup.1e are defined
according to any one of (a) R.sup.1b and R.sup.1d is halogen, and
R.sup.1a, R.sup.1c and R.sup.1e is H; (b) R.sup.1a and R.sup.1c is
halogen, and R.sup.1b, R.sup.1d and R.sup.1e is H; (c) R.sup.1c is
C.sub.1-4haloalkyl, in particular CF.sub.3, or C.sub.1-4haloalkoxy,
and R.sup.1a, R.sup.1b and R.sup.1e are H, and R.sup.1d is halogen,
C.sub.1-4alkyl, particularly methyl, or H; (d) R.sup.1b is
C.sub.1-4haloalkyl, in particular CF.sub.3, or C.sub.1-4haloalkoxy,
and R.sup.1a, R.sup.1c and R.sup.1e are H, and R.sup.1d is halogen,
C.sub.1-4alkyl, particularly methyl, or H; (e) R.sup.1b is
C.sub.1-4alkyl, R.sup.1d is halogen, and R.sup.1a, R.sup.1c and
R.sup.1e is H; and (f) R.sup.1b is CN, R.sup.1d is halogen, and
R.sup.1a, R.sup.1c and R.sup.1e is H; R.sup.2 is selected from H,
C.sub.1-4alkyl and halogen; R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3,
R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.5a, R.sup.5b,
R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d, R.sup.6e,
R.sup.6f, R.sup.6g and R.sup.6h are independently selected from H
and C.sub.1-4alkyl.
[0018] In an embodiment 2 of the invention, there is provided a
compound of formula (I)
##STR00014##
or a pharmaceutically acceptable salt thereof, wherein A is
selected from
##STR00015##
A' is selected from O, S and NR.sup.2a; A'' is selected from O and
S; Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m-- or --CH.dbd.CH--; X is
selected from --C(.dbd.O)--, --N(R.sup.3)--C(.dbd.O)-- and
--C(.dbd.O)--N(R.sup.3)--; Y.sup.2 is
--(CR.sup.4aR.sup.4b).sub.n--; m is selected from 0, 1, 2, 3, 4 and
5; n is selected from 0, 1, 2, 3, 4 and 5; wherein when Y.sup.1 is
--(CR.sup.2bR.sup.2c).sub.m-- the sum of m and n is not less than 2
and no more than 5; or
A-Y.sup.1--X-- is
##STR00016##
[0019] L is selected from
##STR00017##
W is CH or N;
[0020] Z is selected from CH.sub.2, O and NR.sup.5c; Y.sup.3 is
selected from --O--(CR.sup.6aR.sup.6b)--,
--(CR.sup.6cR.sup.6d)--O--, --CH.dbd.CH-- and
--CR.sup.6eR.sup.6f--CR.sup.6gR.sup.6h--; R.sup.1a, R.sup.1b,
R.sup.1c, R.sup.1d and R.sup.1e are defined according to any one of
(a) R.sup.1b and R.sup.1d is halogen, and R.sup.1a, R.sup.1c and
R.sup.1e is H; (b) R.sup.1c is C.sub.1-4haloalkyl, in particular
CF.sub.3, and R.sup.1a, R.sup.1b, R.sup.1d and R.sup.1e are H; (c)
R.sup.1b is C.sub.1-4alkyl, R.sup.1d is halogen, and R.sup.1a,
R.sup.1c and R.sup.1e is H; (d) R.sup.1b is CN, R.sup.1d is
halogen, and R.sup.1a, R.sup.1c and R.sup.1e is H; and (e) R.sup.1a
and R.sup.1c is halogen, and R.sup.1b, R.sup.1d and R.sup.1e is H;
R.sup.2 is selected from H, C.sub.1-4alkyl and halogen; R.sup.2a,
R.sup.2b, R.sup.2c, R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c,
R.sup.4d, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b,
R.sup.6c, R.sup.6d, R.sup.6e, R.sup.6f, R.sup.6g and R.sup.6h are
independently selected from H and C.sub.1-4alkyl.
DEFINITIONS
[0021] "Halo" or "halogen", as used herein, may be fluoro, chloro,
bromo or iodo.
[0022] "C.sub.1-4 alkyl", as used herein, denotes straight chain or
branched alkyl having 1-4 carbon atoms. If a different number of
carbon atoms is specified, such as C.sub.6 or C.sub.3, then the
definition is to be amended accordingly, such as "C.sub.1-C.sub.4
alkyl" will represent methyl, ethyl, propyl, isopropyl, butyl,
isobutyl, sec-butyl and tert-butyl.
[0023] "C.sub.1-4 haloalkyl", as used herein, denotes straight
chain or branched alkyl having 1-4 carbon atoms with at least one
hydrogen substituted with a halogen. If a different number of
carbon atoms is specified, such as C.sub.6 or C.sub.3, then the
definition is to be amended accordingly, such as
"C.sub.1-C.sub.4-Haloalkyl" will represent methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at
least one hydrogen substituted with halogen, such as where the
halogen is fluorine: CF.sub.3CF.sub.2--, (CF.sub.3).sub.2CH--,
CH.sub.3--CF.sub.2--, CF.sub.3CF.sub.2--, CF.sub.3, CF.sub.2H--,
CF.sub.3CF.sub.2CHCF.sub.3 or
CF.sub.3CF.sub.2CF.sub.2CF.sub.2--.
"C.sub.1-4 haloalkoxy" as used herein refers to an --O--C.sub.1-4
alkyl group wherein C.sub.1-4 alkyl is as defined herein and
substituted with one or more halogen groups, e.g.
--O--CF.sub.3.
[0024] The term "a," "an," "the" and similar terms used in the
context of the present invention (especially in the context of the
claims) are to be construed to cover both the singular and plural
unless otherwise indicated herein or clearly contradicted by the
context.
[0025] As used herein, the term "subject" refers to an animal.
Typically the animal is a mammal. A subject also refers to for
example, primates (e.g., humans, male or female), cows, sheep,
goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the
like. In certain embodiments, the subject is a primate. In yet
other embodiments, the subject is a human.
[0026] As used herein, the term "inhibit", "inhibition" or
"inhibiting" refers to the reduction or suppression of a given
condition, symptom, or disorder, or disease, or a significant
decrease in the baseline activity of a biological activity or
process.
[0027] As used herein, the term "treat", "treating" or "treatment"
of any disease or disorder refers in one embodiment, to
ameliorating the disease or disorder (i.e., slowing or arresting or
reducing the development of the disease or at least one of the
clinical symptoms thereof). In another embodiment "treat",
"treating" or "treatment" refers to alleviating or ameliorating at
least one physical parameter including those which may not be
discernible by the patient. In yet another embodiment, "treat",
"treating" or "treatment" refers to modulating the disease or
disorder, either physically, (e.g., stabilization of a discernible
symptom), physiologically, (e.g., stabilization of a physical
parameter), or both. In yet another embodiment, "treat", "treating"
or "treatment" refers to preventing or delaying the onset or
development or progression of the disease or disorder.
[0028] As used herein, a subject is "in need of" a treatment if
such subject would benefit biologically, medically or in quality of
life from such treatment.
[0029] As used herein, when one embodiment refers to several other
embodiments by using the term "according to any one of", for
example "according to any one of embodiments 1 to 5", then said
embodiment refers not only to embodiments indicated by the integers
such as 1 and 2 but also to embodiments indicated by numbers with a
decimal component such as 1.1, 1.2 or 2.1, 2.2, 2.3. For example,
"according to any one of embodiments 1 to 3" means according to any
one of embodiments 1, 1.1, 2, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6,
3.7.
[0030] Various embodiments of the invention are described herein.
It will be recognized that features specified in each embodiment
may be combined with other specified features to provide further
embodiments.
[0031] In an embodiment 3 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d and R.sup.1e are defined
according to any one of (a) R.sup.1b is halogen, R.sup.1d is
halogen, CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy, and R.sup.1a, R.sup.1c and R.sup.1e is H; (b)
R.sup.1b is halogen, R.sup.1d is halogen, CN, C.sub.1-4alkyl,
C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy, R.sup.1c is halogen, and
R.sup.1a and R.sup.1e is H; (c) R.sup.1b is C.sub.1-4alkyl,
R.sup.1d is C.sub.1-4alkyl, C.sub.1-4haloalkyl, C.sub.1-4haloalkoxy
or CN, R.sup.1a, R.sup.1c and R.sup.1e is H; (d) R.sup.1b is CN,
R.sup.1d is C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy, and
R.sup.1a, R.sup.1c and R.sup.1e is H; (f) R.sup.1a is halogen,
R.sup.1c is halogen, CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy, and R.sup.1b, R.sup.1d and R.sup.1e is H; and
(g) R.sup.1c is halogen, CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy, and R.sup.1a, R.sup.1b and R.sup.1e are H, and
R.sup.1d is halogen, CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy, or H.
[0032] In an embodiment 3.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d and R.sup.1e are defined
according to any one of (a) R.sup.1b is halogen, R.sup.1d is
halogen, CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or
C.sub.1-4haloalkoxy, and R.sup.1a, R.sup.1c and R.sup.1e is H; (c)
R.sup.1b is C.sub.1-4alkyl, R.sup.1d is C.sub.1-4alkyl,
C.sub.1-4haloalkyl, C.sub.1-4haloalkoxy or CN, R.sup.1a, R.sup.1c
and R.sup.1e is H; (f) R.sup.1a is halogen, R.sup.1c is halogen,
CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy, and
R.sup.1b, R.sup.1d and R.sup.1e is H; and (g) R.sup.1c is halogen,
CN, C.sub.1-4alkyl, C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy, and
R.sup.1a, R.sup.1b and R.sup.1e are H, and R.sup.1d is halogen, CN,
C.sub.1-4alkyl, C.sub.1-4haloalkyl or C.sub.1-4haloalkoxy, or
H.
[0033] In an embodiment 3.2 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d and R.sup.1e are defined
according to any one of (a) R.sup.1b is fluoro, chloro or bromo;
R.sup.1d is fluoro, chloro, bromo, CN, methyl, trifluoromethyl or
trifluoromethoxy; and R.sup.1a, R.sup.1c and R.sup.1e are H; (c)
R.sup.1b is methyl; R.sup.1d is methyl, trifluoromethyl,
trifluoromethoxy or CN; R.sup.1a, R.sup.1c and R.sup.1e are H; (f)
R.sup.1a is fluoro, chloro or bromo; R.sup.1c is fluoro, chloro,
bromo, CN, methyl, trifluoromethyl or trifluoromethoxy; and
R.sup.1b, R.sup.1d and R.sup.1e are H; and (g) R.sup.1c is fluoro,
chloro, bromo, CN, methyl, trifluoromethyl or trifluoromethoxy; and
R.sup.1a, Rib and R.sup.1e are H; and R.sup.1d is fluoro, chloro,
bromo, CN, methyl, trifluoromethyl, trifluoromethoxy, or H.
[0034] In an embodiment 3.3 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1b is fluoro, chloro or bromo; R.sup.1d is fluoro, chloro,
bromo, CN, methyl, trifluoromethyl or trifluoromethoxy; and
R.sup.1a, R.sup.1c and R.sup.1e are H.
[0035] In an embodiment 3.4 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1b is methyl; R.sup.1d is methyl, trifluoromethyl,
trifluoromethoxy or CN; R.sup.1a, R.sup.1c and R.sup.1e are H.
[0036] In an embodiment 3.5 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1a is fluoro, chloro or bromo; R.sup.1c is fluoro, chloro,
bromo, CN, methyl, trifluoromethyl or trifluoromethoxy; and
R.sup.1b, R.sup.1d and R.sup.1e are H.
[0037] In an embodiment 3.6 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein
R.sup.1c is fluoro, chloro, bromo, CN, methyl, trifluoromethyl or
trifluoromethoxy; R.sup.1a, R.sup.1b and R.sup.1e are H; and
R.sup.1d is fluoro, chloro, bromo, CN, methyl, trifluoromethyl,
trifluoromethoxy, or H.
[0038] In an embodiment 3.7 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 2,
wherein R.sup.1b and R.sup.1d is halogen and R.sup.1a, R.sup.1c and
R.sup.1e is H.
[0039] In an embodiment 4 of the invention, there is provided a
compound or salt according to embodiment 3.7, wherein R.sup.1b and
R.sup.1d is chloro and R.sup.1a, R.sup.1c and R.sup.1e is H.
[0040] In an embodiment 4.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is CN, R.sup.d is methyl, and R.sup.a, R.sup.c and
R.sup.e are H.
[0041] In an embodiment 4.2 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is fluoro, R.sup.d is chloro, and R.sup.a, R.sup.c
and R.sup.e are H.
[0042] In an embodiment 4.3 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is chloro, R.sup.c is chloro, and R.sup.a, R.sup.d
and R.sup.e are H.
[0043] In an embodiment 4.4 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is CN, R.sup.d is chloro, and R.sup.a, R.sup.c and
R.sup.e are H.
[0044] In an embodiment 4.5 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is methyl, R.sup.d is methyl, and R.sup.a, R.sup.c
and R.sup.e are H.
[0045] In an embodiment 4.6 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.c is CF.sub.3, and R.sup.a, R.sup.b, R.sup.d and
R.sup.e are H.
[0046] In an embodiment 4.7 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is methyl, R.sup.d is chloro, and R.sup.a, R.sup.c
and R.sup.e are H.
[0047] In an embodiment 4.8 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is methyl, R.sup.d is CF.sub.3, and R.sup.a,
R.sup.c and R.sup.e are H.
[0048] In an embodiment 4.9 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is bromo, R.sup.d is CF.sub.3, and R.sup.a, R.sup.c
and R.sup.e are H.
[0049] In an embodiment 4.10 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is CN, R.sup.d is CF.sub.3, and R.sup.a, R.sup.c
and R.sup.e are H.
[0050] In an embodiment 4.11 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is trifluoromethoxy, R.sup.d is chloro, and
R.sup.a, R.sup.c and R.sup.e are H.
[0051] In an embodiment 4.12 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 3,
wherein R.sup.b is chloro, R.sup.c is fluoro, R.sup.d is CN and
R.sup.a and R.sup.e are H.
[0052] In an embodiment 5 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 4,
wherein Y.sup.3 is selected from --O--(CH.sub.2)--,
--(CH.sub.2)--O--, --CH.dbd.CH--, --CH.sub.2--CH.sub.2--, and
--O--(CH.sub.2--CH.sub.2)--.
[0053] In an embodiment 5.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 4,
wherein Y.sup.3 is --O--(CR.sup.6aR.sup.6b)-- or
--(CR.sup.6cR.sup.6d)--O--, particularly
--O--(CR.sup.6aR.sup.6b)--.
[0054] In an embodiment 6 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 5,
wherein X is selected from --N(R.sup.3)--C(.dbd.O)-- and
--C(.dbd.O)--N(R.sup.3)--, in particular --N(H)--C(.dbd.O)-- and
--C(.dbd.O)--N(H)--
[0055] In an embodiment 6.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 5,
wherein X is selected from --C(.dbd.O)--, --N(H)--C(.dbd.O)--,
--C(.dbd.O)--N(H)-- and --C(.dbd.O)--N(CH.sub.3)--.
[0056] In an embodiment 7 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 6,
wherein L is selected from
##STR00018##
[0057] In an embodiment 7.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 6,
wherein L is selected from
##STR00019##
[0058] In an embodiment 8 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 7 with
formula (II)
##STR00020##
or a pharmaceutically acceptable salt thereof.
[0059] In an embodiment 8.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 7,
wherein
Y.sup.1 is --(CR.sup.2bR.sup.2c).sub.m-- and Y.sup.2 is
--(CR.sup.4aR.sup.4b).sub.n--; m is selected from 0, 1, 2, 3, 4 and
5; n is selected from 0, 1, 2 and 3; and wherein the sum of m and n
is not less than 2 and no more than 5.
[0060] In an embodiment 9 of the invention, there is provided a
compound or salt according to embodiment 8, wherein
m is selected from 2, 3 and 4, and n is selected from 0 and 1; or m
is selected from 0 and 1, and n is selected from 2 and 3.
[0061] In an embodiment 10 of the invention, there is provided a
compound or salt according to embodiment 9, wherein
m is selected from 2, 3 and 4, and n is 0.
[0062] In an embodiment 11 of the invention, there is provided a
compound or salt according to embodiment 10, wherein
m is 3 or 4, and n is 0.
[0063] In an embodiment 12 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 11,
wherein
X is --C(.dbd.O)--N(R.sup.3)--.
[0064] In an embodiment 12.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 7,
wherein --Y.sup.1--X--Y.sup.2-- is selected from
##STR00021##
[0065] In an embodiment 12.2 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 7,
wherein --Y.sup.1--X--Y.sup.2-- is selected from
##STR00022##
[0066] In an embodiment 12.3 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 7,
wherein --Y.sup.1--X--Y.sup.2-- is selected from
##STR00023##
[0067] In an embodiment 13 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 12,
wherein
A is selected from
##STR00024##
[0068] In an embodiment 14 of the invention, there is provided a
compound or salt according to embodiment 13, wherein
A is selected from
##STR00025##
[0069] In an embodiment 15 of the invention, there is provided a
compound or salt according to embodiment 14, wherein A is
##STR00026##
[0070] In an embodiment 16 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 5,
wherein A-Y.sup.1--X--Y.sup.2-L- is selected from
##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032##
[0071] In an embodiment 16.1 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 5,
wherein A-Y.sup.1--X--Y.sup.2-L- is selected from
##STR00033## ##STR00034##
[0072] In an embodiment 16.2 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 5,
wherein A-Y.sup.1--X--Y.sup.2-L- is selected from
##STR00035##
[0073] In an embodiment 17 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 6,
wherein W is CH.
[0074] In an embodiment 18 of the invention, there is provided a
compound or salt according to any one of embodiments 1 to 7, of
formula (III)
##STR00036##
or a pharmaceutically acceptable salt thereof.
[0075] In an embodiment 19 of the invention, there is provided a
compound or salt according to embodiment 18, wherein
L is selected from
##STR00037##
[0076] In an embodiment 20 of the invention, there is provided a
compound or salt according to embodiment 18 or 19, wherein
Y.sup.2 is --(CR.sup.4aR.sup.4b).sub.n-- and n is 1 or 2,
particularly 2.
[0077] In an embodiment 21 of the invention, there is provided a
compound or salt according to any one of embodiments 18 to 20,
wherein
R.sup.4c is methyl or ethyl and R.sup.4d is methyl or H.
[0078] In an embodiment 22 of the invention, there is provided a
compound according to embodiment 1 or 2 selected from the group
consisting of [0079] 3,5-dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0080] 3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate; [0081] 3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate; [0082] 3,5-dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate; [0083] 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate; [0084] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carb-
oxylate; [0085] 3,5-dichlorobenzyl
4-(2-(2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate;
[0086] 3,5-dichlorobenzyl
4-(2-(N,5-dimethyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0087] (E)-3,5-dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate; [0088]
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-6-oxohexan-
oic acid; [0089] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate; [0090] 3,5-dichlorobenzyl
2-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
morpholine-4-carboxylate; [0091] 3,5-dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)
ethyl)morpholine-4-carboxylate; [0092] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate; [0093] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0094] 3,5-dichlorobenzyl
4-(2-(2H-tetrazole-5-carboxamido)ethyl)piperidine-1-carboxylate;
[0095] 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0096] 3,5-dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0097] 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0098] 3,5-dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0099] 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te; [0100] 3,5-dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e; [0101] 3,5-dichlorobenzyl
4-(3-(3-hydroxyisoxazol-5-yl)propanamido)piperidine-1-carboxylate;
[0102] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0103] 3,5-dichlorobenzyl
4-(2-(5-hydroxy-N-methyl-1H-pyrazole-3-carboxamido)ethyl)piperidine-1-car-
boxylate; [0104] 3,5-dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate; [0105] 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te; [0106] 3,5-dichlorobenzyl
4-(2-(N-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxamido)ethyl)
piperidine-1-carboxylate; [0107] 3,5-dichlorobenzyl
4-(2-(N-methyl-2H-tetrazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0108]
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamide;
[0109] (E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-2-oxo-2,3-dihydrooxazole-5-carboxamide;
[0110] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0111] 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate-
; [0112] 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate;
[0113] 3,5-dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late; and [0114] 3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0115] 3-Chloro-5-fluorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0116]
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; [0117]
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; [0118]
8-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-8-oxooctan-
oic acid; [0119] 3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate;
[0120]
N-(1-(3-(3,5-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3--
triazol-4-yl)butanamide; [0121]
N-(1-(3-(2,4-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-
-4-yl)butanamide; [0122] 3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0123] 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate; [0124] 3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)azepane-1-carboxylate;
[0125] 3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl)butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carb-
amate; [0126] 3,5-Dichlorobenzyl
(1-(4-(1H-1,2,3-triazol-4-yl)butanoyl)azepan-4-yl)carbamate; [0127]
3,5-dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0128] (S)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0129] (R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0130] 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)azetidine-1-carboxylate;
[0131] 3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0132] 3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4-yl)pentanoyl)piperidin-4-yl)carbamate;
[0133] 4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0134]
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl)phenyl)propanoyl)pi-
peridin-4-yl)butanamide; [0135]
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-4-
-yl)butanamide; [0136] 3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0137] 3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5-yl)propanamido)methyl)piperidine-1-carboxylate;
[0138] 2,4-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0139] 3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0140] 3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate; [0141] 3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)
piperidine-1-carboxylate; [0142] 3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0143] 3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0144] 3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0145] 3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0146] 3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0147] 3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0148] 3-cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0149] 3,5-dichlorobenzyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0150] In an embodiment 22.1 of the invention, there is provided a
compound according to embodiment 1 or 2 selected from the group
consisting of [0151] 3,5-dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0152] 3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate; [0153] 3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate; [0154] 3,5-dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate; [0155] 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate; [0156] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carb-
oxylate; [0157] 3,5-dichlorobenzyl
4-(2-(2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate;
[0158] 3,5-dichlorobenzyl
4-(2-(N,5-dimethyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0159] (E)-3,5-dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate; [0160]
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-6-oxohexan-
oic acid; [0161] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate; [0162] 3,5-dichlorobenzyl
2-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
morpholine-4-carboxylate; [0163] 3,5-dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)
ethyl)morpholine-4-carboxylate; [0164] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate; [0165] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0166] 3,5-dichlorobenzyl
4-(2-(2H-tetrazole-5-carboxamido)ethyl)piperidine-1-carboxylate;
[0167] 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0168] 3,5-dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0169] 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0170] 3,5-dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0171] 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te; [0172] 3,5-dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e; [0173] 3,5-dichlorobenzyl
4-(3-(3-hydroxyisoxazol-5-yl)propanamido)piperidine-1-carboxylate;
[0174] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0175] 3,5-dichlorobenzyl
4-(2-(5-hydroxy-N-methyl-1H-pyrazole-3-carboxamido)ethyl)piperidine-1-car-
boxylate; [0176] 3,5-dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate; [0177] 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te; [0178] 3,5-dichlorobenzyl
4-(2-(N-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxamido)ethyl)
piperidine-1-carboxylate; [0179] 3,5-dichlorobenzyl
4-(2-(N-methyl-2H-tetrazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0180]
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamide;
[0181] (E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-2-oxo-2,3-dihydrooxazole-5-carboxamide;
[0182] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0183] 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate-
; [0184] 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate;
[0185] 3,5-dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late; and [0186] 3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; or a pharmaceutically acceptable salt
thereof.
[0187] In an embodiment 22.2 of the invention, there is provided a
compound according to embodiment 1 or 2 selected from the group
consisting of [0188] 3-Chloro-5-fluorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0189]
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; [0190]
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; [0191]
8-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-8-oxooctan-
oic acid; [0192] 3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate;
[0193]
N-(1-(3-(3,5-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3--
triazol-4-yl)butanamide; [0194]
N-(1-(3-(2,4-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-
-4-yl)butanamide; [0195] 3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0196] 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate; [0197] 3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)azepane-1-carboxylate;
[0198] 3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl)butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carb-
amate; [0199] 3,5-Dichlorobenzyl
(1-(4-(1H-1,2,3-triazol-4-yl)butanoyl)azepan-4-yl)carbamate; [0200]
3,5-dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0201] (S)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0202] (R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0203] 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)azetidine-1-carboxylate;
[0204] 3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0205] 3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4-yl)pentanoyl)piperidin-4-yl)carbamate;
[0206] 4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0207]
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl)phenyl)propanoyl)pi-
peridin-4-yl)butanamide; [0208]
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-4-
-yl)butanamide; [0209] 3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0210] 3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5-yl)propanamido)methyl)piperidine-1-carboxylate;
[0211] 2,4-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0212] 3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0213] 3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate; [0214] 3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)
piperidine-1-carboxylate; [0215] 3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0216] 3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0217] 3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0218] 3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0219] 3-cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0220] 3,5-dichlorobenzyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0221] In an embodiment 23 of the invention, there is provided a
compound according to embodiment 1 or 2 selected from the group
consisting of [0222] 3,5-dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0223] 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate; [0224] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carb-
oxylate; [0225] 3,5-dichlorobenzyl
4-(2-(2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate;
[0226] 3,5-dichlorobenzyl
4-(2-(N,5-dimethyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0227] (E)-3,5-dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate; [0228]
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-6-oxohexan-
oic acid; [0229] 3,5-dichlorobenzyl
2-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
morpholine-4-carboxylate; [0230] 3,5-dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)
ethyl)morpholine-4-carboxylate; [0231] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0232] 3,5-dichlorobenzyl
4-(2-(2H-tetrazole-5-carboxamido)ethyl)piperidine-1-carboxylate;
[0233] 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0234] 3,5-dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0235] 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0236] 3,5-dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0237] 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te; [0238] 3,5-dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e; [0239] 3,5-dichlorobenzyl
4-(3-(3-hydroxyisoxazol-5-yl)propanamido)piperidine-1-carboxylate;
[0240] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; [0241] 3,5-dichlorobenzyl
4-(2-(5-hydroxy-N-methyl-1H-pyrazole-3-carboxamido)ethyl)piperidine-1-car-
boxylate; [0242] 3,5-dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate; [0243] 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te; [0244] 3,5-dichlorobenzyl
4-(2-(N-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxamido)ethyl)
piperidine-1-carboxylate; [0245] 3,5-dichlorobenzyl
4-(2-(N-methyl-2H-tetrazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0246]
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamide;
[0247] (E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-2-oxo-2,3-dihydrooxazole-5-carboxamide;
[0248] 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate; [0249] 3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate-
; [0250] 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate;
[0251] 3,5-dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late; and [0252] 3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate; or a pharmaceutically acceptable salt
thereof.
[0253] In an embodiment 24 of the invention, there is provided a
compound according to embodiment 1 or 2 selected from the group
consisting of [0254] 3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate; [0255] 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0256] 3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate; [0257] 3,5-dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate; [0258] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate; and [0259] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate; [0260]
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; [0261] 3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0262] 3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate;
[0263] 3,5-dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
[0264] 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)azetidine-1-carboxylate;
[0265] 3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0266] 4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0267] 3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0268] 3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0269] 3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
[0270] 3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
[0271] 3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate; [0272] 3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)
piperidine-1-carboxylate; [0273] 3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
and [0274] 3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0275] In an embodiment 24.1 of the invention, there is provided a
compound according to embodiment 1 or 2 selected from the group
consisting of [0276] 3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate; [0277] 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate;
[0278] 3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate; [0279] 3,5-dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate; [0280] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate; and [0281] 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate; or a pharmaceutically acceptable salt thereof.
[0282] In an embodiment 25 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate, or pharmaceutically acceptable salt
thereof.
[0283] In an embodiment 26 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate; or a pharmaceutically acceptable salt
thereof.
[0284] In an embodiment 27 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate, or a pharmaceutically acceptable salt thereof.
[0285] In an embodiment 28 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate, or a pharmaceutically acceptable salt thereof.
[0286] In an embodiment 29 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate, or a pharmaceutically acceptable salt thereof.
[0287] In an embodiment 30 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N-methyl-2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carb-
oxylate, or a pharmaceutically acceptable salt thereof.
[0288] In an embodiment 31 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate,
or a pharmaceutically acceptable salt thereof.
[0289] In an embodiment 32 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N,5-dimethyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)piperidin-
e-1-carboxylate, or a pharmaceutically acceptable salt thereof.
[0290] In an embodiment 33 of the invention, there is provided a
compound according to embodiment 1 which is
(E)-3,5-dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate, or a
pharmaceutically acceptable salt thereof.
[0291] In an embodiment 34 of the invention, there is provided a
compound according to embodiment 1 which is
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-6-oxohexan-
oic acid, or a pharmaceutically acceptable salt thereof.
[0292] In an embodiment 35 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate, or a pharmaceutically acceptable salt thereof.
[0293] In an embodiment 36 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
2-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
morpholine-4-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0294] In an embodiment 37 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)
ethyl)morpholine-4-carboxylate, or a pharmaceutically acceptable
salt thereof.
[0295] In an embodiment 38 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate, or a pharmaceutically acceptable salt thereof.
[0296] In an embodiment 39 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)
piperidine-1-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0297] In an embodiment 40 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(2H-tetrazole-5-carboxamido)ethyl)piperidine-1-carboxylate, or
a pharmaceutically acceptable salt thereof.
[0298] In an embodiment 41 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, or
a pharmaceutically acceptable salt thereof.
[0299] In an embodiment 42 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate,
or a pharmaceutically acceptable salt thereof.
[0300] In an embodiment 43 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate,
or a pharmaceutically acceptable salt thereof.
[0301] In an embodiment 44 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate,
or a pharmaceutically acceptable salt thereof.
[0302] In an embodiment 45 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te, or a pharmaceutically acceptable salt thereof.
[0303] In an embodiment 46 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e, or a pharmaceutically acceptable salt thereof.
[0304] In an embodiment 47 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(3-(3-hydroxyisoxazol-5-yl)propanamido)piperidine-1-carboxylate,
or a pharmaceutically acceptable salt thereof.
[0305] In an embodiment 48 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0306] In an embodiment 49 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(5-hydroxy-N-methyl-1H-pyrazole-3-carboxamido)ethyl)piperidine-1-car-
boxylate, or a pharmaceutically acceptable salt thereof.
[0307] In an embodiment 50 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate, or a pharmaceutically acceptable salt thereof.
[0308] In an embodiment 51 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te, or a pharmaceutically acceptable salt thereof.
[0309] In an embodiment 52 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxamido)ethyl)pip-
eridine-1-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0310] In an embodiment 53 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl 4-(2-(N-methyl-2H-tetrazole-5-carboxamido)ethyl)
piperidine-1-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0311] In an embodiment 54 of the invention, there is provided a
compound according to embodiment 1 which is
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)
piperidin-4-yl)ethyl)-N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamide,
or a pharmaceutically acceptable salt thereof.
[0312] In an embodiment 55 of the invention, there is provided a
compound according to embodiment 1 which is
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)-2-oxo-2-
, 3-dihydrooxazole-5-carboxamide, or a pharmaceutically acceptable
salt thereof.
[0313] In an embodiment 56 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0314] In an embodiment 57 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate-
, or a pharmaceutically acceptable salt thereof.
[0315] In an embodiment 58 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate,
or a pharmaceutically acceptable salt thereof.
[0316] In an embodiment 59 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late, or a pharmaceutically acceptable salt thereof.
[0317] In an embodiment 60 of the invention, there is provided a
compound according to embodiment 1 which is
3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate, or a pharmaceutically acceptable salt
thereof.
[0318] In an embodiment 60.1 of the invention, there is provided a
compound according to embodiment 1 which is
3-Chloro-5-fluorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0319] In an embodiment 60.2 of the invention, there is provided a
compound according to embodiment 1 which is
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; or a pharmaceutically acceptable salt
thereof.
[0320] In an embodiment 60.3 of the invention, there is provided a
compound according to embodiment 1 which is
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide; or a pharmaceutically acceptable salt
thereof.
[0321] In an embodiment 60.4 of the invention, there is provided a
compound according to embodiment 1 which is
8-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-8-oxooctan-
oic acid; or a pharmaceutically acceptable salt thereof.
[0322] In an embodiment 60.5 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0323] In an embodiment 60.6 of the invention, there is provided a
compound according to embodiment 1 which is
N-(1-(3-(3,5-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-
-4-yl)butanamide; or a pharmaceutically acceptable salt
thereof.
[0324] In an embodiment 60.7 of the invention, there is provided a
compound according to embodiment 1 which is
N-(1-(3-(2,4-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-
-4-yl)butanamide; or a pharmaceutically acceptable salt
thereof.
[0325] In an embodiment 60.8 of the invention, there is provided a
compound according to embodiment 1 which is
3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0326] In an embodiment 60.9 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate; or a pharmaceutically acceptable salt thereof.
[0327] In an embodiment 60.10 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)azepane-1-carboxylate; or a
pharmaceutically acceptable salt thereof.
[0328] In an embodiment 60.11 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl)butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carb-
amate; or a pharmaceutically acceptable salt thereof.
[0329] In an embodiment 60.12 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
(1-(4-(1H-1,2,3-triazol-4-yl)butanoyl)azepan-4-yl)carbamate; or a
pharmaceutically acceptable salt thereof.
[0330] In an embodiment 60.13 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0331] In an embodiment 60.14 of the invention, there is provided a
compound according to embodiment 1 which is
(S)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0332] In an embodiment 60.15 of the invention, there is provided a
compound according to embodiment 1 which is
(R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0333] In an embodiment 60.16 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)azetidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0334] In an embodiment 60.17 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0335] In an embodiment 60.18 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4-yl)pentanoyl)piperidin-4-yl)carbamate; or
a pharmaceutically acceptable salt thereof.
[0336] In an embodiment 60.19 of the invention, there is provided a
compound according to embodiment 1 which is
4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0337] In an embodiment 60.20 of the invention, there is provided a
compound according to embodiment 1 which is
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl)phenyl)propanoyl)pi-
peridin-4-yl)butanamide; or a pharmaceutically acceptable salt
thereof.
[0338] In an embodiment 60.21 of the invention, there is provided a
compound according to embodiment 1 which is
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-4-
-yl)butanamide; or a pharmaceutically acceptable salt thereof.
[0339] In an embodiment 60.22 of the invention, there is provided a
compound according to embodiment 1 which is
3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0340] In an embodiment 60.23 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5-yl)propanamido)methyl)piperidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0341] In an embodiment 60.24 of the invention, there is provided a
compound according to embodiment 1 which is
2,4-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0342] In an embodiment 60.25 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0343] In an embodiment 60.26 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate; or a pharmaceutically acceptable salt thereof.
[0344] In an embodiment 60.27 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)
piperidine-1-carboxylate; or a pharmaceutically acceptable salt
thereof.
[0345] In an embodiment 60.28 of the invention, there is provided a
compound according to embodiment 1 which is
3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0346] In an embodiment 60.29 of the invention, there is provided a
compound according to embodiment 1 which is
3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate; or
a pharmaceutically acceptable salt thereof.
[0347] In an embodiment 60.30 of the invention, there is provided a
compound according to embodiment 1 which is
3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0348] In an embodiment 60.31 of the invention, there is provided a
compound according to embodiment 1 which is
3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate;
or a pharmaceutically acceptable salt thereof.
[0349] In an embodiment 60.32 of the invention, there is provided a
compound according to embodiment 1 which is
3-cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, or
a pharmaceutically acceptable salt thereof.
[0350] In an embodiment 60.33 of the invention, there is provided a
compound according to embodiment 1 which is
3,5-dichlorobenzyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate, or
a pharmaceutically acceptable salt thereof.
[0351] The reason for the disclaimer in embodiment 1.1 "when L
is
##STR00038##
n is not 1" is that a compound where L is
##STR00039##
X is --C(.dbd.O)--N(R.sup.3)-- and n is was observed not to be
stable.
[0352] The term "compounds of the (present) invention" or "a
compound of the (present) invention" refers to a compound as
defined in any one of embodiments 1 to 60.
[0353] The compounds of the present invention may be prepared by
the routes described in the following Schemes or the Examples.
[0354] Compound of the present invention where X is
--C(.dbd.O)--N(R.sup.3)-- may be prepared according to Scheme 1 or
2.
##STR00040##
where A, L, R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e,
R.sup.3, Y.sup.1, Y.sup.2, Y.sup.3 are as defined in embodiment 1,
X is --C(.dbd.O)--N(R.sup.3)--.
[0355] When R.sup.7 is H, then step (a) involves reacting the
compounds shown in scheme 1 in a suitable solvent such as DMF in
the presence of a suitable amide coupling reagent, for example
.RTM.T3P or HATU, and a suitable base such as DIPEA at a suitable
temperature such as room temperature.
[0356] When R.sup.7 is an alkyl group, such as methyl or ethyl,
then step (a) involves reacting the compounds shown in scheme 1 in
a suitable solvent such as acetonitrile or methanol in the presence
of a suitable base such as
2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine or sodium
methoxide at a suitable temperature such as room temperature.
##STR00041##
where A, L, R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e,
R.sup.3, Y.sup.1, Y.sup.2, Y.sup.3 are as defined in embodiment 1,
X is --C(.dbd.O)--N(R.sup.3)--, R.sup.7 is H and P represents a
suitable protection group, for example a BOC (tert-butoxy carbonyl)
group.
[0357] Step (a) involves reaction of a mono protected amine with an
acid in a suitable solvent such as DMF with a suitable base such as
diisopropylethylamine with a suitable amide coupling reagent such
as T3P.COPYRGT. or HATU at a suitable temperature such as room
temperature.
[0358] Step (b) involves the removal of a suitable protection group
P which is well known in the art.
[0359] For example, when P is BOC, a compound is treated in a
suitable solvent, for example DCM, under acidic conditions, for
example by the addition of TFA, at a suitable temperature such as
room temperature.
[0360] Step (c) involves reaction of an amine with a chloroformate
in a suitable solvent such as DCM with a suitable base such as
aqueous sodium hydroxide at a suitable temperature such as room
temperature; alternatively reaction of an amine with an acid
chloride in a suitable solvent such as DCM with a suitable base
such as triethylamine at a suitable temperature such as room
temperature.
[0361] Compounds of the present invention where X is
--N(R.sup.3)--C(.dbd.O)-- may be prepared according to Scheme
3.
##STR00042##
where A, L, R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e,
R.sup.3, Y.sup.1, Y.sup.2, Y.sup.3 are as defined in embodiment 1,
X is --N(R.sup.3)--C(.dbd.O)--.
[0362] Step (a) involves reaction of a mono protected amine with an
acid in a suitable solvent such as DMF with a suitable base such as
diisopropylethylamine with a suitable amide coupling reagent such
as T3P.COPYRGT. or HATU at a suitable temperature such as room
temperature.
[0363] Compounds of the present invention where A-Y.sup.1--X-- is
dioxocyclobutenyl may be prepared according to Scheme 4.
##STR00043##
where A, L, R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e,
R.sup.3, R.sup.4c, R.sup.4d, Y.sup.1, Y.sup.2, Y.sup.3 are as
defined in embodiment 1.
[0364] Step (a) involves reacting a suitable
dialkoxycyclobutene-1,2-dione with the amine (XII) in a suitable
solvent such as methanol with a suitable base such as triethylamine
at a suitable temperature such as room temperature.
[0365] Step (b) involves hydrolysis of the squarate ester in a
suitable solvent such as tetrahydrofuran with a suitable acid such
as hydrochloric acid at a suitable temperature such as room
temperature.
[0366] Compounds (IV) are either commercially available or may be
prepared according to Scheme 5 and 6.
##STR00044##
where R.sup.7 is an alkyl group, such as methyl or ethyl, and
R.sup.2 is as defined in embodiment 1.
[0367] Step (a) involves reacting a compound (XIII) in a suitable
solvent such as acetonitrile and methanol in the presence of a
suitable base such as sodium methoxide and sodium hydroxide at a
suitable temperature such as 80.degree. C. or reflux.
##STR00045##
[0368] Step (a) involves reacting the acetylene (XIV) with a
suitable azide (XV) such as benzyl or 4-methoxybenzyl in suitable
solvents such as tert-butanol and water in the presence of a
suitable catalyst such as that formed in-situ from copper acetate
and sodium ascorbate at a suitable temperature such as room
temperature.
[0369] Step (b) involves removal of the benzyl group in a suitable
solvent such as acetonitrile with a suitable oxidising agent such
as ceric ammonium nitrate at a suitable temperature such as room
temperature; or alternatively in a suitable solvent such as
ethanol, with a suitable catalyst such as palladium on carbon, at a
suitable temperature such as 70.degree. C., and a suitable pressure
of hydrogen such as 30 bar.
[0370] Compounds (X) may either be commercially available or may be
prepared according to Scheme 7.
##STR00046##
where Z'' is Cl or O-succinyl and L, R.sup.1a, R.sup.1b, R.sup.1c,
R.sup.1d, R.sup.1e, Y.sup.2, Y.sup.3 are as defined in embodiment
1.
[0371] Step (a) is carried out in a suitable solvent such as DCM
with a suitable base such as aqueous sodium hydroxide at a suitable
temperature such as room temperature.
[0372] Compounds (IX) may either be commercially available or may
be prepared according to Scheme 8.
##STR00047##
where P represents a suitable protection group, for example
p-methoxybenzyl (PMB) or pivaloyloxymethyl (POM), R.sup.7 is an
alkyl group, such as ethyl, and A, Y.sup.1, R.sup.3 are defined as
in embodiment 1.
[0373] Step (a) involves reaction of an acid (IXX) with a suitable
chloroformate such as ethyl chloroformate in a suitable solvent
such as acetone and water with a suitable base such as
triethylamine at a suitable temperature such as 0.degree. C.
[0374] Step (b) involves reaction with sodium azide in a suitable
solvent such as acetone at a suitable temperature such as 0.degree.
C.
[0375] Step (c) involves heating of compound (XXI) in a suitable
solvent such as toluene at a suitable temperature such as
110.degree. C., followed by acid hydrolysis of the resulting
isocyanate in a suitable acid, such as hydrochloric acid, at a
suitable temperature such as 100.degree. C.
[0376] Step (d) involves reductive alkylation of the amine (XXII)
with a suitable aldehyde such as formaldehyde in a suitable solvent
such as DCM with a suitable reducing agent such as sodium
triacetoxyborohydride at a suitable temperature such as room
temperature.
[0377] Step (e) involves the removal of a suitable protection group
P which is well known in the art. For example, when P is POM, a
compound is treated in a suitable solvent, for example MeOH, under
basic conditions, for example by the addition of sodium hydroxide,
at a suitable temperature such as room temperature. Alternatively,
when P is PMB, a compound is treated in a suitable solvent, for
example acetonitrile, with a suitable oxidising agent such as ceric
ammonium nitrate, at a suitable temperature such as room
temperature.
[0378] Compounds (IX) where A is triazole may also be prepared
according to the following Scheme 8a.
##STR00048##
where P represents a suitable protection group, for example
tert-butylcarbamate (BOC), Z' is H or OMe, and Y.sup.1 and R.sup.3
are defined as in embodiment 1.
[0379] Step (a) involves protection of an acetylene amine (XXXVI)
with a suitable protecting group such as BOC in a suitable solvent
such as THF with a suitable base such as triethylamine at a
suitable temperature such as RT.
[0380] Step (b) involves reacting the acetylene (XXXVII) with a
suitable azide (XV) such as benzyl or 4-methoxybenzyl in suitable
solvents such as tert-butanol and water in the presence of a
suitable catalyst such as that formed in-situ from copper acetate
and sodium ascorbate at a suitable temperature such as room
temperature, with in-situ deprotection of the amine by a suitable
method such as an acid wash.
[0381] Step (c) involves reductive alkylation of the amine (XXIIa)
with a suitable aldehyde such as formaldehyde in a suitable solvent
such as DCM with a suitable reducing agent such as sodium
triacetoxyborohydride at a suitable temperature such as room
temperature.
[0382] Step (d) involves the removal of a benzyl protecting group
which is well known in the art. For example, when Z' is OMe, the
compound is treated in a suitable solvent, for example
acetonitrile, with a suitable oxidising agent such as ceric
ammonium nitrate, at a suitable temperature such as room
temperature. When Z' is H, the compound is treated in a suitable
solvent, for example, ethanol, with a suitable catalyst, such as
palladium on carbon, under a suitable pressure of hydrogen, such as
30 bar, at a suitable temperature, such as 70.degree. C.
[0383] Compounds (V) may either be commercially available or may be
prepared according to Scheme 9.
##STR00049##
where Z'' is Cl or O-succinyl, P represents a suitable protection
group, for example a BOC (tert-butoxy carbonyl) group and L,
R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e, R.sup.3, Y.sup.2,
Y.sup.3 are as defined in embodiment 1.
[0384] Step (a) involves reaction of a mono protected diamine
(XXIV) with a chloroformate or O-succinyl ester (XVII) in a
suitable solvent such as dichloromethane with a suitable base such
as aqueous sodium hydroxide at a suitable temperature such as room
temperature; alternatively reaction of an amine with an acid
chloride in a suitable solvent such as DCM with a suitable base
such as triethylamine at a suitable temperature such as room
temperature.
[0385] Step (b) involves the removal of a suitable protection group
P which is well known in the art. For example, when P is BOC, a
compound is treated in a suitable solvent, for example DCM, under
acidic conditions, for example by the addition of TFA, at a
suitable temperature such as room temperature.
[0386] Step (c) involves reductive alkylation of an amine (XXVI)
with a suitable aldehyde such as formaldehyde in a suitable solvent
such as dichloromethane with a suitable reducing agent such as
sodium triacetoxyborohydride at a suitable temperature such as room
temperature.
[0387] Step (d) involves deprotonation of a carbamate with a
suitable base such as sodium hydride in a suitable solvent such as
N,N'-dimethylformamide at a suitable temperature such as 0.degree.
C., followed by alkylation with a suitable alkylating agent such as
iodomethane at a suitable temperature such as room temperature.
[0388] Compounds (XVII) may either be commercially available or may
be prepared according to Scheme 10.
##STR00050##
where R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e, R.sup.6a,
R.sup.6b are as defined in embodiment 1.
[0389] Step (a) involves reaction of a benzyl alcohol (XXVIII)
dissolved in a suitable solvent such as tetrahydrofuran with
phosgene in a suitable solvent such as toluene at a suitable
temperature such as 10.degree. C.
[0390] Compounds (XXVII) where Y.sup.3 is --CH.dbd.CH-- or
--CR.sup.6eR.sup.6fCR.sup.6gR.sup.6h-- may either be commercially
available or may be prepared according to Scheme 11.
##STR00051##
where R.sup.7 is an alkyl group, such as methyl or ethyl, P
represents a suitable protection group, for example a BOC
(tert-butoxy carbonyl) group, L, R.sup.1a, R.sup.1b, R.sup.1c,
R.sup.1d, R.sup.1e, Y.sup.2 are as defined in embodiment 1.
[0391] Step (a) involves reaction of an iodobenzene (XXIX) with an
acrylate ester in a suitable solvent such as N,N'-dimethylformamide
with a suitable base such as triethylamine and a suitable catalyst
such as palladium bis(tritert-butylphosphine) at a suitable
temperature such as 80.degree. C.
[0392] Step (b) involves hydrolysis of the ester in a suitable
solvent such as tetrahydrofuran with a suitable base such as sodium
hydroxide at a suitable temperature such as room temperature.
[0393] Step (c) involves reaction of a monoprotected diamine (XXIV)
with an acid (XXXI) in a suitable solvent such as DMF in the
presence of a suitable amide coupling reagent, for example .RTM.T3P
or HATU, and a suitable base such as DIPEA at a suitable
temperature such as room temperature.
[0394] Step (d) involves reduction of a cinnamide in a suitable
solvent such as ethanol in the presence of a suitable catalyst such
as platinum on carbon under a suitable pressure of hydrogen such as
at a suitable temperature such as room temperature.
[0395] Compounds (XXVII) where L is piperazine (XXXII) is either
commercially available or may also be prepared according to Scheme
12.
##STR00052##
where W is specifically N, P represents a suitable protection
group, for example a BOC (tert-butoxy carbonyl) group, R.sup.1a,
R.sup.1b, R.sup.1c, R.sup.1d, R.sup.1e, Y.sup.2, Y.sup.3 are as
defined in embodiment 1 and L is specifically
##STR00053##
[0396] Step (a) involves reaction of an amine (XXXII) with a
chloroformate (XXXIII) in a suitable solvent such as DCM with a
suitable base such as aqueous sodium hydroxide at a suitable
temperature such as room temperature; alternatively reaction of an
amine with an acid chloride in a suitable solvent such as DCM with
a suitable base such as triethylamine at a suitable temperature
such as room temperature.
[0397] Step (b) involves the removal of a suitable protection group
P which is well known in the art. For example, when P is BOC, a
compound is treated in a suitable solvent, for example DCM, under
acidic conditions, for example by the addition of TFA, at a
suitable temperature such as room temperature.
[0398] Step (c) involves reaction of an amine (XXXV) with a
suitable aldehyde such as tert-butyl methyl(3-oxopropyl)carbamate
in suitable solvent such as dichloromethane in the presence of a
suitable reducing agent such as sodium triacetoxyborohydride at a
suitable temperature such as room temperature.
[0399] Compounds (VI), (XI), (XIII), (XIV), (XV), (XVII), (XVIII),
(IXX), (XVII), (XXVIII), (XXIX), (XXXII) and (XXXIII) are either
commercially available or may be prepared according to known
methods.
[0400] Compounds of the present invention and intermediates can
also be converted into each other according to methods generally
known to those skilled in the art.
[0401] Within the scope of this text, only a readily removable
group that is not a constituent of the particular desired end
product of the compounds of the present invention is designated a
"protecting group", unless the context indicates otherwise. The
protection of functional groups by such protecting groups, the
protecting groups themselves, and their cleavage reactions are
described for example in standard reference works, such as J. F. W.
McOmie, "Protective Groups in Organic Chemistry", Plenum Press,
London and New York 1973, in T.
[0402] W. Greene and P. G. M. Wuts, "Protective Groups in Organic
Synthesis", Third edition, Wiley, New York 1999, in "The Peptides";
Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press,
London and New York 1981, in "Methoden der organischen Chemie"
(Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume
15/I, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H.
Jeschkeit, "Aminosauren, Peptide, Proteine" (Amino acids, Peptides,
Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel
1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate:
Monosaccharide und Derivate" (Chemistry of Carbohydrates:
Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart
1974. A characteristic of protecting groups is that they can be
removed readily (i.e. without the occurrence of undesired secondary
reactions) for example by solvolysis, reduction, photolysis or
alternatively under physiological conditions (e.g. by enzymatic
cleavage).
[0403] Salts of compounds of the present invention having at least
one salt-forming group may be prepared in a manner known to those
skilled in the art. For example, salts of compounds of the present
invention having acid groups may be formed, for example, by
treating the compounds with metal compounds, such as alkali metal
salts of suitable organic carboxylic acids, e.g. the sodium salt of
2-ethylhexanoic acid, with organic alkali metal or alkaline earth
metal compounds, such as the corresponding hydroxides, carbonates
or hydrogen carbonates, such as sodium or potassium hydroxide,
carbonate or hydrogen carbonate, with corresponding calcium
compounds or with ammonia or a suitable organic amine,
stoichiometric amounts or only a small excess of the salt-forming
agent preferably being used. Acid addition salts of compounds of
the present invention are obtained in customary manner, e.g. by
treating the compounds with an acid or a suitable anion exchange
reagent. Internal salts of compounds of the present invention
containing acid and basic salt-forming groups, e.g. a free carboxy
group and a free amino group, may be formed, e.g. by the
neutralisation of salts, such as acid addition salts, to the
isoelectric point, e.g. with weak bases, or by treatment with ion
exchangers.
[0404] Salts can be converted into the free compounds in accordance
with methods known to those skilled in the art. Metal and ammonium
salts can be converted, for example, by treatment with suitable
acids, and acid addition salts, for example, by treatment with a
suitable basic agent.
[0405] Mixtures of isomers obtainable according to the invention
can be separated in a manner known to those skilled in the art into
the individual isomers; diastereoisomers can be separated, for
example, by partitioning between polyphasic solvent mixtures,
recrystallisation and/or chromatographic separation, for example
over silica gel or by e.g. medium pressure liquid chromatography
over a reversed phase column, and racemates can be separated, for
example, by the formation of salts with optically pure salt-forming
reagents and separation of the mixture of diastereoisomers so
obtainable, for example by means of fractional crystallisation, or
by chromatography over optically active column materials.
[0406] Intermediates and final products can be worked up and/or
purified according to standard methods, e.g. using chromatographic
methods, distribution methods, (re-) crystallization, and the
like.
[0407] The following applies in general to all processes mentioned
herein before and hereinafter.
[0408] All the above-mentioned process steps can be carried out
under reaction conditions that are known to those skilled in the
art, including those mentioned specifically, in the absence or,
customarily, in the presence of solvents or diluents, including,
for example, solvents or diluents that are inert towards the
reagents used and dissolve them, in the absence or presence of
catalysts, condensation or neutralizing agents, for example ion
exchangers, such as cation exchangers, e.g. in the H+ form,
depending on the nature of the reaction and/or of the reactants at
reduced, normal or elevated temperature, for example in a
temperature range of from about -100.degree. C. to about
190.degree. C., including, for example, from approximately
-80.degree. C. to approximately 150.degree. C., for example at from
-80 to -60.degree. C., at room temperature, at from -20 to
40.degree. C. or at reflux temperature, under atmospheric pressure
or in a closed vessel, where appropriate under pressure, and/or in
an inert atmosphere, for example under an argon or nitrogen
atmosphere.
[0409] At all stages of the reactions, mixtures of isomers that are
formed can be separated into the individual isomers, for example
diastereoisomers or enantiomers, or into any desired mixtures of
isomers, for example racemates or mixtures of diastereoisomers, for
example analogously to the methods described under "Additional
process steps".
[0410] The solvents from which those solvents that are suitable for
any particular reaction may be selected include those mentioned
specifically or, for example, water, esters, such as lower
alkyl-lower alkanoates, for example ethyl acetate, ethers, such as
aliphatic ethers, for example diethyl ether, or cyclic ethers, for
example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons,
such as benzene or toluene, alcohols, such as methanol, ethanol or
1- or 2-propanol, nitriles, such as acetonitrile, halogenated
hydrocarbons, such as methylene chloride or chloroform, acid
amides, such as dimethylformamide or dimethyl acetamide, bases,
such as heterocyclic nitrogen bases, for example pyridine or
N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower
alkanoic acid anhydrides, for example acetic anhydride, cyclic,
linear or branched hydrocarbons, such as cyclohexane, hexane or
isopentane, methycyclohexane, or mixtures of those solvents, for
example aqueous solutions, unless otherwise indicated in the
description of the processes. Such solvent mixtures may also be
used in working up, for example by chromatography or
partitioning.
[0411] The compounds of the present invention, including their
salts, may also be obtained in the form of hydrates, or their
crystals may, for example, include the solvent used for
crystallization. Different crystalline forms may be present.
[0412] The invention relates also to those forms of the process in
which a compound obtainable as an intermediate at any stage of the
process is used as starting material and the remaining process
steps are carried out, or in which a starting material is formed
under the reaction conditions or is used in the form of a
derivative, for example in a protected form or in the form of a
salt, or a compound obtainable by the process according to the
invention is produced under the process conditions and processed
further in situ.
[0413] All starting materials, building blocks, reagents, acids,
bases, dehydrating agents, solvents and catalysts utilized to
synthesize the compounds of the present invention are either
commercially available or can be produced by organic synthesis
methods known to one of ordinary skill in the art (Houben-Weyl
4.sup.th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume
21).
[0414] As used herein, the term "an optical isomer" or "a
stereoisomer" refers to any of the various stereo isomeric
configurations which may exist for a given compound of the present
invention and includes geometric isomers. It is understood that a
substituent may be attached at a chiral center of a carbon atom.
The term "chiral" refers to molecules which have the property of
non-superimposability on their mirror image partner, while the term
"achiral" refers to molecules which are superimposable on their
mirror image partner. Therefore, the invention includes
enantiomers, diastereomers or racemates of the compounds of the
present invention. "Enantiomers" are a pair of stereoisomers that
are non-superimposable mirror images of each other. A 1:1 mixture
of a pair of enantiomers is a "racemic" mixture. The term is used
to designate a racemic mixture where appropriate.
"Diastereoisomers" are stereoisomers that have at least two
asymmetric atoms, but which are not mirror-images of each other.
The absolute stereochemistry is specified according to the
Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer
the stereochemistry at each chiral carbon may be specified by
either R or S. Resolved compounds whose absolute configuration is
unknown can be designated (+) or (-) depending on the direction
(dextro- or levorotatory) which they rotate plane polarized light
at the wavelength of the sodium D line. Certain compounds of the
present invention described herein may contain one or more
asymmetric centers or axes and may thus give rise to enantiomers,
diastereomers, and other stereoisomeric forms that may be defined,
in terms of absolute stereochemistry, as (R)- or (S)-.
[0415] Depending on the choice of the starting materials and
procedures, the compounds of the present invention may be present
in the form of one of the possible isomers or as mixtures thereof,
for example as pure optical isomers, or as isomer mixtures, such as
racemates and diastereoisomer mixtures, depending on the number of
asymmetric carbon atoms. The present invention is meant to include
all such possible isomers, including racemic mixtures,
diasteriomeric mixtures and optically pure forms. Optically active
(R)- and (S)-isomers may be prepared using chiral synthons or
chiral reagents, or resolved using conventional techniques. If the
compound of the present invention contains a double bond, the
substituent may be E or Z configuration. If the compound of the
present invention contains a disubstituted cycloalkyl, the
cycloalkyl substituent may have a cis- or trans-configuration. All
tautomeric forms, for example for group A in embodiment 1, are also
intended to be included.
[0416] As used herein, the terms "salt" or "salts" refers to an
acid addition or base addition salt of a compound of the present
invention. "Salts" include in particular "pharmaceutical acceptable
salts". The term "pharmaceutically acceptable salts" refers to
salts that retain the biological effectiveness and properties of
the compounds of the present invention and, which typically are not
biologically or otherwise undesirable. In many cases, the compounds
of the present invention are capable of forming acid and/or base
salts by virtue of the presence of amino and/or carboxyl groups or
groups similar thereto.
[0417] Pharmaceutically acceptable acid addition salts can be
formed with inorganic acids and organic acids, e.g., acetate,
aspartate, benzoate, besylate, bromide/hydrobromide,
bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate,
chloride/hydrochloride, chlortheophyllonate, citrate,
ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate,
hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate,
laurylsulfate, malate, maleate, malonate, mandelate, mesylate,
methylsulphate, naphthoate, napsylate, nicotinate, nitrate,
octadecanoate, oleate, oxalate, palmitate, pamoate,
phosphate/hydrogen phosphate/dihydrogen phosphate,
polygalacturonate, propionate, stearate, succinate,
sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
[0418] Thus, in an embodiment 61, there is provided a
pharmaceutically acceptable salt of a compound according to any one
of embodiments 25 to 60, wherein the salt is selected from acetate,
aspartate, benzoate, besylate, bromide/hydrobromide,
bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate,
chloride/hydrochloride, chlortheophyllonate, citrate,
ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate,
hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate,
laurylsulfate, malate, maleate, malonate, mandelate, mesylate,
methylsulphate, naphthoate, napsylate, nicotinate, nitrate,
octadecanoate, oleate, oxalate, palmitate, pamoate,
phosphate/hydrogen phosphate/dihydrogen phosphate,
polygalacturonate, propionate, stearate, succinate,
sulfosalicylate, tartrate, tosylate and trifluoroacetate salt.
[0419] Inorganic acids from which salts can be derived include, for
example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, and the like.
[0420] Organic acids from which salts can be derived include, for
example, acetic acid, propionic acid, glycolic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, mandelic acid, methanesulfonic
acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic
acid, and the like. Pharmaceutically acceptable base addition salts
can be formed with inorganic and organic bases.
[0421] Inorganic bases from which salts can be derived include, for
example, ammonium salts and metals from columns I to XII of the
periodic table. In certain embodiments, the salts are derived from
sodium, potassium, ammonium, calcium, magnesium, iron, silver,
zinc, and copper; particularly suitable salts include ammonium,
potassium, sodium, calcium and magnesium salts.
[0422] Thus, in an embodiment 62, there is provided a
pharmaceutically acceptable salt of a compound according to any one
of embodiments 25 to 60, wherein the salt is selected from
ammonium, potassium, sodium, calcium and magnesium salt.
[0423] Organic bases from which salts can be derived include, for
example, primary, secondary, and tertiary amines, substituted
amines including naturally occurring substituted amines, cyclic
amines, basic ion exchange resins, and the like. Certain organic
amines include isopropylamine, benzathine, cholinate,
diethanolamine, diethylamine, lysine, meglumine, piperazine and
tromethamine.
[0424] Thus, in an embodiment 63, there is provided a
pharmaceutically acceptable salt of a compound according to any one
of embodiments 25 to 60, wherein the salt is selected from
isopropylamine, benzathine, cholinate, diethanolamine,
diethylamine, lysine, meglumine, piperazine and tromethamine
salt.
[0425] The pharmaceutically acceptable salts of the compounds of
the present invention can be synthesized from a basic or acidic
moiety, by conventional chemical methods. Generally, such salts can
be prepared by reacting free acid forms of the compounds of the
present invention with a stoichiometric amount of the appropriate
base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or
the like), or by reacting free base forms of the compounds of the
present invention with a stoichiometric amount of the appropriate
acid. Such reactions are typically carried out in water or in an
organic solvent, or in a mixture of the two. Generally, use of
non-aqueous media like ether, ethyl acetate, ethanol, isopropanol,
or acetonitrile is desirable, where practicable. Lists of
additional suitable salts can be found, e.g., in "Remington's
Pharmaceutical Sciences", 20th ed., Mack Publishing Company,
Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts:
Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH,
Weinheim, Germany, 2002).
[0426] Any formula given herein is also intended to represent
unlabeled forms as well as isotopically labeled forms of the
compounds of the present invention. Isotopically labeled compounds
of the present invention have structures depicted by the formulas
given herein except that one or more atoms are replaced by an atom
having a selected atomic mass or mass number. Examples of isotopes
that can be incorporated into compounds of the present invention
include isotopes of hydrogen, carbon, nitrogen, oxygen,
phosphorous, fluorine, and chlorine, such as .sup.2H, .sup.3H,
.sup.11C, .sup.13C, .sup.14C, .sup.15N, .sup.18F .sup.31P,
.sup.32P, .sup.35S, .sup.36C, .sup.125I respectively. The invention
includes various isotopically labeled compounds of the present
invention, for example those into which radioactive isotopes, such
as .sup.3H and .sup.14C, or those into which non-radioactive
isotopes, such as .sup.2H and .sup.13C are present. Such
isotopically labelled compounds of the present invention are useful
in metabolic studies (with .sup.14C), reaction kinetic studies
(with, for example .sup.2H or .sup.3H), detection or imaging
techniques, such as positron emission tomography (PET) or
single-photon emission computed tomography (SPECT) including drug
or substrate tissue distribution assays, or in radioactive
treatment of patients. In particular, an .sup.18F or labeled
compound of the present invention may be particularly desirable for
PET or SPECT studies. Isotopically-labeled compounds of the present
invention can generally be prepared by conventional techniques
known to those skilled in the art or by processes analogous to
those described in the accompanying Generic Schemes, Examples and
Preparations using an appropriate isotopically-labeled reagent in
place of the non-labeled reagent previously employed.
[0427] Further, substitution with heavier isotopes, particularly
deuterium (i.e., .sup.2H or D) may afford certain therapeutic
advantages resulting from greater metabolic stability, for example
increased in vivo half-life or reduced dosage requirements or an
improvement in therapeutic index. It is understood that deuterium
in this context is regarded as a substituent of a compound of the
present invention. The concentration of such a heavier isotope,
specifically deuterium, may be defined by the isotopic enrichment
factor. The term "isotopic enrichment factor" as used herein means
the ratio between the isotopic abundance and the natural abundance
of a specified isotope. If a substituent in a compound of the
present invention is denoted deuterium, such compound has an
isotopic enrichment factor for each designated deuterium atom of at
least 3500 (52.5% deuterium incorporation at each designated
deuterium atom), at least 4000 (60% deuterium incorporation), at
least 4500 (67.5% deuterium incorporation), at least 5000 (75%
deuterium incorporation), at least 5500 (82.5% deuterium
incorporation), at least 6000 (90% deuterium incorporation), at
least 6333.3 (95% deuterium incorporation), at least 6466.7 (97%
deuterium incorporation), at least 6600 (99% deuterium
incorporation), or at least 6633.3 (99.5% deuterium
incorporation).
[0428] Pharmaceutically acceptable solvates in accordance with the
invention include those wherein the solvent of crystallization may
be isotopically substituted, e.g. D.sub.2O, d.sub.6-acetone,
d.sub.6-DMSO.
[0429] Compounds of the invention, i.e. compounds of the present
invention that contain groups capable of acting as donors and/or
acceptors for hydrogen bonds may be capable of forming co-crystals
with suitable co-crystal formers. These co-crystals may be prepared
from compounds of the present invention by known co-crystal forming
procedures. Such procedures include grinding, heating,
co-subliming, co-melting, or contacting in solution compounds of
the present invention with the co-crystal former under
crystallization conditions and isolating co-crystals thereby
formed. Suitable co-crystal formers include those described in WO
2004/078163. Hence the invention further provides co-crystals
comprising a compound of the present invention.
[0430] Any asymmetric atom (e.g., carbon or the like) of the
compound(s) of the present invention can be present in racemic or
enantiomerically enriched, for example the (R)-, (S)- or
(R,S)-configuration. In certain embodiments, each asymmetric atom
has at least 50% enantiomeric excess, at least 60% enantiomeric
excess, at least 70% enantiomeric excess, at least 80% enantiomeric
excess, at least 90% enantiomeric excess, at least 95% enantiomeric
excess, or at least 99% enantiomeric excess in the (R)- or
(S)-configuration. Substituents at atoms with unsaturated double
bonds may, if possible, be present in cis-(Z)- or
trans-(E)-form.
[0431] Accordingly, as used herein a compound of the present
invention can be in the form of one of the possible isomers,
rotamers, atropisomers, tautomers or mixtures thereof, for example,
as substantially pure geometric (cis or trans) isomers,
diastereomers, optical isomers (antipodes), racemates or mixtures
thereof.
[0432] Any resulting mixtures of isomers can be separated on the
basis of the physicochemical differences of the constituents, into
the pure or substantially pure geometric or optical isomers,
diastereomers, racemates, for example, by chromatography and/or
fractional crystallization.
[0433] Any resulting racemates of final products or intermediates
can be resolved into the optical antipodes by known methods, e.g.,
by separation of the diastereomeric salts thereof, obtained with an
optically active acid or base, and liberating the optically active
acidic or basic compound. In particular, a basic moiety may thus be
employed to resolve the compounds of the present invention into
their optical antipodes, e.g., by fractional crystallization of a
salt formed with an optically active acid, e.g., tartaric acid,
dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl
tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic
acid. Racemic products can also be resolved by chiral
chromatography, e.g., high pressure liquid chromatography (HPLC)
using a chiral adsorbent.
[0434] Furthermore, the compounds of the present invention,
including their salts, can also be obtained in the form of their
hydrates, or include other solvents used for their crystallization.
The compounds of the present invention may inherently or by design
form solvates with pharmaceutically acceptable solvents (including
water); therefore, it is intended that the invention embrace both
solvated and unsolvated forms. The term "solvate" refers to a
molecular complex of a compound of the present invention (including
pharmaceutically acceptable salts thereof) with one or more solvent
molecules. Such solvent molecules are those commonly used in the
pharmaceutical art, which are known to be innocuous to the
recipient, e.g., water, ethanol, and the like. The term "hydrate"
refers to the complex where the solvent molecule is water.
[0435] The compounds of the present invention, including salts,
hydrates and solvates thereof, may inherently or by design form
polymorphs.
[0436] The compounds of the present invention in free form or in
salt form, exhibit valuable pharmacological properties, e.g. as
indicated in in vitro tests as provided herein, and are therefore
indicated for therapy or for use as research chemicals, e.g. as
tool compounds.
[0437] Thus, in an embodiment 64, there is provided a compound
according to any one of embodiments 1 to 60 for use in
medicine.
[0438] The compounds according to any one of embodiments 1 to 60
are potent inhibitors of ATX (see IC.sub.50 data disclosed herein).
The compound of the present invention are hence useful in the
treatment of an ATX-dependent or ATX-mediated disease or
condition.
[0439] Thus, in an embodiment 65, there is provided a compound
according to any one of embodiments 1 to 60 for use in the
treatment of an ATX-dependent or ATX-mediated disease or condition.
In an embodiment 66, there is provided the use of a compound
according to any one of embodiments 1 to 60 in the treatment of an
ATX-dependent or ATX-mediated disease or condition. In an
embodiment 67, there is provided the use of a compound according to
any one of embodiments 1 to 60 in the manufacture of a medicament
for the treatment of an ATX-dependent or ATX-mediated disease or
condition. In an embodiment 68, there is provided a method of
treating an ATX-dependent or ATX-mediated disease or condition
comprising administering to the subject a therapeutically effective
amount of a compound according to any one of embodiments 1 to
60.
[0440] Hence, in a further embodiment 69, the compounds of the
invention are useful for the treatment of a disease or condition
according to embodiments 65, 66, 67 and 68, wherein the disease or
condition is selected from fibrosis, pruritus, cirrhosis, cancer,
diabetes, kidney diseases and pain.
[0441] In an embodiment 70, the compounds of the invention are
useful for the treatment of a disease or condition according to
embodiment 69, wherein the disease or condition is selected from
pulmonary fibrosis, idiopathic pulmonary fibrosis, a diffuse
parenchymal interstitial lung disease including iatrogenic
drug-induced fibrosis, occupational and/or environmental induced
fibrosis (Farmer lung), radiation induced fibrosis, bleomycin
induced pulmonary fibrosis, asbestos induced pulmonary fibrosis,
acute respiratory distress syndrome (ARDS), kidney fibrosis,
tubulointerstitium fibrosis, gut fibrosis, liver fibrosis, alcohol
induced liver fibrosis, toxic/drug induced liver fibrosis,
infection induced liver fibrosis, viral induced liver fibrosis,
cutaneous fibrosis, spinal cord injury/fibrosis, myelofibrosis,
renal fibrosis, skin fibrosis, ocular fibrosis, post-transplant
fibrosis, hepatic fibrosis with or without cirrhosis, cardiac
fibrosis, neuropathic pruritus, neurogenic pruritus, psychogenic
pruritus, cholestatic pruritus, primary biliary cirrhosis, liver
cirrhosis, breast cancer, pancreatic cancer, ovarian cancer,
prostate cancer, glioblastoma, bone cancer, colon cancer, bowel
cancer, head and neck cancer, diabetes, polycystic kidney disease,
acute kidney injury, chronic kidney disease, neuropathic pain and
cancer pain.
[0442] In an embodiment 71, the compounds of the invention are
useful for the treatment of a disease or condition according to
embodiment 70, wherein the disease or condition is selected from
idiopathic pulmonary fibrosis, breast cancer, pancreatic cancer,
prostate cancer, cholestatic pruritus, primary biliary cirrhosis
and polycystic kidney disease, particularly idiopathic pulmonary
fibrosis.
[0443] The compounds of the invention will be typically formulated
as pharmaceutical compositions.
[0444] Thus, in an embodiment 72 of the invention, the present
invention provides a pharmaceutical composition comprising a
compound according to any one of embodiments 1 to 60, or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier.
[0445] The pharmaceutical composition can be formulated for
particular routes of administration such as oral administration,
parenteral administration, and rectal administration, etc. In
addition, the pharmaceutical compositions of the present invention
can be made up in a solid form (including without limitation
capsules, tablets, pills, granules, powders or suppositories), or
in a liquid form (including without limitation solutions,
suspensions or emulsions). The pharmaceutical compositions can be
subjected to conventional pharmaceutical operations such as
sterilization and/or can contain conventional inert diluents,
lubricating agents, or buffering agents, as well as adjuvants, such
as preservatives, stabilizers, wetting agents, emulsifers and
buffers, etc.
[0446] Typically, the pharmaceutical compositions are tablets or
gelatin capsules comprising the active ingredient together with
a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol,
cellulose and/or glycine; b) lubricants, e.g., silica, talcum,
stearic acid, its magnesium or calcium salt and/or
polyethyleneglycol; for tablets also c) binders, e.g., magnesium
aluminum silicate, starch paste, gelatin, tragacanth,
methylcellulose, sodium carboxymethylcellulose and/or
polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches,
agar, alginic acid or its sodium salt, or effervescent mixtures;
and/or e) absorbents, colorants, flavors and sweeteners.
[0447] Tablets may be either film coated or enteric coated
according to methods known in the art.
[0448] Suitable compositions for oral administration include an
effective amount of a compound of the present invention in the form
of tablets, lozenges, aqueous or oily suspensions, dispersible
powders or granules, emulsion, hard or soft capsules, or syrups or
elixirs. Compositions intended for oral use are prepared according
to any method known in the art for the manufacture of
pharmaceutical compositions and such compositions can contain one
or more agents selected from the group consisting of sweetening
agents, flavoring agents, coloring agents and preserving agents in
order to provide pharmaceutically elegant and palatable
preparations. Tablets may contain the active ingredient in
admixture with nontoxic pharmaceutically acceptable excipients
which are suitable for the manufacture of tablets. These excipients
are, for example, inert diluents, such as calcium carbonate, sodium
carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, corn starch, or
alginic acid; binding agents, for example, starch, gelatin or
acacia; and lubricating agents, for example magnesium stearate,
stearic acid or talc. The tablets are uncoated or coated by known
techniques to delay disintegration and absorption in the
gastrointestinal tract and thereby provide a sustained action over
a longer period. For example, a time delay material such as
glyceryl monostearate or glyceryl distearate can be employed.
Formulations for oral use can be presented as hard gelatin capsules
wherein the active ingredient is mixed with an inert solid diluent,
for example, calcium carbonate, calcium phosphate or kaolin, or as
soft gelatin capsules wherein the active ingredient is mixed with
water or an oil medium, for example, peanut oil, liquid paraffin or
olive oil.
[0449] Certain injectable compositions are aqueous isotonic
solutions or suspensions, and suppositories are advantageously
prepared from fatty emulsions or suspensions. Said compositions may
be sterilized and/or contain adjuvants, such as preserving,
stabilizing, wetting or emulsifying agents, solution promoters,
salts for regulating the osmotic pressure and/or buffers. In
addition, they may also contain other therapeutically valuable
substances. Said compositions are prepared according to
conventional mixing, granulating or coating methods, respectively,
and contain about 0.1-75%, or contain about 1-50%, of the active
ingredient.
[0450] Suitable compositions for transdermal application include an
effective amount of a compound of the invention with a suitable
carrier. Carriers suitable for transdermal delivery include
absorbable pharmacologically acceptable solvents to assist passage
through the skin of the host. For example, transdermal devices are
in the form of a bandage comprising a backing member, a reservoir
containing the compound optionally with carriers, optionally a rate
controlling barrier to deliver the compound of the skin of the host
at a controlled and predetermined rate over a prolonged period of
time, and means to secure the device to the skin.
[0451] Suitable compositions for topical application, e.g., to the
skin and eyes, include aqueous solutions, suspensions, ointments,
creams, gels or sprayable formulations, e.g., for delivery by
aerosol or the like. Such topical delivery systems will in
particular be appropriate for dermal application, e.g., for the
treatment of skin cancer, e.g., for prophylactic use in sun creams,
lotions, sprays and the like. They are thus particularly suited for
use in topical, including cosmetic, formulations well-known in the
art. Such may contain solubilizers, stabilizers, tonicity enhancing
agents, buffers and preservatives.
[0452] As used herein a topical application may also pertain to an
inhalation or to an intranasal application. They may be
conveniently delivered in the form of a dry powder (either alone,
as a mixture, for example a dry blend with lactose, or a mixed
component particle, for example with phospholipids) from a dry
powder inhaler or an aerosol spray presentation from a pressurised
container, pump, spray, atomizer or nebuliser, with or without the
use of a suitable propellant.
[0453] Where the inhalable form of the active ingredient is an
aerosol composition, the inhalation device may be an aerosol vial
provided with a valve adapted to deliver a metered dose, such as 10
to 100 .mu.l, e.g. 25 to 50 .mu.l, of the composition, i.e. a
device known as a metered dose inhaler. Suitable such aerosol vials
and procedures for containing within them aerosol compositions
under pressure are well known to those skilled in the art of
inhalation therapy. For example, an aerosol composition may be
administered from a coated can, for example as described in
EP-A-0642992. Where the inhalable form of the active ingredient is
a nebulizable aqueous, organic or aqueous/organic dispersion, the
inhalation device may be a known nebulizer, for example a
conventional pneumatic nebulizer such as an airjet nebulizer, or an
ultrasonic nebulizer, which may contain, for example, from 1 to 50
ml, commonly 1 to 10 ml, of the dispersion; or a hand-held
nebulizer, sometimes referred to as a soft mist or soft spray
inhaler, for example an electronically controlled device such as an
AERx (Aradigm, US) or Aerodose (Aerogen), or a mechanical device
such as a RESPIMAT (Boehringer Ingelheim) nebulizer which allows
much smaller nebulized volumes, e.g. 10 to 100 .mu.l, than
conventional nebulizers. Where the inhalable form of the active
ingredient is the finely divided particulate form, the inhalation
device may be, for example, a dry powder inhalation device adapted
to deliver dry powder from a capsule or blister containing a dry
powder comprising a dosage unit of (A) and/or (B) or a multidose
dry powder inhalation (MDPI) device adapted to deliver, for
example, 3-25 mg of dry powder comprising a dosage unit of (A)
and/or (B) per actuation. The dry powder composition preferably
contains a diluent or carrier, such as lactose, and a compound that
helps to protect against product performance deterioration due to
moisture e.g. magnesium stearate. Suitable such dry powder
inhalation devices include devices disclosed in U.S. Pat. No.
3,991,761 (including the AEROLIZER.TM. device), WO 05/113042
(including the BREEZHALER.TM. device), WO 97/20589 (including the
CERTIHALER.TM. device), WO 97/30743 (including the TWISTHALER.TM.
device), WO 05/37353 (including the GYROHALER.TM. device), U.S.
Pat. No. 6,536,427 (including the DISKUS.TM. device), WO 97/25086
(including the DISKHALER.TM. device), WO 95/14089 (including the
GEMINI.TM. device), WO 03/77979 (including the PROHALER.TM.
device), and also the devices disclosed in WO 08/51621, WO
09/117112 and US 2005/0183724.
[0454] Hence, the invention also includes (A) a compound of the
present invention, or a pharmaceutically acceptable salt thereof,
in inhalable form; (B) an inhalable medicament comprising a
compound of the present invention in inhalable form together with a
pharmaceutically acceptable carrier in inhalable form; (C) a
pharmaceutical product comprising a compound of the present
invention in inhalable form in association with an inhalation
device; and (D) an inhalation device containing a compound of the
present invention in inhalable form.
[0455] Dosages of agents of the invention employed in practising
the present invention will of course vary depending, for example,
on the particular condition to be treated, the effect desired and
the mode of administration. In general, suitable daily dosages for
administration by inhalation are of the order of 0.0001 to 30
mg/kg, typically 0.01 to 10 mg per patient, while for oral
administration suitable daily doses are of the order of 0.01 to 100
mg/kg.
[0456] The present invention further provides anhydrous
pharmaceutical compositions and dosage forms comprising the
compounds of the present invention as active ingredients, since
water may facilitate the degradation of certain compounds.
[0457] Anhydrous pharmaceutical compositions and dosage forms of
the invention can be prepared using anhydrous or low moisture
containing ingredients and low moisture or low humidity conditions.
An anhydrous pharmaceutical composition may be prepared and stored
such that its anhydrous nature is maintained. Accordingly,
anhydrous compositions are packaged using materials known to
prevent exposure to water such that they can be included in
suitable formulary kits. Examples of suitable packaging include,
but are not limited to, hermetically sealed foils, plastics, unit
dose containers (e. g., vials), blister packs, and strip packs.
[0458] The invention further provides pharmaceutical compositions
and dosage forms that comprise one or more agents that reduce the
rate by which the compound of the present invention as an active
ingredient will decompose. Such agents, which are referred to
herein as "stabilizers," include, but are not limited to,
antioxidants such as ascorbic acid, pH buffers, or salt buffers,
etc.
[0459] The compound of the present invention may be administered
either simultaneously with, or before or after, one or more other
therapeutic agent. The compound of the present invention may be
administered separately, by the same or different route of
administration, or together in the same pharmaceutical composition
as the other agents.
[0460] In one embodiment, the invention provides a product
comprising a compound of the present invention and at least one
other therapeutic agent as a combined preparation for simultaneous,
separate or sequential use in therapy. In one embodiment, the
therapy is the treatment of a disease or condition mediated by
blockade of the epithelial sodium channel.
[0461] Products provided as a combined preparation include a
composition comprising the compound of the present invention and
the other therapeutic agent(s) together in the same pharmaceutical
composition, or the compound of the present invention and the other
therapeutic agent(s) in separate form, e.g. in the form of a
kit.
[0462] Thus, in an embodiment 73, the invention provides a
pharmaceutical composition comprising a compound according to any
one of embodiments 1 to 60 and one or more therapeutically active
co-agent. Optionally, the pharmaceutical composition may comprise a
pharmaceutically acceptable excipient, as described above.
[0463] In one embodiment, the invention provides a kit comprising
two or more separate pharmaceutical compositions, at least one of
which contains a compound of the present invention. In one
embodiment, the kit comprises means for separately retaining said
compositions, such as a container, divided bottle, or divided foil
packet. An example of such a kit is a blister pack, as typically
used for the packaging of tablets, capsules and the like.
[0464] The kit of the invention may be used for administering
different dosage forms, for example, oral and parenteral, for
administering the separate compositions at different dosage
intervals, or for titrating the separate compositions against one
another. To assist compliance, the kit of the invention typically
comprises directions for administration.
[0465] In an embodiment 74 of the invention, there is provided a
pharmaceutical combination, comprising:
a therapeutically effective amount of the compound according to any
one of embodiments 1 to 60, or a pharmaceutically acceptable salt
thereof, and one or more therapeutically active co-agent.
[0466] In an embodiment 75 of the invention, there is provided a
pharmaceutical combination according to embodiment 74, wherein the
therapeutically active co-agent is selected from immunosuppresants,
analgesics, anti-cancer agent, anti-inflammatories, chemokine
receptor antagonists, bronchodilators, leukotriene receptor
antagonists, leukotriene formation inhibitors, monoacylglycerol
kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2
inhibitors, lysophospholipase D (lysoPLD) inhibitors,
decongestants, antihistamines, mucolytics, anticholinergics,
antitussives, expectorants, and .beta.-2 agonists.
[0467] Suitable anti-inflammatory drugs include steroids, for
example corticosteroids. Suitable steroids include budesonide,
beclamethasone (e.g. dipropionate), butixocort (e.g. propionate),
CHF5188, ciclesonide, dexamethasone, flunisolide, fluticasone (e.g.
propionate or furoate), GSK-685698, GSK-870086, LAS40369, methyl
prednisolone, mometasone (e.g. furoate), prednisolone, rofleponide,
and triamcinolone (e.g. acetonide). In certain preferred
embodiments the steroid is long-acting corticosteroids such as
budesonide, ciclesonide, fluticasone propionate, fluticasone
furoate or mometasone furoate.
[0468] Suitable .beta..sub.2-agonists include arformoterol (e.g.
tartrate), albuterol/salbutamol (e.g. racemate or single enantiomer
such as the R-enantiomer, or salt thereof especially sulfate),
AZD3199, bambuterol, BI-171800, bitolterol (e.g. mesylate),
carmoterol, clenbuterol, etanterol, fenoterol (e.g. racemate or
single enantiomer such as the R-enantiomer, or salt thereof
especially hydrobromide), flerbuterol, formoterol (e.g. racemate or
single diastereomer such as the R,R-diastereomer, or salt thereof
especially fumarate or fumarate dihydrate), GSK-159802, GSK-597901,
GSK-678007, indacaterol (e.g. racemate or single enantiomer such as
the R-enantiomer, or salt thereof especially maleate, acetate or
xinafoate), LAS100977, metaproterenol, milveterol (e.g.
hydrochloride), naminterol, olodaterol (e.g. racemate or single
enantiomer such as the R-enantiomer, or salt thereof especially
hydrochloride), PF-610355, pirbuterol (e.g. acetate), procaterol,
reproterol, salmefamol, salmeterol (e.g. racemate or single
enantiomer such as the R-enantiomer, or salt thereof especially
xinafoate), terbutaline (e.g. sulphate) and vilanterol (or a salt
thereof especially trifenatate. In certain preferred embodiments
the .beta..sub.2-agonist is an ultra-long-acting
.beta..sub.2-agonist such as indacaterol, or potentially
carmoterol, LAS-100977, milveterol, olodaterol, PF-610355 or
vilanterol. A preferred embodiment one of the second active
ingredients is indacaterol (i.e.
(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quino-
lin-2-one) or a salt thereof. This is a .beta..sub.2-adrenoceptor
agonist that has an especially long duration of action (i.e. over
24 hours) and a short onset of action (i.e. about 10 minutes). This
compound is prepared by the processes described in international
patent applications WO 2000/75114 and WO 2005/123684. It is capable
of forming acid addition salts, particularly pharmaceutically
acceptable acid addition salts. A preferred salt of
(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quino-
lin-2-one is the maleate salt. Another preferred salt is
(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quino-
lin-2-one acetate. Another preferred salt is
(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quino-
lin-2-one xinafoate.
[0469] Suitable bronchodilatory drugs include anticholinergic or
antimuscarinic agents, such as aclidinium (e.g. bromide), BEA-2108
(e.g. bromide), BEA-2180 (e.g. bromide), CHF-5407, darifenacin
(e.g. bromide), darotropium (e.g. bromide), glycopyrrolate (e.g.
racemate or single enantiomer, or salt thereof especially bromide),
dexpirronium (e.g. bromide), iGSK-202405, GSK-203423, GSK-573719,
GSK-656398, ipratropium (e.g. bromide), LAS35201, LAS186368,
otilonium (e.g. bromide), oxitropium (e.g. bromide), oxybutynin,
PF-3715455, PF-3635659, pirenzepine, revatropate (e.g.
hydrobromide), solifenacin (e.g. succinate), SVT-40776, TD-4208,
terodiline, tiotropium (e.g. bromide), tolterodine (e.g. tartrate),
and trospium (e.g. chloride). In certain preferred embodiments the
muscarinic antagonists is long-acting muscarinic antagonist such as
darotropium bromide, glycopyrrolate or tiotropium bromide. Suitable
dual anti-inflammatory and bronchodilatory drugs include dual
beta-2 adrenoceptor agonist/muscarinic antagonists such as
GSK-961081 (e.g. succinate). and those disclosed in USP
2004/0167167, WO 04/74246 and WO 04/74812.
[0470] Suitable antihistamine drug substances include cetirizine
hydrochloride, acetaminophen, clemastine fumarate, promethazine,
loratidine, desloratidine, diphenhydramine and fexofenadine
hydrochloride, activastine, astemizole, azelastine, ebastine,
epinastine, mizolastine and tefenadine, as well as those disclosed
in JP 2004107299, WO 03/099807 and WO 04/026841.
EXPERIMENTAL
Examples
[0471] The following examples are intended to illustrate the
invention and are not to be construed as being limitations
thereon.
General Conditions
[0472] Mass spectra were acquired on LC-MS, SFC-MS, or GC-MS
systems using electrospray, chemical and electron impact ionization
methods from a range of instruments of the following
configurations: Agilent 1100 HPLC systems with an Agilent 6110 Mass
Spectrometer, or Micromass Platform Mass Spectrometer or Thermo LTQ
Mass Spectrometer; a Waters Acquity UPLC system with SQD Mass
Spectrometer, a Waters FractionLynx HPLC system with 3100 Mass
Spectrometer, a Waters UPC2 system with TQD Mass Spectrometer or a
Waters Prep100 SFC-MS system with SQD2 Mass Spectrometer. [M+H]+
refers to protonated molecular ion of the chemical species.
[0473] NMR spectra were run on Bruker AVANCE 400 MHz or 500 MHz NMR
spectrometers using ICON-NMR, under TopSpin program control.
Spectra were measured at 298K, unless indicated otherwise, and were
referenced relative to the solvent resonance.
[0474] Temperatures are given in degrees centigrade. If not
mentioned otherwise, all evaporations are performed under reduced
pressure, preferably between about 15 mm Hg and 100 mm Hg (=20-133
mbar). The structure of final products, intermediates and starting
materials is confirmed by standard analytical methods, e.g.,
microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR.
Abbreviations used are those conventional in the art. If not
defined, the terms have their generally accepted meanings.
Abbreviations:
[0475] anh anhydrous [0476] aq aqueous [0477] BOC tert-butoxy
carbonyl [0478] br broad [0479] BSA bovine serum albumin [0480] CDI
1,1'-carbonyldiimidazole [0481] d doublet [0482] dd doublet of
doublets [0483] DCM dichloromethane [0484] DIPEA
diisopropylethylamine [0485] DMF N,N-dimethylformamide [0486] DMSO
dimethylsulfoxide [0487] EDC
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide [0488] EtOAc ethyl
acetate [0489] EtOH ethanol [0490] H or hrs hour(s) [0491] HATU
(O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate) [0492] HBSS Hanks' balanced salt solution
[0493] HPLC high pressure liquid chromatography [0494] HRP
Horseradish peroxidase [0495] Int. intermediate [0496] LCMS liquid
chromatography and mass spectrometry [0497] MeOH methanol [0498] Me
methyl [0499] MS mass spectrometry [0500] m multiplet [0501] min
minutes [0502] ml milliliter(s) [0503] m/z mass to charge ratio
[0504] NMR nuclear magnetic resonance [0505] NMM N-methylmorpholine
[0506] O/N overnight [0507] PS polymer supported [0508] PE-AX
PE-anion exchange (e.g. Isolute.RTM. PE-AX columns from Biotage)
[0509] T3P.RTM. Propylphosphonic anhydride [0510] RT room
temperature [0511] Rt retention time [0512] s singlet [0513] SCX-2
strong cation exchange (e.g. Isolute.RTM. SCX-2 columns from
Biotage) [0514] sol solution [0515] t triplet [0516] TEA
triethylamine [0517] TFA trifluoroacetic acid [0518] THF
tetrahydrofuran
[0519] Referring to the examples that follow, compounds of the
Examples were synthesized using the methods described herein, or
other methods, which are known in the art.
[0520] The various starting materials, intermediates, and compounds
of the Examples may be isolated and purified, where appropriate,
using conventional techniques such as precipitation, filtration,
crystallization, evaporation, distillation, and chromatography.
Unless otherwise stated, all starting materials are obtained from
commercial suppliers and used without further purification. Salts
may be prepared from compounds by known salt-forming
procedures.
[0521] It should be understood that the organic compounds according
to the preferred embodiments may exhibit the phenomenon of
tautomerism. As the chemical structures within this specification
can only represent one of the possible tautomeric forms, it should
be understood that the compounds of the Examples encompasses any
tautomeric form of the drawn structure.
[0522] If not indicated otherwise, the analytical HPLC conditions
are as follows:
Method 2minLowpHv02: [0523] Column: Waters Acquity CSH 1.7 .mu.m,
2.1.times.50 mm [0524] Temperature: 50.degree. C. [0525] Mobile
Phase: A: Water +0.1% TFA B: Acetonitrile +0.1% TFA [0526] Flow
rate: 1.0 mL/min [0527] Gradient: 0.0 min 5% B, 0.2-1.55 min 5-98%
B, 1.55-1.75 min 98% B, 1.75-1.8 min 98-5% B Method 2minLowpHv01:
[0528] Column: Waters Acquity CSH 1.7 .mu.m, 2.1.times.50 mm [0529]
Temperature: 50.degree. C. [0530] Mobile Phase: A: Water +0.1%
Formic Acid B: Acetonitrile +0.1% Formic Acid [0531] Flow rate: 1.0
mL/min [0532] Gradient: 0.0 min 5% B, 0.2-1.55 min 5-98% B,
1.55-1.75 min 98% B, 1.75-1.8 min 98-5% B Method 2minLowpHv03:
[0533] Column: Waters Acquity CSH 1.7 .mu.m, 2.1.times.50 mm [0534]
Temperature: 50.degree. C. [0535] Mobile Phase: A: Water +0.1%
Formic Acid B: Acetonitrile +0.1% Formic Acid [0536] Flow rate: 1.0
mL/min [0537] Gradient: 0.0 min 5% B, 0.2-1.8 min 5-98% B, 1.8-2.1
min 98% B, 2.1-2.3 min 98% B Method 2minLC_v001 [0538] Column
Waters BEH C18 100.times.2.1 mm, 1.7 .mu.m [0539] Column
Temperature 50.degree. C. [0540] Eluents A: H.sub.2O, B:
acetonitrile, both containing 0.1% TFA [0541] Flow Rate 0.7 mL/min
[0542] Gradient 0.25 min 5% B; 5% to 95% B in 1.00 min, 0.25 min
95% B 8minLowpHv01: [0543] Column: Waters Acquity CSH 1.7 .mu.m,
2.1.times.100 mm [0544] Temperature: 50.degree. C. [0545] Mobile
Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
[0546] Flow rate: 0.7 mL/min [0547] Gradient: 0.0 min 2% B, 0.3-6.5
min 2-98% B, 6.5-7.5 min 98% B, 7.5-8.0 min 5-98% B Method
10minLowpHv01: [0548] Column: Waters Acquity CSH 1.7 .mu.m,
2.1.times.100 mm [0549] Temperature: 50.degree. C. [0550] Mobile
Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
[0551] Flow rate: 0.7 mL/min [0552] Gradient: 0.0 min 2% B, 0.5-8.0
min 2-98% B, 8.0-9.0 min 98% B, 9.0-9.1 min 98-2% B
Example 1
3,5-Dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate
##STR00054##
[0553] Step 1: 3,5-Dichlorobenzyl
4-(2-((tert-butoxycarbonyl)amino)ethyl)piperidine-1-carboxylate
[0554] A mixture comprising of tert-butyl
(2-(piperidin-4-yl)ethyl)carbamate (1.85 g, 8.10 mmol) in DCM (80
ml), sat. aqueous sodium bicarbonate solution (20 ml, 8.10 mmol)
and 3,5-dichlorobenzyl carbonochloridate (prepared according to
Bioorganic & Medicinal Chemistry Letters, 21(21), 6608-6612;
2011, Intermediate 33) (1.940 g, 8.10 mmol) was stirred at room
temperature for 3 hours. The resulting mixture was treated with 2M
NaOH soln. (50 ml). The organics were separated, dried (MgSO.sub.4)
and concentrated under reduced pressure to afford the title
compound;
[0555] 1H NMR (400 MHz, CDCl.sub.3) 7.3 (1H, s), 7.2 (2H, s), 5.1
(2H, s), 4.5 (1H, s), 4.2 (2H, s), 3.2 (2H, bs), 2.8 (2H, bs), 1.75
(2H, d), 1.5 (11H, m), 1.15 (2H, m)
Step 2: 3,5-Dichlorobenzyl
4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)piperidine-1-carboxylate
[0556] A solution of 3,5-dichlorobenzyl
4-(2-((tert-butoxycarbonyl)amino)ethyl)piperidine-1-carboxylate
(step 1) (3.5 g, 8.11 mmol) in DMF (40 ml) was cooled to 0.degree.
C. 60% sodium hydride/oil (0.487 g, 12.17 mmol) was added. The
solution was stirred at 0.degree. C. for 15 mins and then was
warmed to RT. Iodomethane (0.761 ml, 12.17 mmol) was added and the
resulting mixture was stirred at room temperature for 5 hours. The
reaction was quenched with ammonium chloride (20 ml). The mixture
was diluted with water (200 ml) and extracted with EtOAc
(2.times.200 ml). The organic portion was dried using MgSO.sub.4,
filtered and concentrated under reduced pressure. The residue was
applied to an 80 g silica cartridge in DCM and eluted with 0-100%
EtOAc in iso-hexane to afford the title compound;
[0557] LCMS: Rt=1.58 mins; MS m/z 345.2 and 347.2 [M-BOC+H]+;
Method 2minLowpHv02
[0558] 1H NMR (400 MHz, CDCl.sub.3) 7.3 (1H, s), 7.2 (2H, s), 5.1
(2H, s), 4.2 (1H, bs), 3.3 (2H, t), 3.2 (2H, bs), 2.85 (3H, s), 2.8
(2H, bs), 1.8 (2H, d), 1.5 (11H, s), 1.15 (2H, m),
Step 3: 3,5-Dichlorobenzyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate
[0559] To a solution of 3,5-dichlorobenzyl
4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)piperidine-1-carboxylate
(step 2) (2.73 g, 6.13 mmol) in DCM (20 mL) was added
trifluoroacetic acid (19 ml, 247 mmol). The reaction mixture was
stirred at room temperature for 1 hour. The mixture was
concentrated under pressure and the residue was suspended in sat.
sodium bicarbonate solution (100 ml). The resultant mixture was
extracted with EtOAc (2.times.100 ml). The organic portion was
dried using MgSO.sub.4, filtered and concentrated under reduced
pressure. The oil was applied to a 40 g silica cartridge in DCM and
eluted with 0-20% MeOH/DCM containing 1% aqueous ammonia to afford
the title compound;
[0560] LCMS; Rt=0.83 mins; MS m/z 354.3 and 347.3 [M+H]+; Method
2minLowpHv01
[0561] 1H NMR (400 MHz, MeOD) 7.45 (1H, s), 7.4 (2H, s), 5.1 (2H,
s), 4.2 (2H, d), 2.8 (4H, M), 2.6 (3H, s), 1.8 (2H, d), 1.6 (3H,
m), 1.2 (2H, m).
Step 4: 3,5-Dichlorobenzyl
4-(2-(3-hydroxy-N-methylisoxazole-5-carboxamido)ethyl)
piperidine-1-carboxylate
[0562] A solution comprising of methyl
3-hydroxyisoxazole-5-carboxylate (20.72 mg, 0.145 mmol),
3,5-dichlorobenzyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate
(step 3) (50 mg, 0.145 mmol) and
2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine (20.16 mg, 0.145
mmol) in DMF (483 .mu.l) was refluxed for 18 hours. The reaction
mixture was diluted with EtOAc and washed with water. The organic
portion was separated, dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to afford the title
compound;
[0563] 1H NMR (400 MHz, MeOD) 7.4 (1H, s), 7.3 (2H, s), 6.35 (1H,
d), 5.1 (2H, s), 4.15 (2H, bs), 3.6 (2H, q), 3.2 (3H, d), 2.9 (2H,
bs), 1.9 (1H, d), 1.6 (4H, m), 1.1 (2H, m),
[0564] LC-MS: Rt 5.24 mins; MS m/z 456 [M+H]+; Method
10minLowpHv01
Example 2
3,5-Dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)piperidi-
ne-1-carboxylate
##STR00055##
[0566] A solution of 3,4-dimethoxycyclobut-3-ene-1,2-dione (20.58
mg, 0.145 mmol) and triethylamine (81 .mu.l, 0.579 mmol) in MeOH
(483 .mu.l) was warmed to 45.degree. C. for 30 mins.
3,5-Dichlorobenzyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate
(Example 1, step 3) (50 mg, 0.145 mmol) was added drop wise and the
reaction mixture was stirred at room temperature for 18 hours. The
resulting mixture was concentrated under reduced pressure and the
crude oily product was dissolved in water and extracted with EtOAc.
The organic portion was dried over MgSO4, filtered and solvent
concentrated under reduced pressure. The crude product was
suspended in MeOH and sonicated. The resulting white solid was
filtered and dried to afford the title compound;
[0567] 1H NMR (400 MHz, DMSO-d6) 7.6 (1H, s), 7.45 (2H, s) 5.1 (2H,
s), 4.3 (3H, s), 4 (2H, d), 3.65 (1H, t), 3.2 (1H, s), 3.05 (1H,
s), 2.8 (1H, bs), 1.7 (2H, bs), 1.55 (2H, bs), 1.5 (1H, bs), 1 (1H,
m),
[0568] LC-MS: Rt 5.51 mins; MS m/z 455.6 [M+H]+; Method
10minLowpH
Example 3
3,5-Dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate
##STR00056##
[0569] Step 1: 3,5-Dichlorobenzyl
4-(2-aminoethyl)piperidine-1-carboxylate
[0570] The title compound was prepared from 3,5-dichlorobenzyl
4-(2-(tert-butoxycarbonylamino) ethyl)piperidine-1-carboxylate
(Example 1, step 1) analogously to Example 1, step 3;
[0571] LCMS: Rt=0.94 mins; MS m/z 331.1 [M+H]+; Method
2minLowpHv02
Step 2: 3,5-Dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate
[0572] The title compound was prepared from
3,4-diethoxycyclobut-3-ene-1,2-dione and 3,5-dichlorobenzyl
4-(2-aminoethyl)piperidine-1-carboxylate (step 1) analogously to
Example 2;
[0573] 1H NMR (400 MHz, DMSO-d6) 7.6 (1H, s), 7.4 (2H, s), 5.1 (2H,
s), 4.65 (2H, d), 4 (2H, d), 3.55 (1H, bs), 2.8 (2H, bs), 1.7 (2H,
d), 1.5 (3H, m), 1.35 (4H, M), 1 (2H, m)
[0574] LC-MS: Rt 5.38 mins; MS m/z 455 [M+H]+; Method
10minLowpHv01
Example 4
3,5-Dichlorobenzyl
4-(2-((2-hydroxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-car-
boxylate
##STR00057##
[0576] A mixture comprising 3,5-dichlorobenzyl
4-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)piperidine-1-carb-
oxylate (Example 3) (35 mg, 0.077 mmol) and 6M HCl (aq) (38.4
.mu.l, 0.077 mmol) in THF (256 .mu.l) was stirred overnight at room
temperature. The reaction mixture was concentrated under pressure
to give an aqueous suspension. The suspension was filtered, air
dried and partitioned between EtOAc and water. The organic portion
was separated, dried over MgSO.sub.4, filtered and concentrated
under reduced pressure. Further purification was carried out using
preparative LC-MS. The resulting product fractions were
concentrated under reduced pressure to give an aqueous solution and
then extracted with EtOAc. The organic extracts were dried over
MgSO.sub.4, filtered and concentrated under reduced pressure to
afford the title compound.
[0577] 1H NMR (400 MHz, MeOD) 7.4 (1H, s), 7.35 (2H, s), 5.1 (2H,
s), 4.15 (2H, d), 3.65 (2H, t), 2.9 (2H, bs), 1.85 (2H, d), 1.6
(2H, m), 1.3 (1H, s), 1.15 (2H, m)
[0578] LC-MS: Rt 1.39 mins; MS m/z 425 [M+H]+; Method
10minLowpH
Example 5
3,5-Dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate
##STR00058##
[0579] Step 1: (2-Methylpiperidin-4-yl)methanamine
[0580] A mixture comprising tert-butyl
4-(aminomethyl)-2-methylpiperidine-1-carboxylate (2 g, 8.76 mmol)
and trifluoroacetic acid (10 ml, 130 mmol) in DCM (29.2 ml) was
stirred at room temperature for 1 hour. The resulting mixture was
loaded on to an Isolute.RTM. SCX-2 10 g cartridge and washed with
DCM. The product was eluted with 7M ammonia in MeOH and
concentrated under reduced pressure. The crude material was
suspended in EtOH and filtered. The filtrate was concentrated under
pressure to afford the title compound which was used in the next
step without further purification;
Step 2: Tert-butyl ((2-methylpiperidin-4-yl)methyl)carbamate
[0581] A mixture comprising (2-methylpiperidin-4-yl)methanamine
(step 1) (1.123 g 8.76 mmol), di-t-butyl dicarbonate (2.237 ml,
9.63 mmol) and 4-dimethylaminopyridine (0.535 g, 4.38 mmol) in DCM
(29.2 ml) was stirred at room temperature for 18 hours. The
resulting mixture was diluted with DCM and washed with a minimal
volume of water. The organic portion was dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to afford the
title compound;
[0582] LC-MS: Rt 0.45 mins; MS m/z 227 [M+H]+; Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
4-(((tert-butoxycarbonyl)amino)methyl)-2-methylpiperidine-1-carboxylate
[0583] A mixture comprising tert-butyl
((2-methylpiperidin-4-yl)methyl)carbamate (step 2) (1.15 g, 5.04
mmol) and 3,5-dichlorobenzyl carbonochloridate (1.327 g, 5.54 mmol)
in DCM (15 ml) was treated with aq. saturated sodium bicarbonate
(0.504 ml, 5.04 mmol) and stirred at room temperature for 18 hours.
The organic portion was separated and the aqueous phase extracted
with DCM (2.times.10 ml). The combined organic extracts were dried
over MgSO.sub.4, filtered and concentrated under reduced pressure.
Further purification by chromatography on silica, eluting in 0-20%
2M ammonia in MeOH in DCM afforded the title compound;
[0584] LC-MS: Rt 1.38 mins; MS m/z 429 [M+H]+; Method
2minLowpH_v01
Step 4: 3,5-Dichlorobenzyl
4-(aminomethyl)-2-methylpiperidine-1-carboxylate
[0585] A mixture comprising of 3,5-dichlorobenzyl
4-(((tert-butoxycarbonyl)amino)methyl)-2-methylpiperidine-1-carboxylate
(step 3) (970 mg, 2.249 mmol) and trifluoroacetic acid (173 .mu.l,
2.249 mmol) in DCM (7.5 ml) was left stirring at room temperature
18 hours. The resulting mixture was loaded on to a 10 g
Isolute.RTM. SCX-2 cartridge and washed with MeOH. The product was
eluted with 2M ammonia in MeOH and the product fractions were
concentrated under reduced pressure to afford the title
compound;
[0586] LC-MS: Rt 0.84 mins; MS m/z 331[M+H]+; Method
2minLowpH_v01
Step 5: 3,5-Dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-ca-
rboxylate
[0587] A mixture comprising of 3-(3-hydroxyisoxazol-5-yl)propanoic
acid (40.2 mg, 0.256 mmol), 3,5-dichlorobenzyl
4-(aminomethyl)-2-methylpiperidine-1-carboxylate (step 4) (84.7 mg,
0.128 mmol), Huenig's base (89 .mu.l, 0.511 mmol) and T3P.RTM. (50%
solution in DMF)(149 .mu.l, 0.256 mmol) in DMF (426 .mu.l) was left
stirring at room temperature 18 hours. The resulting mixture was
concentrated under pressure and diluted with water. The aqueous
solution was extracted with EtOAc and the combined organic extracts
were dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. Further purification was carried out using preparative
LC-MS. The resulting product fractions were concentrated under
reduced pressure to give an aqueous solution and then extracted
with EtOAc. The organic extracts were dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to afford the
title compound.
[0588] 1H NMR (400 MHz, MeOD) 7.45 (1H, s), 7.35 (2H, s), 5.1 (2H,
t), 4 (1H, m), 3.75 (1H, m), 3.2 (2H, m), 3.1 (1H, m), 3 (2H, t),
2.6 (2H, t), 1.85 (1H, m), 1.75 (2H, m), 1.3 (4H, m),
[0589] LC-MS: Rt 4.65 mins; MS m/z 470 [M+H]+; Method
10minLowpH
Example 6
3,5-Dichlorobenzyl
4-(2-(N-methyl-2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carb-
oxylate
##STR00059##
[0591] A mixture comprising of 3,5-dichlorobenzyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate (Example 1, step
3) (100 mg, 0.290 mmol), 2-(1H-1,2,3-triazol-4-yl)acetic acid (55.2
mg, 0.434 mmol), T3P.RTM. (50% solution in DMF) (338 .mu.l, 0.579
mmol) and Huenig's base (101 .mu.l, 0.579 mmol) in DMF was stirred
at room temperature for 18 hours. The resulting mixture was
concentrated under pressure. The crude residue was diluted with
water and extracted with EtOAc. The organic portion was dried over
MgSO.sub.4, filtered and solvent concentrated under reduced
pressure. Further purification was carried out using preparative
LC-MS. The resulting product fractions were concentrated under
reduced pressure to give an aqueous solution and then extracted
with EtOAc. The organic extracts were dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to afford the
title compound.
[0592] 1H NMR (400 MHz, MeOD) 7.75 (1H, bs), 7.5 (1H, s), 7.35 (2H,
s), 5.1 (2H, s), 4.15 (2H, bs), 3.9 (2H, s), 3.5 (2H, m), 3.15 (2H,
s), 3 (1H, s), 2.9 (2H, bs), 1.8 (2H, d), 1.5 (3H, m), 1.15 (2H,
m)
[0593] LC-MS: Rt 4.78 mins; MS m/z 454 [M+H]+; Method
10minLowpH
Example 7
3,5-Dichlorobenzyl
4-(2-(2-(1H-1,2,3-triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate
##STR00060##
[0595] A mixture comprising of 3,5-dichlorobenzyl
4-(2-aminoethyl)piperidine-1-carboxylate (Example 3, step 1) (100
mg, 0.302 mmol), 2-(1H-1,2,3-triazol-4-yl)acetic acid (57.6 mg,
0.453 mmol), 1-propanephosphonic anhydride solution (0.353 mL,
0.604 mmol) and Huenig's Base (0.105 mL, 0.604 mmol) in DMF (1 mL)
was stirred at room temperature for hours, and then concentrated
under reduced pressure. The mixture was diluted with water and
extracted with EtOAc. The organic portion was dried over
MgSO.sub.4, filtered and the solvent concentrated under pressure.
Further purification was carried out using preparative LC-MS. The
resulting product fractions were concentrated under reduced
pressure to give an aqueous solution and then extracted with EtOAc.
The organic extracts were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to afford the title
compound;
[0596] 1H NMR (400 MHz, MeOD) 7.7 (1H, bs), 7.45 (1H, s), 7.35 (2H,
s), 5.1 (2H, s), 4.15 (2H, d), 3.7 (2H, s), 3.25 (2H, t), 2.85 (2H,
bs), 1.75 (2H, d), 1.5 (3H, m), 1.1 (2H, m)
[0597] LC-MS: Rt 4.58 mins; MS m/z 440 [M+H]+; Method
10minLowpH
Example 8
3,5-Dichlorobenzyl
4-(2-(N,5-dimethyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)piperidin-
e-1-carboxylate
##STR00061##
[0599] The title compound was prepared from 3,5-dichlorobenzyl
4-(2-methylamino)ethyl)piperidine-1-carboxylate (Example 1, step 3)
and 5-methyl-2-oxo-2,3-dihydrooxazole-4-carboxylic acid analogously
to Example 6;
[0600] LC-MS: Rt 1.22 mins; MS m/z 470.4 and 472.4 (M+H)+; Method
2minLowpHv01.
Example 9
(E)-3,5-Dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate
##STR00062##
[0601] Step 1: 3,5-Dichlorobenzyl
4-(tert-butoxycarbonylamino)piperidine-1-carboxylate
[0602] A mixture comprising tert-butyl piperidin-4-ylcarbamate (5
g, 24.97 mmol), 3,5-dichlorobenzyl alcohol (4.42 g, 24.97 mmol) and
carbonyldiimidazole (4.05 g, 24.97 mmol) in DMF (83 ml) was heated
at 50.degree. C. with stirring for 3 days. The resulting mixture
was concentrated under reduced pressure. The crude material was
redissolved in EtOAc and washed with 1M HCl, a saturated solution
of sodium bicarbonate and brine. The organic phase was dried over
MgSO.sub.4, filtered and concentrated under reduced pressure. The
mixture was purified by chromatography on silica eluting with
50-100% EtOAc in iso-hexane and then 1-10% MeOH in EtOAc to afford
the title product;
[0603] LC-MS: Rt 1.26 mins; MS m/z 303.2 [M-BOC+H]+; Method
2minLowpH
Step 2: 3,5-Dichlorobenzyl 4-aminopiperidine-1-carboxylate
[0604] To a solution of 3,5-dichlorobenzyl
4-(tert-butoxycarbonylamino)piperidine-1-carboxylate (step
1)(5.3098 g, 13.17 mmol) in DCM (20 ml) was added 4M HCl in dioxane
(33 ml, mmol) and the mixture was stirred at RT for 2 hrs. The
reaction mixture was concentrated under reduced pressure to afford
the title product as hydrochloride salt; LC-MS: Rt 0.70 mins; MS
m/z 303.2 and 305.2 [M+H]+; Method 2minLowpH
[0605] Step 3: (E)-3,5-Dichlorobenzyl
4-(3-(1H-imidazol-4-yl)acrylamido)piperidine-1-carboxylate
[0606] To a solution of urocanic acid (122 mg, 0.883 mmol) and
3,5-dichlorobenzyl 4-amino piperidine-1-carboxylate HCl salt (step
2) (300 mg, 0.883 mmol) in DCM (2 mL) was added
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (169
mg, 0.883 mmol) and N-methylmorpholine (0.291 mL, 2.65 mmol) and
the mixture was stirred at RT for 3 h. The resulting mixture was
diluted with EtOAc, washed with a saturated solution of sodium
bicarbonate and brine. The organic portion was dried over
MgSO.sub.4, filtered and concentrated under reduced pressure. The
resulting mixture was dissolved in MeOH and purified on an
Isolute.RTM. SCX-2 cartridge eluting with MeOH followed by 2N
ammonia in MeOH. Further purification was carried out using 0-100%
EtOAc in iso-hexane and then 0-15% MeOH in EtOAc to afford the
title product as a solid;
[0607] LC-MS: Rt 0.84 mins; MS m/z 423.3 and 425.3 [M+H]+; Method
2minLowpHv01
[0608] 1H NMR (400 MHz, d.sub.6-DMSO) .delta. 12.15-11.90 (1H, br
s), 7.67-7.60 (2H, m), 7.48 (1H, s), 7.40-7.37 (2H, m), 7.32-7.28
(2H, m), 6.52-6.47 (1H, br d), 5.10 (2H, s), 3.94-3.85 (3H, m),
3.09-2.97 (2H, m), 1.85-1.78 (2H, m), 1.44-1.35 (2H, m) (acquired
at 363K)
Example 10
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-6-oxohexano-
ic acid
##STR00063##
[0609] Step 1: 3,5-Dichlorobenzyl
4-(6-ethoxy-6-oxohexanamido)piperidine-1-carboxylate
[0610] To a suspension of adipic acid mono ethyl ester (154 mg,
0.883 mmol) and 3,5-dichlorobenzyl 4-aminopiperidine-1-carboxylate
HCl salt (Example 9, step 2)(300 mg, 0.883 mmol) in DMF (2 mL) was
added Huenig's base (0.771 mL, 4.42 mmol) and T3P.RTM. (50% in DMF)
(1.031 mL, 1.767 mmol) and the mixture was stirred at RT for 4 hrs.
The resulting mixture was diluted with EtOAc and washed with a
saturated solution of sodium bicarbonate. The organic portion was
dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. Purification was carried out by chromatography on silica
using 0-100% EtOAc in iso-hexane to afford the title product;
[0611] LC-MS; Rt 1.24 mins; MS m/z 459.1 and 461.1 [M+H]+; Method
2minLowpHv01
Step 2:
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-6-o-
xohexanoic acid
[0612] To a suspension of 3,5-dichlorobenzyl
4-(6-ethoxy-6-oxohexanamido)piperidine-1-carboxylate (step 1) (130
mg, 0.283 mmol) in THF (3 mL)/water (1 mL) was added LiOH.H.sub.2O
(26.1 mg, 0.623 mmol) and the reaction mixture stirred at RT for 3
hrs. The resulting mixture was diluted with water and EtOAc and the
aqueous portion acidified with 0.1M HCl solution (pH 5-6). The
resulting precipitate was collected by filtration and washed with
water to afford the title product;
[0613] LC-MS: Rt 4.35 mins; MS m/z 431.1, 433.1 [M+H]+; Method
10minLowpHv01
[0614] 1H NMR (400 MHz, d.sub.6-DMSO) .delta.12.0 (1H, s),
7.78-7.76 (1H, d), 7.58 (1H, s), 7.42 (2H, s), 5.08 (2H, s),
3.92-3.89 (2H, br d), 3.80-3.70 (1H, m), 3.10-2.87 (2H, br m),
2.2-2.18 (2H, t), 2.07-2.03 (2H, t), 1.77-1.7 (2H, m), 1.54-1.42
(4H, m), 1.32-1.20 (2H, m)
Example 11
3,5-Dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate
##STR00064##
[0615] Step 1: 3,5-Dichlorobenzyl
2-(2-((tert-butoxycarbonyl)amino)ethyl)morpholine-4-carboxylate
[0616] To a mixture comprising of t-butyl
(2-morpholin-2-ylethyl)carbamate (3 g, 13.03 mmol) in DCM (100 ml),
was added saturated aqueous sodium bicarbonate solution (100 ml,
13.03 mmol), followed by 3,5-dichlorobenzyl carbonochloridate (3.43
g, 14.33 mmol). The biphasic mixture was stirred at room
temperature for 2 hours. The resulting mixture was treated with 2M
NaOH solution (50 ml). The reaction mixture was separated and the
organic portion was dried over MgSO.sub.4 and concentrated under
reduced pressure to afford the title compound.
[0617] LCMS Rt=1.36 mins; MS m/z 433.4 [M+H]+; Method
2minLowpHv01.
Step 2: 3,5-Dichlorobenzyl
2-(2-aminoethyl)morpholine-4-carboxylate
[0618] A mixture comprising of 3,5-dichlorobenzyl
2-(2-((tert-butoxycarbonyl)amino)ethyl) morpholine-4-carboxylate
(step 1)(500 mg, 1.154 mmol) and trifluoroacetic acid (3556 .mu.l,
46.2 mmol) in DCM (3.8 ml) was stirred for 1 hour at room
temperature. The resulting mixture was concentrated under reduced
pressure and the crude product was diluted with EtOAc. The mixture
was washed with sat. NaHCO.sub.3 and the organic portion was
separated, dried over MgSO.sub.4, filtered and concentrated under
reduced pressure to afford the title compound;
[0619] LC-MS: Rt: 0.72 mins; MS m/z 333 [M+H]+; Method
2minLowpH_v01.
Step 3: 3,5-Dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)morpholine-4-carb-
oxylate
[0620] A mixture comprising of 3,4-diethoxycyclobut-3-ene-1,2-dione
(77 mg, 0.453 mmol) and triethylamine (253 .mu.l, 1.813 mmol) in
EtOH (1511 .mu.l) was stirred at 40.degree. C. for 20 minutes under
nitrogen. After cooling to room temperature, 3,5-dichlorobenzyl
2-(2-aminoethyl) morpholine-4-carboxylate (step 2) (151 mg, 0.453
mmol) was added dropwise and the reaction mixture was allowed to
stir at room temperature for a further 30 minutes. The resulting
reaction mixture was concentrated under reduced pressure and
diluted with EtOAc. The organic portion was washed with water,
dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. The crude material was dried loaded using silica onto an
ISCO 4 g column, eluting with 0-100% EtOAc in iso-hexane. The
product fractions were concentrated under reduced pressure to
afford the title compound;
[0621] LC-MS: Rt: 1.18 mins; MS m/z 457.0 [M+H]+; Method
2minLowpH_v01
[0622] 1H NMR (400 MHz, CDCl3). .delta. 7.35 (1H, d), 7.25 (2H, d),
6.45 (1H, d), 5.10 (2H, s), 4.80 (2H, s), 4.00 (3H, d), 3.70 (1H,
s), 3.55 (3H, s), 3.10 (1H, s), 2.75 (1H, s), 1.80 (5H, s).
Example 12
3,5-Dichlorobenzyl
2-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)morpholine-4-carboxyla-
te
##STR00065##
[0624] A mixture comprising of 3,5-dichlorobenzyl
2-(2-aminoethyl)morpholine-4-carboxylate (Example 11, step 2) (178
mg, 0.534 mmol), 2-oxo-2,3-dihydrooxazole-5-carboxylic acid
(Example 21, step 1) (68.9 mg, 0.534 mmol), T3P.RTM. (50% in DMF)
(510 mg, 0.801 mmol), Huenig's base (466 .mu.l, 2.67 mmol) in DMF
(1781 .mu.l) was stirred at room temperature. Another 1 equivalent
of 2-oxo-2,3-dihydrooxazole-5-carboxylic acid was added and the
reaction mixture was left stirring at room temperature overnight.
The resulting reaction mixture was concentrated under reduced
pressure and the crude product was diluted with EtOAc. The organic
portion was dried with MgSO.sub.4, filtered and concentrated under
reduced pressure. The crude material was dried loaded using silica
onto an ISCO 4 g column eluting with 0-100% EtOAc (1% acetic acid)
in iso-hexane. The product fractions were concentrated under
reduced pressure to afford the title compound;
[0625] 1H NMR (400 MHz, MeOD) .delta. 7.42 (2H, d), 7.43 (2H, s),
5.15 (2H, s), 3.95 (3H, d), 3.45 (4H, m), 3.08 (1H, s), 1.70 (3H,
m), 1.40 (1H, q).
Example 13
3,5-Dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)
ethyl)morpholine-4-carboxylate
##STR00066##
[0626] Step 1: 3,5-Dichlorobenzyl
2-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)morpholine-4-carboxylate
[0627] A mixture comprising of 3,5-dichlorobenzyl
2-(2-((tert-butoxycarbonyl)amino)ethyl) morpholine-4-carboxylate
(Example 11, step 1) (1 g, 2.308 mmol) and sodium hydride (60% in
oil) (0.111 g, 2.77 mmol) in DMF (20 mL) was stirred at 0.degree.
C. for 15 minutes. Iodomethane (0.216 mL, 3.46 mmol) was added and
the mixture was left to stir at room temperature for 16 hours. The
reaction was quenched with water (10 ml) to form a suspension. The
suspension was diluted with H.sub.2O (100 ml) and extracted with
EtOAc (200 ml). The organic portion was separated and washed with
H.sub.2O (100 ml), dried over MgSO.sub.4, filtered and concentrated
under reduced pressure to afford the title compound;
[0628] 1H NMR (400 MHz, CDCl3) .delta. 7.35 (1H, s), 7.25 (2H, s),
5.15 (2H, s), 3.50 (1H, d), 2.85 (2H, s), 2.75 (2H, s), 1.70 (9H,
s), 1.35 (6H, t), 0.85 (3H, d).
Step 2: 3,5-Dichlorobenzyl
2-(2-(methylamino)ethyl)morpholine-4-carboxylate
[0629] A mixture comprising of 3,5-dichlorobenzyl
2-(2-((tert-butoxycarbonyl)(methyl)amino)
ethyl)morpholine-4-carboxylate (step 1) (0.9984 g, 2.232 mmol) and
triflouroacetic acid (6.88 ml, 89 mmol) in DCM (7.44 ml) was
stirred at room temperature for 1 hour. The reaction mixture was
diluted with DCM (7.44 ml) and washed with water followed by sat
NaHCO.sub.3. The organic portion was separated, dried over
MgSO.sub.4, filtered and concentrated under reduced pressure to
afford the title compound.
[0630] 1H NMR (400 MHz, CDCl3) .delta. 7.35 (1H, d), 7.25 (2H, s),
5.10 (2H, s), 3.95 (3H, s), 3.60 (2H, t), 3.20 (3H, t), 2.75 (3H,
s), 1.90 (2H, d), 1.65 (1H, t), 1.30 (1H, s).
Step 3: 3,5-Dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)
morpholine-4-carboxylate
[0631] A mixture comprising of 3,5-dichlorobenzyl
2-(2-(methylamino)ethyl)morpholine-4-carboxylate (step 2)(169 mg,
0.487 mmol), 2-oxo-2,3-dihydrooxazole-5-carboxylic acid ((Example
21, step 1)) (161 mg, 0.487 mmol), T3P.RTM. (50% in DMF) (426
.mu.l, 0.730 mmol) and Huenig's base (425 .mu.l, 2.433 mmol) in DMF
(1622 .mu.l) was stirred at room temperature for 20 hours. The
resulting mixture was diluted with EtOAc and washed with water. The
organic portion was dried with MgSO.sub.4, filtered and
concentrated under reduced pressure. The crude material was dry
loaded with silica onto an ISCO 4 g column eluting with 0-100%
EtOAc (1% acetic acid) in iso-hexane. The product fractions were
concentrated under reduced pressure to afford the title
compound;
[0632] LC-MS: Rt: 0.48 mins; MS m/z 458 [M+H]+; Method
2minLowpH_v01.
[0633] 1H NMR (400 MHz, MeOD) .delta. 7.40 (1H, s). 7.35 (2H, d),
5.15 (2H, s), 3.95 (3H, s), 3.70 (1H, s), 3.55 (1H, m), 3.40 (2H,
m), 3.10 (4H, m), 2.85 (1H, m), 1.80 (2H, d), 1.35 (1H, d).
Example 14
3,5-Dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)(methyl)amino)ethyl)morpholin-
e-4-carboxylate
##STR00067##
[0635] A mixture comprising of 3,4-diethoxycyclobut-3-ene-1,2-dione
(29.0 .mu.l, 0.196 mmol) and triethylamine (1093 .mu.l, 7.84 mmol)
in EtOH (654 .mu.l) was stirred at 40.degree. C. for 20 minutes.
The reaction was allowed to cool back to room temperature and
3,5-dichlorobenzyl 2-(2-(methylamino)ethyl)morpholine-4-carboxylate
(Example 13, step 2) (68.1 mg, 0.196 mmol) was added. The reaction
mixture was allowed to stir at room temperature for 16 hours. The
resulting reaction mixture was concentrated under reduced pressure
and purification was carried our using preparative LC-MS. The
resulting product fractions were concentrated under reduced
pressure to give an aqueous solution and then extracted with EtOAc.
The organic extracts were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to afford the title
compound;
[0636] 1H NMR (400 MHz, CDCl3) .delta. 7.45 (1H, s), 7.25 (2H, s),
5.10 (2H, s), 4.40 (3H, s), 3.90 (4H, s), 3.5 (3H, s), 3.35 (1H,
s), 3.15 (1H, s), 3.05 (1H, s), 2.70 (1H, s), 1.25 (4H, s), 0.90
(1H, s).
Example 15
3,5-Dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)piperidine-1-
-carboxylate
##STR00068##
[0637] Step 1: 2-Methoxythiazole-5-carboxylic acid
[0638] To a solution of tert-butyl 2-chlorothiazole-5-carboxylate
(100 mg, 0.455 mmol) in MeCN (880 .mu.l) and MeOH (880 ul) was
added 5.4M NaOMe in MeOH (337 .mu.l, 1.821 mmol) followed by 2M
NaOH (881 .mu.l, 1.762 mmol). The reaction mixture was heated to
80.degree. C. overnight and, after cooling to RT, the mixture was
evaporated under reduced pressure. The residue was acidified with a
minimal volume of 6M aqueous hydrochloric acid. The resulting
precipitate was filtered, washed with water and dried in a high
vacuum oven overnight to afford the title compound;
[0639] LCMS: Rt 0.68 mins MS m/z 160.3 [M+H]+ Method
2minLowpHv01
Step 2: 2-Oxo-2,3-dihydrothiazole-5-carboxylic acid
[0640] 2-Methoxythiazole-5-carboxylic acid (step 1) (45.5 mg, 0.286
mmol) was solubilised in MeOH (2 ml) and treated with 5.4M NaOMe in
MeOH (212 .mu.l, 1.143 mmol) followed by 2M NaOH (572 .mu.l, 1.143
mmol). The reaction mixture was refluxed overnight and after
cooling to RT, the solvent was evaporated under reduced pressure.
The residue was acidified with 6M aqueous hydrochloric acid and
aqueous layer extracted with EtOAc. The organics were combined and
dried over MgSO.sub.4 (anh) filtered and evaporated under reduced
pressure resulting in a pale yellow solid.
[0641] LCMS: Rt 0.33 mins MS m/z 146.1 [M+H]+ Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrothiazole-5-carboxamido)ethyl)
piperidine-1-carboxylate
[0642] 2-Oxo-2,3-dihydrothiazole-5-carboxylic acid (33 mg, 0.227
mmol) and 3,5-dichlorobenzyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate (Example 1, step
3) (79 mg, 0.227 mmol) was dissolved in DMF (1 ml) and treated with
DIPEA (159 .mu.l, 0.909 mmol). The reaction mixture was stirred for
5 mins at RT and then treated with 50% T3P.RTM. solution in DMF
(265 .mu.l, 0.455 mmol) and stirring continued at RT overnight. The
reaction mixture was evaporated under reduced pressure and the
residue was dissolved in EtOAc and washed with 10% citric acid. The
organic layer was dried over MgSO.sub.4 (anh), filtered and
evaporated under reduced pressure. The resultant crude material was
solubilised in minimal DCM and loaded on to a 1 g Isolute.RTM.
SCX/PEAX cartridge pre-wetted with DCM and eluted with MeOH and the
product fractions were evaporated under reduced pressure. Further
purification was carried out using preparative LC-MS to afford the
title compound together with a small amount of TFA. To remove the
TFA, the mixture was dissolved in EtOAc and washed with water,
dried over MgSO4 (anh), filtered and evaporated to yield an oil.
The oil was dried in the high vacuum oven overnight to afford the
title compound;
[0643] LCMS: Rt 1.26 mins MS m/z 472.1 [M+H]+ Method
2minLowpHv01
[0644] NMR: 1H NMR (400 MHz, CDCl3) .delta. 9.01 (1H, s), 7.33 (1H,
s), 7.28 (2H, s), 5.09 (2H, s), 4.18 (2H, m), 3.54 (2H, t), 3.17
(3H, s), 2.83 (2H, br m), 1.76 (2H, d), 1.60 (2H, m), 1.50 (1H, m),
1.22 (2H, m).
Example 16
3,5-Dichlorobenzyl
4-(2-(2H-tetrazole-5-carboxamido)ethyl)piperidine-1-carboxylate
##STR00069##
[0646] Under nitrogen, oxalyl chloride (58 .mu.l, 0.657 mmol) was
dissolved in MeCN (0.5 ml) and cooled to -20.degree. C. DMF (25
.mu.l, 0.329 mmol) was added and the reaction mixture was stirred
for 15 minutes. Potassium 5-carboxytetrazol-1-ide (50 mg, 0.329
mmol) was added and the reaction mixture was stirred for a further
20 minutes. A suspension of 3,5-dichlorobenzyl
4-(2-aminoethyl)piperidine-1-carboxylate (Example 3, step 1) (109
mg, 0.329 mmol) and pyridine (32 .mu.l, 0.394 mmol) in MeCN (2 ml)
was added and after warming to RT, the reaction mixture was heated
at reflux for 1 hr then was allowed to cool. The mixture was
evaporated under reduced pressure and the crude product was
purified by preparative LC-MS. The product fractions were
evaporated under reduced pressure and the residue was partitioned
between EtOAc and water. The organic layer was separated, dried
over MgSO.sub.4 (anh), filtered and evaporated under reduced
pressure to afford the title product.
[0647] LCMS: Rt 1.30 mins MS m/z 427.6 [M+H]+ Method
2minLowpHv01
[0648] NMR: 1H NMR (400 MHz, CDCl3) .delta. 7.70 (1H, s), 7.32 (1H,
t), 7.27 (2H, s), 5.09 (2H, s), 4.21 (2H, br s), 3.64 (2H, q), 2.83
(2H, br s), 1.81 (2H, d), 1.71-1.55 (3H, m), 1.30-1.20 (4H, m--2
extra protons seen from impurity in sample).
Example 17
3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00070##
[0649] Step 1: 3,5-Dichlorobenzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate
[0650] A solution of tert-butyl piperidin-4-ylcarbamate (2.0 g,
9.99 mmol) in DCM (40 ml) was treated with sodium bicarbonate
solution (50 ml, 9.99 mmol) followed by a solution of
3,5-dichlorobenzyl carbonochloridate (2.392 g, 9.99 mmol) in DCM
(10 ml). The reaction mixture was stirred vigorously at RT until
gas evolution ceased. The organic layer was separated, dried over
MgSO4 (anh), filtered and evaporated under reduced pressure,
yielding the title compound as colourless oil that solidified on
standing;
[0651] LCMS: Rt 1.38 mins MS m/z 303.2 [M+H-Boc]+ Method
2minLowpHv01
Step 2: 3,5-Dichlorobenzyl 4-aminopiperidine-1-carboxylate
[0652] 3,5-Dichlorobenzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate (step 1)
(3.53 g, 8.75 mmol) was dissolved in DCM (20 ml). 4M HCl in dioxane
(22 ml, 88 mmol) was added which resulted in the formation of a
white solid. After gas evolution ceased, DCM (20 ml) was added and
the reaction mixture was stirred vigorously for 4 hrs. The
resulting mixture was filtered and the white solid was dried in a
vacuum oven under reduced pressure to afford the title compound as
a hydrochloride salt;
[0653] LCMS: Rt 0.75 mins MS m/z 303.1 [M+H]+ Method
2minLowpHv01
Step 3: 4-(1-Benzyl-1H-1,2,3-triazol-4-yl)butanoic acid
[0654] Benzyl azide (2.82 ml, 21.18 mmol) was dissolved in
tert-butanol (212 ml) and water (212 ml). Hex-5-ynoic acid (2.337
ml, 21.18 mmol) was added followed by copper (II) acetate (385 mg,
2.118 mmol) and sodium L-ascorbate (837 mg, 4.24 mmol) and the
reaction mixture was stirred vigorously for 72 hrs. Sodium chloride
(solid) was added to the reaction mixture followed by EtOAc (100
ml). The phases separated and the aqueous layer was further
extracted with EtOAc. The organics phases were combined, dried over
MgSO.sub.4 (anh), filtered and evaporated under reduced pressure to
afford the title compound;
[0655] LCMS: Rt 0.81 mins MS m/z 246.5 [M+H]+ Method
2minlowpHv01
Step 4: 4-(1H-1,2,3-Triazol-4-yl)butanoic acid
[0656] 4-(1-Benzyl-1H-1,2,3-triazol-4-yl)butanoic acid (step 3)
(5.34 g, 21.77 mmol) was dissolved in EtOH (435 ml) and
re-circulated through a 75 mm 10% Pd/C catalyst cartridge and
hydrogenated using the H-Cube continuous flow hydrogenation at
60.degree. C., 30 bar pressure for hr. The reaction mixture was
evaporated under reduced pressure to afford the title compound;
[0657] LCMS: Rt 0.33 mins MS m/z 156.2 [M+H]+ Method
2minLowpHv01
Step 5: 3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0658] 4-(1H-1,2,3-Triazol-4-yl)butanoic acid (step 4) (882 mg,
4.95 mmol) and 3,5-dichlorobenzyl 4-aminopiperidine-1-carboxylate
hydrochloride (step 2) (1.5 g, 4.95 mmol) were suspended in DMF (20
ml). DIPEA (4.32 ml, 24.74 mmol) was added and the reaction mixture
stirred until all components were in solution. 50% T3P.RTM.
solution in DMF (5.78 ml, 9.89 mmol) was added and the reaction
mixture was stirred at RT for 48 hrs. The reaction mixture was
diluted with EtOAc and washed twice with 10% citric acid. The
aqueous citric acid wash was extracted with DCM (3.times.) and the
combined extracted were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified by
flash chromatography, using a gradient solvent system of 0-10% MeOH
in EtOAc. The resulting product was further purified by stirring in
diethyl ether over 72 hours. The mixture was filtered and the solid
was dried in a vacuum oven to afford the title compound;
[0659] LCMS: Rt 1.06 mins MS m/z 440.2 [M+H]+ Method
2minLowpHv01.
[0660] NMR: 1H NMR (400 MHz, DMSO-d6) .delta. 15.09-14.21 (1H, br
s), 7.77 (1H, d), 7.58 (1H, br s), 7.56 (1H, d), 7.41 (2H, d), 5.06
(2H, s), 3.89 (2H, m), 3.76 (1H, m), 2.96 (2H, m), 2.61 (2H, t),
2.08 (2H, t), 1.84 (2H, m), 1.72 (2H, m), 1.24 (2H, m).
Example 18
3,5-Dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00071##
[0661] Step 1: 3,5-Dichlorobenzyl
4-((tert-butoxycarbonyl)(methyl)amino)piperidine-1-carboxylate
[0662] A solution of tert-butyl methyl(piperidin-4-yl)carbamate
(1.25 g, 5.83 mmol), 3,5-dichlorobenzyl carbonochloridate (1.537 g,
6.42 mmol) and sat. sodium bicarbonate (0.583 ml, 5.83 mmol) in DCM
(15 ml) was stirred at RT for 72 hrs. The resulting mixture was
extracted with DCM and the combined organic extracts were dried
over MgSO.sub.4, filtered and concentrated under pressure to afford
the title compound which was used without further purification.
Step 2: 3,5-Dichlorobenzyl
4-(methylamino)piperidine-1-carboxylate
[0663] 3,5-Dichlorobenzyl
4-((tert-butoxycarbonyl)(methyl)amino)piperidine-1-carboxylate (2.4
g, 5.75 mmol) in DCM (13 ml) was treated with and 4M HCl in dioxane
(14.38 ml, 57.5 mmol) to give a colourless solution. The mixture
was stirred for 3.5 hours at room temperature and then concentrated
under reduced pressure to afford the title compound which was used
without further purification;
[0664] LC-MS: Rt 0.73 mins; MS m/z 315 [M+H]+; Method
2minLowpH_v01
Step 3: 3,5-Dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0665] 4-(1H-1,2,3-Triazol-4-yl)butanoic acid (Example 17, step 4)
(200 mg, 1.289 mmol) and 3,5-dichlorobenzyl
4-(methylamino)piperidine-1-carboxylate (Step 2) (456 mg, 1.289
mmol) were dissolved in DMF (6 ml) and treated with DIPEA (1.126
ml, 6.45 mmol) followed by 50% T3P.RTM. in DMF (1.505 ml, 2.58
mmol). After stirring at RT for 9 days, the mixture was evaporated
under reduced pressure. The crude product was solubilised in DCM
and washed with 10% citric acid. The organic portion was passed
through a phase separating cartridge and the filtrate was
evaporated under reduced pressure. The crude residue was purified
by chromatography on silica eluting with 0-10% MeOH in EtOAc to
afford the title compound;
[0666] LCMS: Rt 1.18 mins MS m/z 454.2 [M+H]+ Method
2minLowpHv01
[0667] NMR 1H (400 MHz, DMSO-d6) .delta. 7.52 (1H, s), 7.48 (1H,
s), 7.39 (2H, d), 5.09 (2H, s), 4.10 (2H, d), 2.90 (2H, t), 2.74
(3H, s), 2.69 (2H, t), 2.37 (2H, t), 1.88 (2H, m), 1.56 (5H, m)
(carried out at 363K)
Example 19
3,5-Dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate
##STR00072##
[0668] Step 1: 3-(1-Benzyl-1H-1,2,3-triazol-4-yl)propanoic acid
[0669] Benzyl azide (2.82 ml, 21.18 mmol) was dissolved in
tert-butanol (212 ml) and water (212 ml). Pent-4-ynoic acid (2.078
g, 21.18 mmol) was added followed by copper (II) acetate (385 mg,
2.118 mmol) and sodium L-ascorbate (837 mg, 4.24 mmol) and the
reaction mixture was stirred vigorously overnight. Sodium chloride
(solid) was added to the reaction mixture followed by EtOAc. The
phases separated and the aqueous layer was further extracted with
EtOAc. The organic phases were combined, dried over MgSO.sub.4
(anh), filtered and evaporated under reduced pressure and dried in
a vacuum oven to afford the title compound;
[0670] LCMS: Rt 0.76 mins MS m/z 232.2 [M+H]+ Method
2minLowpHv01
Step 2: 3-(1H-1,2,3-Triazol-4-yl)propanoic acid
[0671] 3-(1-Benzyl-1H-1,2,3-triazol-4-yl)propanoic acid (step 1)
(4.37 g, 18.90 mmol) was dissolved in EtOH and stirred for 10 mins
with activated charcoal (1.13 g) and of Celite.RTM. (filter
material). The reaction mixture was filtered and transferred into a
400 mL Duran Bottle. The colorless solution was set on a continuous
cycle at 30 bar pressure and 70.degree. C. through the H-Cube
(continuous flow hydrogenation) for 24 hrs. The resulting material
was concentrated under reduced pressure and the crude product was
suspended in ether and filtered to afford the title compound;
Step 3: 3,5-Dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate
[0672] 3-(1H-1,2,3-Triazol-4-yl)propanoic acid (step 2) (42 mg,
0.294 mmol) and 3,5-dichlorobenzyl 4-aminopiperidine-1-carboxylate
hydrochloride (Example 17, step 2) (100 mg, 0.294 mmol) were
dissolved in DMF (1 ml) and treated with DIPEA (257 .mu.l, 1.472
mmol) followed by 50% T3P.RTM. solution in DMF (344 .mu.l, 0.589
mmol). The reaction mixture was stirred at RT for 2 days and then
concentrated under reduced pressure. The crude product was
dissolved in DCM and washed with 10% citric acid. The organic
portion was separated, dried over MgSO4 (anh), filtered and
evaporated under reduced pressure. Purification by chromatography
on silica eluting with 0-10% MeOH in EtOAc afforded the title
compound;
[0673] LCMS: Rt 1.05 mins MS m/z 426.1 [M+H]+ Method
2minLowpHv01
[0674] 1H NMR (400 MHz, MeOD-d4) .delta. 8.00 (1H, d), 7.67-7.49
(1H, br m), 7.40 (1H, t), 7.34 (2H, d), 5.10 (2H, s), 4.07 (2H, d),
3.91-3.81 (1H, m), 3.04 (4H, m), 2.56 (2H, t), 1.84 (2H, dd), 1.34
(2H, m).
Example 20
3,5-Dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate
##STR00073##
[0675] Step 1: 1-(Azidomethyl)-4-methoxybenzene
[0676] To 4-methoxybenzyl chloride (8.52 mL, 62.8 mmol) in DMF (40
ml) was added sodium azide (4.08 g, 62.8 mmol). The suspension
formed was stirred at RT for 24 hrs. The reaction mixture was
diluted with ether (400 ml) and washed with water (2.times.200 mL)
and brine (20 ml). The organic layers were dried (MgSO.sub.4) and
concentrated (water bath temp 20.degree. C.) under reduced pressure
to afford the title compound;
Step 2: 5-(1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)pentanoic
acid
[0677] 1-(Azidomethyl)-4-methoxybenzene (259 mg, 1.585 mmol) was
solubilised in t-BuOH (15.9 ml). Hept-6-ynoic acid (201 .mu.l,
1.585 mmol) was added followed by water (15.9 ml) copper acetate
(28.2 mg, 0.159 mmol) and sodium L-ascorbate (63 mg, 0.317 mmol).
The reaction mixture was stirred at RT for 72 hrs. Sodium chloride
was added and the mixture was stirred vigorously. EtOAc was added
and the phases were separated. The aqueous layer was re-extracted
with EtOAc and the combined organics were treated with charcoal
& MgSO.sub.4 (anh), stirring for 5 minutes. The resulting
mixture was filtered and the filtrate was evaporated under reduced
pressure to afford the title compound;
[0678] LCMS: Rt 0.87 mins MS m/z 290.3 [M+H]+ Method
2minLowpHv01
Step 3: 5-(1H-1,2,3-Triazol-4-yl)pentanoic acid
[0679] 5-(1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)pentanoic acid
(464 mg, 1.604 mmol) was solubilised in EtOH (32.1 ml) and
hydrogenated at 30 bar, 70.degree. C. using a H-Cube apparatus,
with a 10% Pd/C catcart cartridge (small). The reaction mixture was
recirculated overnight and then concentrated under reduced pressure
to afford the title compound;
[0680] LCMS: Rt 0.54 mins MS m/z 170.1 [M+H]+ 170.1 Method
2minLowpHv01
Step 4: 3,5-Dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate
[0681] 5-(1H-1,2,3-Triazol-4-yl)pentanoic acid (step 3) (50 mg,
0.294 mmol) and 3,5-dichlorobenzyl 4-aminopiperidine-1-carboxylate
hydrochloride (Example 17, step 2) (100 mg, 0.294 mmol) were
dissolved in DMF (1 ml). DIPEA (257 .mu.l, 1.472 mmol) was added
followed by 50% T3P.RTM. solution in DMF (344 .mu.l, 0.589 mmol).
The reaction mixture was stirred at RT for 96 hrs and concentrated
under reduced pressure. The crude product was dissolved in DCM and
washed with 10% citric acid. The organic portion was separated,
dried over MgSO4 (anh), filtered and evaporated under reduced
pressure. Purification by preparative HPLC afforded product
fractions that were concentrated to afford a residue. The residue
was dissolved in DCM and washed with a minimal volume of water,
dried over MgSO.sub.4 (anh) filtered and evaporated under reduced
pressure to afford the title compound;
[0682] LCMS Rt 1.10 mins MS m/z 454.2 [M+H]+ Method
2minLowpHv01
[0683] 1H NMR (400 MHz, MeOD-d4) .delta. 8.09 (1/4H, s), 7.99
(1/2H, d), (due to exchange) 7.56 (1H, s) 7.41 (1H, t), 7.34 (2H,
d), 5.11 (2H, s), 4.10 (2H, d), 3.86 (1H, m), 3.110-02.89 (2H, br
m), 2.76 (2H, t), 2.22 (2H, t), 1.87 (2H, m), 1.68 (4H, m), 1.38
(2H, m).
Example 21
3,5-Dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te
##STR00074##
[0684] Step 1: 2-Oxo-2,3-dihydrooxazole-5-carboxylic acid
[0685] Ethyl 2-chlorooxazole-5-carboxylate (1.816 g, 10.34 mmol)
was solubilised in MeCN (20 ml) and MeOH (20 ml). Sodium methoxide
(9 ml, 25% solution in MeOH, 41.4 mmol) was added and the reaction
mixture was heated at reflux overnight. The solvent was removed
under reduced pressure and the crude product was dissolved in MeOH
(20 ml) and 2M NaOH(aq) (20 ml) and stirred at RT overnight. The
resulting mixture was acidified with 1M HCl and evaporated under
reduced pressure. The residue was triturated with a minimal volume
of 5M HCl and filtered. The solid was slurried with ice chips
(approx. 10 ml), filtered, washed with water and dried under high
vacuum to afford the title compound;
[0686] LCMS: Rt 0.26 mins MS m/z 127.8 [M-H]- Method
2minLowpHv01
Step 2: Tert-butyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te
[0687] The title compound was prepared from
2-oxo-2,3-dihydrooxazole-5-carboxylic acid (step 1) and tert-butyl
4-(2-aminoethyl)piperidine-1-carboxylate analogously to Example 20
step 4;
[0688] LCMS: Rt 0.95 mins MS m/z 338.4 [M-H]- Method
2minLowpHv01
Step 3:
2-Oxo-N-(2-(piperidin-4-yl)ethyl)-2,3-dihydrooxazole-5-carboxamide
[0689] Tert-butyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te (step 2) (257.8 mg, 0.760 mmol) was solubilised in DCM (1.5 ml).
4M HCl in dioxane (1.9 ml, 7.60 mmol) was added and the reaction
mixture stirred at RT. After all gas had ceased to be evolved, the
reaction mixture was solubilised with in MeOH and evaporated under
reduced pressure to afford the title compound;
Step 4: 3,5-Dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1-carboxyla-
te
[0690]
2-Oxo-N-(2-(piperidin-4-yl)ethyl)-2,3-dihydrooxazole-5-carboxamide
(step 3) (210 mg, 0.76 mmol) was suspended in DCM (2 ml). DIPEA
(265 .mu.l, 1.52 mmol) was added and the reaction mixture sonicated
to aid dissolution. 3,5-dichlorobenzyl carbonochloridate (182 mg,
0.76 mmol) in DCM (2 ml) was added and the mixture was left
stirring vigorously at RT overnight. The resulting mixture was
diluted with DCM and washed with citric acid (emulsion formed).
Brine was added and organics were separated, dried over MgSO4
(anh), filtered and evaporated under reduced pressure. The crude
product was purified by chromatography on silica eluting with
75-100% EtOAc in iso-hexane to afford the title compound;
[0691] LCMS: Rt 1.17 mins MS m/z 442.4 [M+H]+ Method
2minLowpHv001
[0692] 1H NMR (400 MHz, MeOD-d4) .delta. 7.41 (2H, s), 7.34 (2H,
d), 5.11 (2H, s), 4.20-4.08 (2H, br m), 3.38 (2H, t), 2.96-2.76
(2H, br m), 1.80 (2H, d), 1.55 (3H, m), 1.15 (2H, m).
Example 22
3,5-Dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e
##STR00075##
[0693] Step 1: tert-Butyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e
[0694] The title compound was prepared from commercially available
3-(3-hydroxyisoxazol-5-yl)propanoic acid and tert-butyl
4-(2-aminoethyl)piperidine-1-carboxylate analogously to Example 21
(step 2);
[0695] LCMS: Rt 0.98 mins MS m/z 368.5 [M+H]+ Method
2minLowpHv001
Step 2:
3-(3-Hydroxyisoxazol-5-yl)-N-(2-(piperidin-4-yl)ethyl)propanamide
[0696] The title compound was prepared from tert-butyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e (step 1) analogously to Example 21 step 3;
Step 3: 3,5-Dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylat-
e
[0697]
3-(3-Hydroxyisoxazol-5-yl)-N-(2-(piperidin-4-yl)ethyl)propanamide
(step 2) (201 mg, 0.662 mmol) was suspended in DCM (2 ml). 2M NaOH
(1 ml, 2.00 mmol) was added and the reaction mixture stirred. To
the mixture was added a solution of 3,5-dichlorobenzyl
carbonochloridate (158 mg, 0.662 mmol) in DCM (1 ml) and the
reaction mixture was stirred vigorously overnight. The resulting
mixture was diluted with DCM and washed with citric acid. The
organics were separated and evaporated under reduced pressure. The
crude residue was dissolved in DMSO and purified by preparative
HPLC. The product fractions were concentrated under reduced
pressure and partitioned between EtOAc and water. The organics were
separated, dried over MgSO4 (anh) filtered and evaporated under
reduced pressure and dried in a high vacuum oven to afford the
title compound;
[0698] LCMS: Rt 1.17 mins MS m/z 470.1 [M+H]+ Method
2minLowpHv01
[0699] 1H NMR (400 MHz, MeOD-d4) .delta. 8.04 (1/4H, s), (due to
exchange) 7.41 (1H, t), 7.34 (2H, d), 5.72 (1H, s), 5.10 (2H, s),
4.13 (2H, m), 3.24 (1H, t), 2.87 (4H, m), 2.54 (2H, t), 1.74 (2H,
d), 1.44 (3H, m), 1.11 (2H, m) (1H under solvent peak).
Example 23
3,5-Dichlorobenzyl
4-(3-(3-hydroxyisoxazol-5-yl)propanamido)piperidine-1-carboxylate
##STR00076##
[0701] The title compound was prepared from commercially available
hydroxyisoxazol-5-yl)propanoic acid and 3,5-dichlorobenzyl
4-aminopiperidine-1-carboxylate hydrochloride (Ex 17, step 2)
analogously to Example 21 (step 4);
[0702] LCMS: Rt 1.10 mins MS m/z 442.1 [M+H]+ or 440.2 [M-H]-
Method 2minLowpHv0
Example 24
3,5-Dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)piperidine-1--
carboxylate
##STR00077##
[0703] Step 1: 2-Oxo-2,3-dihydrooxazole-4-carboxylic acid
[0704] The title compound was prepared from ethyl
2-oxo-2,3-dihydrooxazole-4-carboxylate analogously to Example 30
step 6;
[0705] LC-MS: Rt 0.32 mins; MS m/z 130.4 (M+H)+; Method
2minLowpHv01
Step 2: 3,5-Dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-4-carboxamido)ethyl)
piperidine-1-carboxylate
[0706] The title compound was prepared from
2-oxo-2,3-dihydrooxazole-4-carboxylic acid (step 1) and
3,5-dichlorobenzyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate
(Example 1, step 3) analogously to Example 15 step 3;
[0707] LCMS: Rt 1.21 mins MS m/z 454.4 [M-H]- Method
2minLowpHv01
Example 25
3,5-Dichlorobenzyl
4-(2-(5-hydroxy-N-methyl-1H-pyrazole-3-carboxamido)ethyl)piperidine-1-car-
boxylate
##STR00078##
[0709] The title compound was prepared from commercially available
5-hydroxy-1H-pyrazole-3-carboxylic acid and 3,5-dichlorobenzyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate (Example 1, step
3) analogously to Example 15 step 3;
[0710] LCMS Rt 1.17 mins MS m/z 455.5 [M+H]+ Method
2minLowpHv01
Example 26
3,5-Dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate
##STR00079##
[0711] Step 1: 1-tert-Butyl 4-(3,5-dichlorobenzyl)
piperazine-1,4-dicarboxylate
[0712] A solution of 1-Boc-piperazine (2.0 g, 10.74 mmol) in DCM
(30 ml) was treated with 2M NaOH (aq.) (10.74 ml, 21.48 mmol) and
stirred at RT. A solution of 3,5-dichlorobenzyl carbonochloridate
(2.57 g, 10.74 mmol) in DCM (10 ml) was added and stirring
continued at RT for 2.5 hrs. The resulting mixture was separated
and the organic portion was dried over MgSO4, filtered and
concentrated under reduced pressure to afford the title compound as
a white solid;
[0713] LCMS: Rt 1.42 mins MS M/z 291.4 [M+H-Boc]+ Method
2minLowpHv01
Step 2: 3,5-Dichlorobenzyl piperazine-1-carboxylate
[0714] 1-tert-Butyl 4-(3,5-dichlorobenzyl)
piperazine-1,4-dicarboxylate (step 1) (4.093 g, 10.51 mmol) was
solubilised in DCM (20 ml). 4M HCl in dioxane (26 ml, 105 mmol) was
added and the reaction mixture stirred until gas evolution ceased.
The resulting mixture was concentrated under reduced pressure and
treated with NaOH (aq.) to pH14. The organic portion was separated,
dried over MgSO.sub.4 (anh), filtered and evaporated under reduced
pressure to afford the title compound;
[0715] LCMS: Rt 0.69 mins MS m/z 289.3 [M+H]+ Method
2minLowpHv01
Step 3: Tert-butyl methyl(3-oxopropyl)carbamate
[0716] Commercially available tert-butyl
(3-hydroxypropyl)(methyl)carbamate (1.858 g, 9.82 mmol) was
solubilised in DCM (40 ml) and treated with sodium bicarbonate
(4.12 g, 49.1 mmol) followed by Dess-Martin reagent (5.21 g, 12.28
mmol). The reaction mixture was stirred at RT for 2 hrs and then
partitioned between DCM and sodium bicarbonate solution. Sodium
thiosulphate was added and the organic portion was separated. The
aqueous layer was extracted with DCM (.times.2) and the combined
organic extracts were dried over MgSO.sub.4 (anh), filtered and
evaporated under reduced pressure to afford the title compound
without further purification;
Step 4: 3,5-Dichlorobenzyl
4-(3-((tert-butoxycarbonyl)(methyl)amino)propyl)piperazine-1-carboxylate
[0717] Tert-butyl methyl(3-oxopropyl)carbamate (step 3) (1.528 g,
8.16 mmol) was solubilised in DCM (50 ml) and added to
3,5-dichlorobenzyl piperazine-1-carboxylate (step 2) (3.09 g, 9.82
mmol). The resulting mixture was treated with acetic acid (56
.mu.l, 0.982 mmol) and after stirring for 1 hr at RT, sodium
triacetoxyborohydride (4.16 g, 19.64 mmol) was added. The reaction
mixture was stirred at RT overnight and then quenched by addition
of 2M NaOH (aq.). The aqueous layer was basified to pH 14 with conc
NaOH solution. The organic layer was separated and the aqueous
layer was extracted with more DCM. The organic portions were
combined, dried over MgSO.sub.4 (anh), filtered and evaporated
under reduced pressure, yielding a yellow oil. The crude product
was purified by chromatography on silica eluting with 0-10% MeOH
(with ammonia) in DCM to afford the title compound;
[0718] LCMS: Rt 0.94 mins MS m/z 462.6 [M+H]+ Method
2minLowpHv01
Step 5: 3,5-Dichlorobenzyl
4-(3-(methylamino)propyl)piperazine-1-carboxylate
[0719] The title compound was prepared by acid hydrolysis of
3,5-dichlorobenzyl 4-(3-((tert-butoxycarbonyl)(methyl)
amino)propyl)piperazine-1-carboxylate (step 4) analogously to step
2;
[0720] LCMS: Rt 0.56 mins MS m/z 360.4 Method 2minLowpHv01
Step 6: 3,5-Dichlorobenzyl
4-(3-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)propyl)piperazine-1-
-carboxylate
[0721] The title compound was prepared from
2-oxo-2,3-dihydrooxazole-5-carboxylic acid (Example step 1) and
3,5-dichlorobenzyl
4-(3-(methylamino)propyl)piperazine-1-carboxylate (step 5)
analogously to Example 15 step 3;
[0722] LCMS: Rt 0.75 mins MS m/z 471.2 [M+H]+ Method
2minLowpHv01
Example 27
3,5-Dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te
##STR00080##
[0723] Step 1: 3,5-Dichlorobenzyl
4-(2-((tert-butoxycarbonyl)amino)ethyl)piperazine-1-carboxylate
[0724] 3,5-Dichlorobenzyl piperazine-1-carboxylate (Example 26,
step 2) (3.466 mg, 11.99 mmol), potassium carbonate (4.97 g, 36
mmol) and triethlyamine (5.01 ml, 36 mmol) were suspended in MeCN
(60 ml). tert-Butyl (2-bromoethyl)carbamate (3.49 g, 15.58 mmol)
was added and the reaction mixture was refluxed for 18 hrs at
80.degree. C. A further portion of tert-butyl
(2-bromoethyl)carbamate (1.05 g, 4.69 mmol) was added and heating
continued at 80.degree. C. for 3 hrs. After cooling to RT, the
reaction mixture was diluted with EtOAc and filtered. The organic
portion was evaporated under reduced pressure. The crude product
was solubilised in EtOAc and washed with 2M NaOH. The organic
portion was dried over MgSO.sub.4 (anh) filtered and evaporated
under reduced pressure. Purification by chromatography on silica
using a gradient solvent system of DCM to 10% MeOH with ammonia in
DCM afforded product fractions that were concentrated to give the
title compound;
[0725] LCMS: Rt 0.90 mins MS m/z 434.6 [M+H]+ Method
2minlowpHv01
Step 2: 3,5-Dichlorobenzyl
4-(2-aminoethyl)piperazine-1-carboxylate
[0726] The title compound was prepared from 3,5-dichlorobenzyl
4-(2-((tert-butoxycarbonyl)amino) ethyl)piperazine-1-carboxylate
(step 1) analogously to 3,5-dichlorobenzyl 4-(3-(methylamino)
propyl) piperazine-1-carboxylate (Ex 26 step 5);
[0727] LCMS: Rt 0.69 mins MS m/z 332.5 [M+H]+ Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperazine-1-carboxyla-
te
[0728] The title compound was prepared from
2-oxo-2,3-dihydrooxazole-5-carboxylic acid (Example step 1) and
3,5-dichlorobenzyl 4-(2-aminoethyl)piperazine-1-carboxylate (step
2) analogously to Example 15 step 3;
[0729] LCMS: Rt 0.75 mins MS m/z 443.4 [M+H]+ Method
2minLowpHv01
Example 28
3,5-Dichlorobenzyl
4-(2-(N-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxamido)ethyl)pip-
eridine-1-carboxylate
##STR00081##
[0731] The title compound was prepared from commercially available
5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxylic acid and
3,5-dichlorobenzyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate
(Example 1, step 3) analogously to Example 15 step 3;
[0732] LCMS: Rt 1.29 mins MS m/z 459.2 [M+H]+ Method
2minLowpHv0
Example 29
3,5-Dichlorobenzyl
4-(2-(N-methyl-2H-tetrazole-5-carboxamido)ethyl)piperidine-1-carboxylate
##STR00082##
[0734] The title compound was prepared from potassium
5-carboxytetrazol-1-ide and 3,5-dichlorobenzyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate (Example 1 step 3)
analogously to Example 16;
[0735] LCMS: Rt 1.30 mins MS m/z 441.6 [M+H]+ Method
2minLowpHv01
Example 30
(E)-N-(2-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)-N-methyl-
-2-oxo-2,3-dihydrooxazole-5-carboxamide
##STR00083##
[0736] Step 1: (E)-Methyl 3-(3,5-dichlorophenyl)acrylate
[0737] To 1,3-dichloro-5-iodobenzene (300 mg, 1.099 mmol) and
methyl acrylate (0.099 ml, 1.099 mmol) in DMF (10 ml) under
nitrogen was added [Pd(t-BuP)].sub.2 (56.1 mg, 0.110 mmol) and
triethylamine (0.306 ml, 2.199 mmol). The reaction mixture was
heated to 80.degree. C. for 2 h. The reaction mixture was diluted
with EtOAc and filtered through a silica cartridge (2 g). The
organic solution was washed with water, saturated sodium
bicarbonate solution, water and brine. The organic portion was
dried using a phase separating column and the solvent was removed
under reduced pressure to afford the title compound;
[0738] LC-MS Rt=1.34 mins; MS m/z=no mass ion; Method
2minLowpHv01.
[0739] 1H NMR (400 MHz, DMSO-d6): .delta. 7.87 (2H, d), 7.65 (1H,
d), 7.64 (1H, d), 6.85 (1H, d), 3.74 (3H, s).
Step 2: (E)-3-(3,5-Dichlorophenyl)acrylic acid
[0740] To (E)-methyl 3-(3,5-dichlorophenyl)acrylate (step 1) (2 g,
8.66 mmol) in THF (35 ml) was added 2M NaOH (12.98 ml, 26.0 mmol)
and the reaction mixture was stirred at RT overnight. The solvent
was removed under reduced pressure and the residue was dissolved in
water and washed with EtOAc. The aqueous portion was acidified to
pH 4 using 1M HCl and extracted with DCM. The organic portion was
dried using a phase separating column and the solvent removed under
reduced pressure to afford the title compound as a white solid;
[0741] LC-MS: Rt=1.17 mins; MS m/z=217.0 [M+H]+; Method
2minLowpHv01.
[0742] 1H NMR (400 MHz, DMSO-d6): .delta. 12.60 (1H, broad), 7.83
(2H, d), 7.64 (1H, s), 7.55 (1H, d), 6.72 (1H, d).
Step 3: (E)-tert-Butyl
(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)carbamate
[0743] To (E)-3-(3,5-dichlorophenyl)acrylic acid (step 2) (1.365 g,
6.29 mmol) in NMP (12 ml) was added HATU (2.87 g, 7.55 mmol) and
the mixture was stirred for 5 minutes at RT. tert-Butyl
(2-(piperidin-4-yl)ethyl)carbamate (1.436 g, 6.29 mmol) was added
followed by DIPEA (3.30 ml, 18.87 mmol) and stirring continued at
RT overnight. The reaction mixture was poured into water and
extracted with EtOAc. The organic portion was washed with water,
saturated sodium bicarbonate solution, water, brine and dried using
a phase separating column and the solvent removed under reduced
pressure. The crude material was purified by chromatography on
silica eluting with 0-100% EtOAc in iso-hexane to afford the title
compound;
[0744] LC-MS: Rt=1.42 mins; MS m/z=427.2 [M+H]+; Method
2minLowpHv01.
[0745] 1H NMR, (400 MHz, DMSO-d6): .delta. 7.88 (1H, s), 7.87 (1H,
s), 7.58 (1H, s), 7.43 (2H, d), 6.79 (1H, t), 4.45 (1H, d), 4.31
(1H, d), 3.06-2.92 (2H, m), 2.62 (1H, m), 1.73 (2H, m), 1.55 (1H,
m), 1.42-1.28 (12H, m), 1.01 (2H, m)
Step 4:
(E)-1-(4-(2-Aminoethyl)piperidin-1-yl)-3-(3,5-dichlorophenyl)prop--
2-en-1-one
[0746] To (E)-tert-butyl
(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)carbamate
(step 3) (400 mg, 0.936 mmol) in DCM (5 ml) was added TFA (0.865
ml, 11.23 mmol) and the mixture was stirred at RT for 1 h. The
solvent was removed under reduced pressure and the crude material
was dissolved in MeOH and loaded on to an Isolute.RTM. SCX-2
cartridge (10 g). The cartridge was washed with excess MeOH. The
product was eluted using 2.0 M ammonia in MeOH and the solvent
removed under reduced pressure to afford the title compound as a
white solid;
[0747] LC-MS: Rt=0.83 mins; MS m/z=327.2 [M+H]+; Method
2minLowpHv01.
[0748] 1H NMR, (400 MHz, DMSO-d6): .delta. 7.87 (2H, m), 7.58 (1H,
s), 7.48-7.37 (2H, m), 4.45 (1H, d), 4.30 (1H, d), 3.29 (2H,
broad), 3.04 (2H, t), 2.73-2.55 (3H, m), 1.81-1.46 (4H, m), 1.01
(2H, m).
Step 5:
(E)-3-(3,5-Dichlorophenyl)-1-(4-(2-(methylamino)ethyl)piperidin-1--
yl)prop-2-en-1-one
[0749]
(E)-1-(4-(2-Aminoethyl)piperidin-1-yl)-3-(3,5-dichlorophenyl)prop-2-
-en-1-one (step 4) (150 mg, 0.458 mmol) was dissolved in DCM (1.528
ml). Formaldehyde (37% in water, 0.034 ml, 0.458 mmol) was added
followed by acetic acid (2.62 .mu.l, 0.046 mmol) and the mixture
was stirred at RT for 5 mins. Sodium triacetoxyborohydride (194 mg,
0.917 mmol) was added and stirring continued at RT overnight. 2M
NaOH was added and the mixture was stirred for 10 minutes. The
organic portion was separated, diluted with DCM and dried using a
phase separating column. The solvent was removed under reduced
pressure to afford a colourless oil. The oil was loaded onto an
Isolute.RTM. SCX-2 cartridge (1 g) and washed with excess MeOH. The
product was eluted using 2.0M ammonia in MeOH and the solvent
removed under reduced pressure to afford the title compound as a
mixture with
(E)-1-(4-(2-aminoethyl)piperidin-1-yl)-3-(3,5-dichlorophenyl)prop-2--
en-1-one and
(E)-3-(3,5-dichlorophenyl)-1-(4-(2-(dimethylamino)ethyl)piperidin-1-yl)pr-
op-2-en-1-one as a clear film.
Step 6: 2-Oxo-2,3-dihydrooxazole-5-carboxylic acid
[0750] To a solution of ethyl
2-oxo-2,3-dihydrooxazole-5-carboxylate (300 mg, 1.909 mmol) in THF
(5 ml) was added LiOH.H.sub.2O (352 mg, 8.4 mmol) as a solution in
water (5 ml). The mixture was stirred at room temperature
overnight. The solvent was removed under reduced pressure. To the
residue was added 4M HCl in dioxane (6 ml, 24.0 mmol) and the solid
was sonicated for .about.1 minute. The solvent was removed under
reduced pressure to afford a yellow solid. The solid was
redissolved in MeOH and concentrated under reduced pressure. The
solid was dried in the vacuum oven to afford the title
compound;
[0751] LC-MS: Rt 0.26 mins; MS m/z 128.4 M-; Method
2minLowpHv01
[0752] 1H NMR (400 MHz, DMSO-d6) .delta. 11.46 (1H, broad), 7.53
(1H, s)
Step 7:
(E)-N-(2-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)--
N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamide
[0753] To the mixture containing
(E)-3-(3,5-dichlorophenyl)-1-(4-(2-(methylamino)ethyl)piperidin-1-yl)prop-
-2-en-1-one (step 5) (118 mg, 0.346 mmol) and
2-oxo-2,3-dihydrooxazole-5-carboxylic acid (step 7) (2.59 ml, 0.2M
solution in DMF, 0.519 mmol) and DIPEA (0.483 ml, 2.77 mmol) in DMF
(3.458 ml) was added T3P.RTM. (50% solution in EtOAc) (2.421 ml,
4.149 mmol). The reaction mixture was stirred at RT for 1 h. Water
was added to quench the excess T3P.RTM. and the solvent was removed
under reduced pressure. The residue was passed through an Isolute
SCX-2 cartridge (10 g) and washed with excess MeOH. The solvent was
removed under reduced pressure to afford a yellow oil which was
dried using a high vacuum oven. The crude material was purified
using preparative HPLC with water (+0.1% TFA) and acetonitrile
(+0.1% TFA) and the product fractions were concentrated under high
vacuum to afford the title compound as a clear film;
[0754] LC-MS: Rt=4.65 mins; MS m/z=452.2 [M+H]+; Method
10minLowpHv01.
[0755] 1H NMR, (400 MHz, DMSO-d6): .delta. 11.27 (1H, s), 7.91-7.83
(2H, m), 7.58 (1H, t), 7.56 (1H, d), 7.48-7.37 (2H, m), 5.76 (1H,
s), 4.43 (1H, d), 4.30 (1H, d), 3.45 (1H, m), 3.03 (4H, m), 2.63
(1H, m), 1.75 (2H, m), 1.50 (3H, m), 1.07 (2H, m).
Example 31
(E)-N-(2-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)ethyl)-2-oxo-2,-
3-dihydrooxazole-5-carboxamide
##STR00084##
[0757] To
(E)-1-(4-(2-aminoethyl)piperidin-1-yl)-3-(3,5-dichlorophenyl)pro-
p-2-en-1-one (Example 30, step 4) (110 mg, 0.336 mmol) and
2-oxo-2,3-dihydrooxazole-5-carboxylic acid (Example 21, step 1)
(167 mg, 0.504 mmol) in DMF (2 ml) was added DIPEA (0.470 mL, 2.69
mmol) and T3P.RTM. (50% in EtOAc, 1.571 ml, 2.69 mmol). The
reaction mixture was stirred at RT overnight.
[0758] The reaction was quenched with water and the mixture was
partitioned between water and EtOAc. The organic portion was
separated and concentrated under reduced pressure to afford a
yellow oil. Purification by preparative HPLC eluting with water
(+0.1% TFA) and acetonitrile (+0.1% TFA) afforded product fractions
which were concentrated under reduced pressure to afford the title
compound as a white solid;
[0759] LC-MS: Rt=1.10 mins; MS m/z=438.5 [M+H]+; Method
2minLowpHv01.
[0760] 1H NMR, (400 MHz, DMSO-d6): .delta. 11.24 (1H, s), 8.21 (1H,
t), 7.91-7.83 (2H, m), 7.62-7.50 (2H, m), 7.49-7.32 (2H, m), 4.45
(1H, d), 4.31 (1H, d), 3.22 (2H, m), 3.03 (1H, m), 2.63 (1H, m),
1.84-1.68 (2H, m), 1.64-1.50 (1H, m), 1.49-1.38 (2H, m), 1.02 (2H,
m).
Example 32
3,5-Dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1--
carboxylate
##STR00085##
[0762] To 2-oxo-2,3-dihydrooxazole-5-carboxylic acid (Example 21,
step 1) (317 mg, 1.471 mmol) and 3,5-dichlorobenzyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate (Example 1, step
3)(508 mg, 1.471 mmol) in DMF (10 ml) was added DIPEA (0.257 ml,
1.471 mmol) and HATU (559 mg, 1.471 mmol). The orange suspension
formed was stirred at RT for 16 hrs. The mixture was concentrated
under reduced pressure and the residue was dissolved in EtOAc (100
ml). The mixture was filtered and the filtrate was dry loaded in
MeOH onto silica (.about.5 g). Purification was carried out by
chromatography on silica (12 g silica cartridge) eluting with
0-100% EtOAc/iso-hexane. The product fractions were combined and
concentrated to give a gum. This was dissolved in minimum volume of
EtOAc and applied to a combined 10 g Isolute.RTM. PEAX/SCX-2
cartridge. The column was washed with MeOH and the fractions
combined and concentrated under reduced pressure. The resultant
solid was dissolved in DMSO (500 .mu.l), MeCN (2 ml) and water and
applied to a 13 g C18 cartridge which was eluted with 0-100%
MeCN/water. The product fractions were combined and concentrated to
give an aqueous suspension which was extracted with EtOAc (50 ml).
The extracts were dried (MgSO.sub.4) and concentrated to give
3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3-dihydrooxazole-5-carboxamido)ethyl)piperidine-1--
carboxylate as a white solid.
[0763] LCMS: Rt=1.19 mins; MS m/z 456.1 and 458.1 [M+H]+; Method
2minLowpHv01
[0764] .sup.1H NMR (500 MHz, d6-DMSO, 333K) .delta. 11.08 (1H, br
s), 7.51 (1H, dd), 7.46 (1H, s), 7.39 (2H, d), 5.08 (2H, s), 3.97
(2H, m), 3.46 (2H, m), 3.02 (3H, br s), 2.83 (2H, m), 1.70 (2H, m),
1.41-1.54 (3H, m), 1.09 (2H, m).
Example 33
3,5-Dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate
##STR00086##
[0765] Step 1: Tert-butyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate
[0766] To 3-(3-hydroxyisoxazol-5-yl)propanoic acid (300 mg, 1.909
mmol) in DMF (7 mL) was added DIPEA (0.667 mL, 3.82 mmol) followed
by 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)
dimethylaminomorpholino)] uronium hexafluorophosphate (COMU) (981
mg, 2.291 mmol). The resulting brown solution was stirred at RT for
5 mins and then treated with 1-BOC-4-(aminomethyl)piperidine (409
mg, 1.909 mmol). After stirring at RT for hrs, the solution was
concentrated under reduced pressure and the residue suspended in
0.2M aqueous HCl (200 ml). The mixture was extracted with EtOAc
(2.times.100 ml) and the combined extracts were dried (MgSO.sub.4)
and concentrated under reduced pressure. The crude residue was
dissolved in DCM (100 ml) and treated with 2M NaOH (50 ml). The
mixture was stirred vigorously at ambient temperature for 16 hrs.
The mixture was then acidified with citric acid and the organics
removed, dried (MgSO.sub.4) and concentrated under reduced
pressure. The residue was applied to a 24 g silica cartridge and
eluted with 0-100% EtOAc/iso-hexane. The product fractions were
combined and concentrated to give a tert-butyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)
methyl)piperidine-1-carboxylate as a gum.
[0767] LCMS; Rt=0.91 mins; MS m/z 354.5 [M+H]+; Method
2minLowpHv01
Step 2:
3-(3-Hydroxyisoxazol-5-yl)-N-(piperidin-4-ylmethyl)propanamide
[0768] To tert-butyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate
(step 1) (539 mg, 1.525 mmol) in EtOAc (15 mL) was added 4N HCl in
dioxane (15 ml, 60.0 mmol). The suspension was stirred at RT for 2
hrs and then concentrated under reduced pressure to give
3-(3-hydroxyisoxazol-5-yl)-N-(piperidin-4-ylmethyl) propanamide as
a gum.
[0769] LCMS: Rt=0.58 mins; MS m/z 254.5 [M+H]+; Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)piperidine-1-carboxylate
[0770] To 3,5-dichlorobenzyl carbonochloridate (331 mg, 1.380 mmol)
and 3-(3-hydroxyisoxazol-5-yl)-N-(piperidin-4-ylmethyl)propanamide
(step 2) (200 mg, 0.690 mmol) in DCM (7 ml) was added 2M NaOH
solution (6.90 ml, 13.80 mmol) and the mixture stirred vigorously
at RT for hrs. The mixture was diluted with EtOAc (50 ml) and
acidified with 2M HCl. The organics were dried (MgSO.sub.4) and
concentrated under reduced pressure. The residue was dissolved in
MeOH/EtOAc and dry loaded onto silica (10 g). This was applied to a
12 g silica cartridge, eluting with 1% AcOH/EtOAc. The product
fractions were combined and concentrated under reduced pressure and
the residue was triturated with diethyl ether to afford
3,5-dichlorobenzyl
4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)
piperidine-1-carboxylate as a white solid.
[0771] LCMS solid; Rt=1.16 mins; MS m/z 456.2 and 458.2 [M+H]+ for
Cl isotopes; Method 2minLowpHv01
[0772] .sup.1H NMR (400 MHz, d6-DMSO) .delta. 10.99 (1H, s), 7.94
(1H, t), 7.56 (1H, t), 7.40 (2H, d), 5.71 (1H, s), 5.06 (2H, s),
3.97 (2H, m), 2.93 (2H, t), 2.81 (2H, t), 2.75 (2H, m), 2.41 (2H,
t), 1.56-1.60 (3H, m), 0.98 (2H, m).
Example 34
3,5-Dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate
##STR00087##
[0773] Step 1: 3,5-Dichlorobenzyl
4-(3-(tert-butoxycarbonylamino)propyl)piperazine-1-carboxylate
[0774] To tert-butyl 3-oxopropylcarbamate (213 mg, 1.231 mmol) and
3,5-dichlorobenzyl piperazine-1-carboxylate (Example 26, step 2)
(356 mg, 1.231 mmol) in DCM (10 ml) was added sodium
triacetoxyborohydride (522 mg, 2.462 mmol) and the suspension
stirred for 2 hrs. Further tert-butyl 3-oxopropylcarbamate (50 mg)
was added and the mixture stirred at ambient temperature for 16
hrs. The reaction mixture was diluted with DCM (100 ml) and
quenched with saturated sodium bicarbonate solution (50 ml). The
organic phase was separated, dried (MgSO.sub.4) and concentrated
under reduced pressure. The residue was applied to a 12 g silica
cartridge and eluted with 0-100% EtOAc/iso-hexane. The product
fractions were combined and concentrated to give 3,5-dichlorobenzyl
4-(3-(tert-butoxycarbonylamino) propyl)piperazine-1-carboxylate as
a gum.
[0775] LCMS: Rt=0.88 mins, MS m/z 446.5 and 448.5 [M+H]+ for Cl
isotopes; Method 2minLowpHv01
Step 2: 3,5-Dichlorobenzyl
4-(3-aminopropyl)piperazine-1-carboxylate
[0776] To 3,5-dichlorobenzyl
4-(3-(tert-butoxycarbonylamino)propyl)piperazine-1-carboxylate
(step 1) (438 mg, 0.981 mmol) in DCM (6 ml) was added TFA (3 ml,
38.9 mmol). The resulting solution was stirred for 1 hr and then
concentrated under reduced pressure. The residue was basified with
saturated sodium bicarbonate solution (50 ml) and extracted with
EtOAc (2.times.100 ml). The combined extracts were dried
(MgSO.sub.4) and concentrated to give 3,5-dichlorobenzyl
4-(3-aminopropyl) piperazine-1-carboxylate as a tan crystalline
solid; LCMS: Rt=0.54 mins; MS m/z 346.2 and 348.2 [M+H]+ for Cl
isotopes; Method 2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)piperazine-1-carboxylate
[0777] To 1H-1,2,3-triazole-4-carboxylic acid (32.7 mg, 0.289 mmol)
in DMF (2 ml) was added HATU (110 mg, 0.289 mmol) and DIPEA (0.050
ml, 0.289 mmol). The resulting yellow solution was stirred for 10
mins and treated with 3,5-dichlorobenzyl 4-(3-amino
propyl)piperazine-1-carboxylate (step 2) (100 mg, 0.289 mmol).
After stirring at ambient temperature for 4 hrs, the mixture was
diluted with EtOAc (50 ml) and washed with water (2.times.10 ml).
The organic extracts were dried (MgSO.sub.4) and concentrated under
reduced pressure. The residue was dissolved in DCM and applied to a
20 g silica cartridge eluting with 10% MeOH/DCM containing 1%
aqueous 880 ammonia. The product fractions were concentrated to
give 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazole-4-carboxamido)propyl)
piperazine-1-carboxylate as a white foam;
[0778] LCMS: Rt=0.74 mins; MS m/z 439.2 and 441.2 [M-H] for
chlorine isotopes; Method 2minLowpHv01
Example 35
3,5-Dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late
##STR00088##
[0780] The title compound was prepared analogously to Example 34,
step 3 from 1H-1,2,3-triazole-4-carboxylic acid and
3,5-dichlorobenzyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate
(Example 1, step 3) (200 mg, 0.579 mmol);
[0781] LCMS: Rt=1.23 mins; MS m/z 440.5 and 442.5 [M+H]+ for Cl
isotopes; Method 2minLowpHv01
Example 36
3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate
##STR00089##
[0782] Step 1: Tert-butyl
4-(2-(methylamino)ethyl)piperidine-1-carboxylate
[0783] Tert-butyl 4-(2-aminoethyl)piperidine-1-carboxylate (1.0 g,
4.38 mmol) was dissolved in DCM (40 ml) and treated with 36.5%
formaldehyde solution (326 .mu.l, 4.38 mmol) followed by acetic
acid (1 drop). The reaction mixture was stirred for 20 mins and
treated with sodium triacetoxyborohydride (93 mg, 0.438 mmol). The
resulting mixture was stirred at ambient temperature for 16 hrs and
quenched with 2M NaOH (40 ml). The mixture was extracted with DCM
(2.times.100 ml) and the combined organic extracts were dried
(MgSO.sub.4) and concentrated under reduced pressure to give
tert-butyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate as an
oil;
[0784] LCMS: Rt=0.64 mins; MS m/z 242.0 [M]+; Method
2minLowpHv01
Step 2: Tert-butyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late
[0785] To 1H-1,2,3-triazole-4-carboxylic acid (150 mg, 1.327 mmol)
and tert-butyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate
(step 1) (322 mg, 1.327 mmol) in DMF (6 ml) was added DIPEA (0.695
ml, 3.98 mmol) and 50% T3P.RTM. in DMF (1.549 ml, 2.65 mmol). The
resulting orange solution was stirred for 4 hrs. The mixture was
diluted with EtOAc (200 ml) and washed with 1M HCl (2.times.50 ml).
The organics were dried (MgSO.sub.4) and concentrated under reduced
pressure. The crude residue in was dissolved in DCM and applied to
a 12 g silica cartridge eluting with 0-100% EtOAc/iso-hexane. The
product fractions were concentrated to give tert-butyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late as a gum.
[0786] LCMS: Rt=1.01 mins; MS m/z 338.5 [M+H]+; Method
2minLowpHv01
Step 3:
N-Methyl-N-(2-(piperidin-4-yl)ethyl)-1H-1,2,3-triazole-4-carboxami-
de
[0787] To tert-butyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late (step 2) (190 mg, 0.563 mmol) in EtOAc (5 ml) was added 4N HCl
in dioxane (5 ml, 20.00 mmol). The mixture was stirred for 30 mins
and concentrated under reduced pressure to give crude
N-methyl-N-(2-(piperidin-4-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide
as a gum. This was used in the next step without further
purification.
Step 4: 3-Chloro-5-cyanobenzyl carbonochloridate
[0788] 3-Chloro-5-(hydroxymethyl) benzonitrile (25 g, 145 mmol) was
dissolved in THF (200 mL). The resulting yellow solution was cooled
to 10.degree. C. in an ice bath and treated dropwise with phosgene
in toluene (152 mL, 289 mmol). The reaction mixture was stirred at
ambient temperature for 16 hrs. The mixture was concentrated under
reduced pressure and the crude material was diluted with toluene
(200 ml) and re-concentrated under reduced pressure. The residue
was purified by chromatography on silica (Redisep 340 g column on a
Biotage system), eluting with EtOAc/iso-hexane to give
3-chloro-5-cyanobenzyl carbonochloridate as an oil.
[0789] .sup.1H NMR (600 MHz, CDCl.sub.3) .delta. 7.70 (1H, s), 7.66
(1H, s), 7.62 (1H, s), 5.32 (2H, s).
Step 5: 3-Chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)
piperidine-1-carboxylate
[0790] To 3-chloro-5-cyanobenzyl carbonochloridate (step 4) (65.5
mg, 0.285 mmol) and
N-methyl-N-(2-(piperidin-4-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide
(step 3) (78 mg, 0.285 mmol) in DCM (5 mL) was added saturated
aqueous sodium bicarbonate solution (5 mL, 0.285 mmol), and the
mixture stirred vigorously for 16 hrs. The resulting mixture was
acidified with 10% citric acid solution and the organic portion was
separated, dried (MgSO.sub.4) and concentrated under reduced
pressure. The residue was dissolved in DCM and applied to a 12 g
silica cartridge eluting with 0-100% EtOAc/iso-hexane. The product
fractions were combined and concentrated to give a gum. This was
further purified by UV triggered HPLC, to give
3-chloro-5-cyanobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxy-
late as a gum;
[0791] LCMS: Rt=1.07 mins; MS m/z 431.5 and 433.6 [M+H]+ for Cl
isotopes; Method 2minLowpHv01
Example 37
3-Chloro-5-fluorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00090##
[0792] Step 1: 3-Chloro-5-fluorobenzyl 2,5-dioxopyrrolidin-1-yl
carbonate
[0793] To a stirred suspension of N,N'-disuccinimidyl carbonate
[CAS 74124-79-1] (7.08 g, 27.6 mmol) in 2-Me-THF (20 ml) and
triethylamine (10.44 ml, 75 mmol) at 5.degree. C. was added
dropwise 3-chloro-5-fluorophenyl)methanol [CAS 79944-64-2] (3 ml,
25.1 mmol). After 10 minutes the white suspension was allowed to
slowly warm to RT and stirred at RT for 24 hrs.
[0794] The white solid was filtered off, washed with iso-hexane and
the filtrate and washings were combined, diluted with EtOAc, washed
with water and a saturated solution of brine. The organic portion
was dried over MgSO.sub.4, filtered and concentrated under reduced
pressure to yield a pale yellow oily solid. Purification was
carried out by chromatography on silica using 0-100% iso-hexane in
TBME to afford the title product as a white solid;
[0795] LC-MS: Rt 1.09 min; MS m/z 319.2 [M+H2O]+; Method
2minLowpHv01
Step 2: Azidomethyl pivalate
[0796] To a stirred suspension of chloromethyl pivalate (21.2 g,
141 mmol) in water (25 ml) was added sodium azide (13.7 g, 211
mmol) and the mixture was stirred vigorously at 90.degree. C. for
hrs. On cooling the reaction mixture was diluted with H.sub.2O and
the organic portion was filtered through a pad of MgSO.sub.4 to
afford the title compound as a clear liquid;
[0797] 1H NMR (400 MHz, CDCl3) .delta. 5.15 (s, 2H), 1.26 (s,
9H).
Step 3: 4-(1-((Pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanoic
acid
[0798] To a stirred suspension of 5-hexynoic acid (1.375 g, 12.26
mmol) in tBuOH (120 ml) and water (120 ml) was added azidomethyl
pivalate (1.927 g, 12.26 mmol) and copper (II) acetate (0.223 g,
1.226 mmol). Sodium L-ascorbate (0.486 g, 2.452 mmol) was added and
the suspension was stirred at RT for 24 hours. The resulting
suspension was acidified with conc.HCl, saturated with NaCl and
extracted with EtOAc. The organic portions were combined, dried
over MgSO.sub.4, filtered and concentrated under reduced pressure.
Purification was carried out on a Isolute.RTM. PEAX cartridge
eluting with EtOAc, MeCN and then 10% AcOH/EtOAc to afford the
title product;
[0799] LC-MS: Rt 0.88 mins; MS m/z 270.2 [M+H]+; Method
2minLowpHv01
Step 4: Tert-butyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate
[0800] To a stirred solution of
4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanoic acid
(1.63 g, 6.05 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate
(1.212 g, 6.05 mmol) in DMF (10 mL) was added Huenig's Base (3.17
mL, 18.16 mmol) followed by T3P.RTM. 50% in DMF (7.07 mL, 12.11
mmol) at RT. The reaction mixture was allowed to stir at RT for 20
hours. The DMF was removed under reduced pressure and the residue
dissolved in EtOAc and washed with a saturated solution of sodium
bicarbonate, a saturated solution of brine, dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to afford the
title product;
[0801] LC-MS: Rt 1.22 mins; MS m/z 452.4 [M+H]+; Method
2minLowpHv03
Step 5:
(4-(4-Oxo-4-(piperidin-4-ylamino)butyl)-H-1,2,3-triazol-1-yl)methy-
l pivalate
[0802] To a stirred solution of tert-butyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate (2.73 g, 6.05 mmol) in EtOAc (20 ml) was added
dropwise 4M HCl in dioxane (15.11 ml, 60.5 mmol) and the reaction
mixture stirred at RT for hrs. The resulting oily solution was
concentrated under reduced pressure, triturated with ether and
concentrated under reduced pressure to afford the title compound as
the HCl salt;
[0803] LC-MS: Rt 0.61 mins; MS m/z 352.4 [M+H]+; Method
2minLowpHv03
Step 6: 3-Chloro-5-fluorobenzyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate
[0804] To a stirred suspension of
(4-(4-oxo-4-(piperidin-4-ylamino)butyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (step 5) (150 mg, 0.387 mmol) and 3-chloro-5-fluorobenzyl
2,5-dioxopyrrolidin-1-yl carbonate (117 mg, 0.387 mmol) in DCM (5
mL) was added NaOH (1.547 mL, 1.547 mmol) with stirring at RT and
the mixture was stirred at RT for 18 hrs. A further 5 ml DCM was
added followed by 1M NaOH (1 ml). The reaction mixture was diluted
with DCM (30 ml) and the organic portion was dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to afford the
title product; LC-MS: Rt 1.35 mins; MS m/z 538.5, 540.53 [M+H]+;
Method 2minLowpHv03
Step 7: 3-Chloro-5-fluorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0805] To a stirred solution of 3-chloro-5-fluorobenzyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate (200 mg, 0.372 mmol) in MeOH (1 mL) was added 1M
NaOH (0.818 mL, 0.818 mmol). The reaction mixture was allowed to
stir at RT for 1 hour. An equivalent of 1M HCl (0.8 ml) was added
to neutralise the reaction mixture and the MeOH was removed under
reduced pressure. The mixture was diluted with water and extracted
with EtOAc. The organic portion was dried over MgSO.sub.4, filtered
and concentrated under reduced pressure. Purification was carried
out by chromatography on silica using 0-100% EtOAc in hexanes and
then 0-10% MeOH in EtOAc to afford the title product;
[0806] LC-MS: Rt 1.10 mins; MS m/z 424.3, 426.3 [M+H]+; Method
2minLowpHv03
Example 38
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-triaz-
ol-4-yl)butanamide
##STR00091##
[0807] Step 1:
(E)-(4-(4-((1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)amino)-4-oxo-
butyl)-1H-1,2,3-triazol-1-yl)methyl pivalate
[0808] To a stirred suspension of
(4-(4-oxo-4-(piperidin-4-ylamino)butyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (Example 37,step 5)(200 mg, 0.516 mmol) and
(E)-3-(3,5-dichlorophenyl)acrylic acid (Example 30, step 2) (112
mg, 0.516 mmol) in DMF (2 mL) at RT was added Huenig's base (0.450
mL, 2.58 mmol) followed by T3P.RTM. 50% in DMF (0.602 mL, 1.031
mmol) after a few minutes. The reaction mixture was stirred at RT
for 20 hours. The reaction mixture was diluted with EtOAc and
washed with a saturated solution of brine, organics dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure to
afford the title crude product;
[0809] LCMS: Rt 1.35 mins; 550.5, 552.6 [M+H]+; Method
2minLowpHv03
Step 2:
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2-
,3-triazol-4-yl)butanamide
[0810] To a stirred solution of
(E)-(4-(4-((1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)amino)-4-oxo-
butyl)-1H-1,2,3-triazol-1-yl)methyl pivalate (284 mg, 0.516 mmol)
in MeOH (1 mL) was added 1M NaOH (1.135 mL, 1.135 mmol) and the
mixture allowed to stir at RT for 1.5 hrs. An equivalent of 1M HCl
(1.1 ml) was added to neutralise the reaction mixture and the MeOH
was removed under reduced pressure. The reaction mixture was
diluted with EtOAc and washed with water. The organic portion was
dried over MgSO4, filtered and concentrated under reduced pressure.
Purification was carried out by chromatography on silica using
0-10% MeOH in DCM to afford the title product;
[0811] LC-MS: Rt 1.12 mins; MS m/z 436.4, 438.4 [M+H]+; Method
2minLowpHv03
Example 39
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-triaz-
ol-4-yl)butanamide
##STR00092##
[0812] Step 1: (E)-3-(2,4-Dichlorophenyl)acrylic acid
[0813] To a stirred solution of (E)-methyl
3-(2,4-dichlorophenyl)acrylate (5052 mg, 21.86 mmol) in THF (109.00
mL) at RT was added 2M NaOH (32.8 mL, 65.6 mmol) and the mixture
allowed to stir for 24 hrs. The THF was removed under reduced
pressure and on cooling HCl (37%) was added dropwise to the aqueous
solution. A solid precipitated out of solution which was filtered
and dried to afford the title product;
[0814] LC-MS: Rt 1.14 mins; MS m/z 216.9 [M+H]+; Method
2minLowpHv01
Step 2:
(E)-(4-(4-((1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)amino-
)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)methyl pivalate
[0815] The title compound was prepared from
(4-(4-oxo-4-(piperidin-4-ylamino)butyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (Example 37, step 5) (200 mg, 0.516 mmol) and
(E)-3-(2,4-dichlorophenyl)acrylic acid (step 1) analogously to
Example 38 step 1.
[0816] LCMS: Rt 1.33 mins; MS m/z 550.5, 552.6 [M+H]+; Method
2minLowpHv03
Step 3:
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2-
,3-triazol-4-yl)butanamide
[0817] The title compound was prepared from
(E)-(4-(4-((1-(3-(2,4-dichlorophenyl)acryloyl)piperidin-4-yl)amino)-4-oxo-
butyl)-1H-1,2,3-triazol-1-yl)methyl pivalate analogously to Example
38 step 2;
[0818] LC-MS: Rt 1.10 mins; MS m/z 436.4, 438.4 [M+H]+; Method
2minLowpHv03
Example 40
8-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)amino)-8-oxooctano-
ic acid
##STR00093##
[0820] The title compound was prepared from 3,5-dichlorobenzyl
4-aminopiperidine-1-carboxylate (Example 9, step 2) analogously to
Example 10;
[0821] LC-MS: Rt 1.28 mins; MS m/z 459.4, 461.4 [M+H]+; Method
2minLowpHv03
Example 41
3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate
##STR00094##
[0822] Step 1: 3,5-Dichlorobenzyl
4-(((tert-butoxycarbonyl)amino)methyl)piperidine-1-carboxylate
[0823] A reaction mixture comprising tert-butyl
(piperidin-4-ylmethyl)carbamate (1 g, 4.67 mmol),
3,5-dichlorobenzyl carbonochloridate, (1.117 g, 4.67 mmol) and
sodium bicarbonate (15 mL, 4.67 mmol) in DCM (15.55 mL) was stirred
at room temperature for 18 hours. The reaction mixture was
separated and the organic portion was dried over MgSO.sub.4,
filtered and solvent concentrated under reduced pressure to give
the title compound as a yellow oil;
[0824] 1H NMR (400 MHz, DMSO-d6) 7.6 (1H, s) 7.4 (2H, s), 6.9 (1H,
bt), 5.1 (2H, s), 4 (2H, d), 2.8 (3H, m), 1.6 (2H, m), 1.4 (9H, s),
1 (2H, d)
Step 2: 3,5-Dichlorobenzyl 4-(aminomethyl)piperidine-1-carboxylate
hydrochloride
[0825] A reaction mixture comprising of 3,5-dichlorobenzyl
4-(((tert-butoxycarbonyl) amino)methyl)piperidine-1-carboxylate
(947 mg, 2.269 mmol) and 4M HCl in dioxane (2.84 mL, 11.35 mmol) in
DCM (5 mL) was stirred at room temperature for 3 hours. The
reaction mixture was concentrated under reduced pressure to give
the title compound as the hydrochloride salt;
[0826] LCMS; Rt=0.71 mins; MS m/z 317.3 and 319.3; Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5-yl)butanamido)methyl)piperidine-1-carboxylate
[0827] A mixture comprising of 4-(1H-1,2,3-triazol-4-yl)butanoic
acid (Example 17, step 4) (65.8 mg, 0.424 mmol), 3,5-dichlorobenzyl
4-(aminomethyl)piperidine-1-carboxylate hydrochloride (step 2) (100
mg, 0.283 mmol), HATU (215 mg, 0.565 mmol) and TEA (197 .mu.l,
1.414 mmol) in DMF (942 .mu.l) was stirred at room temperature for
3 hours. Purification was carried out using preparative LC-MS under
low pH conditions. The resulting product fractions were
concentrated under reduced pressure to give aqueous solutions which
were extracted with ethyl acetate. The organic extracts were dried
over MgSO.sub.4, filtered and concentrated under reduced pressure
to afford the title compound;
[0828] LC-MS; Rt 3.75 mins; MS m/z 454 [M+H]+; Method
8minLowpHv01
[0829] 1H NMR (400 Hz, MeOD), 8 (1H, bs), 7.6 (1H, s), 7.4 (1H, s),
7.45 (2H, s), 5.6 (2H, s), 4.15 (2H, d), 3.1 (2H, d), 2.8 (3H, m),
2.4 (2H, t), 2 (2H, m), 1.7 (3H, m), 1.35 (1H, m), 1.2 (1H, m),
Example 42
N-(1-(3-(3,5-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol--
4-yl)butanamide
##STR00095##
[0831] A solution of
(E)-N-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin-4-yl)-4-(1H-1,2,3-tria-
zol-4-yl)butanamide (Example 38) (70 mg, 0.160 mmol) in EtOH (6 ml)
was allowed to pass through the H cube fitted with a 10% Pt/C
catalytic cartridge for 3 hours.
[0832] The reaction mixture was concentrated under reduced pressure
to afford the title product;
[0833] LC-MS: Rt 1.10 mins; MS m/z 438.4, 440.4 [M+H]+; Method
2minLowpHv03
Example 43
N-(1-(3-(2,4-Dichlorophenyl)propanoyl)piperidin-4-yl)-4-(1H-1,2,3-triazol--
4-yl)butanamide
##STR00096##
[0835] The title compound was prepared from
(4-(4-oxo-4-(piperidin-4-ylamino)butyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (Example 37, step 5) (200 mg, 0.516 mmol) and commercially
available 3-(2,4-dichlorophenyl)propanoic acid (Fisher) (113 mg,
0.516 mmol) analogously to Example 38, steps 1 and 2;
[0836] LC-MS: Rt 1.08 mins; MS m/z 438.3, 440.3 [M+H]+; Method
2minLowpHv03
Example 44
3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00097##
[0837] Step 1: 3-Chloro-5-cyanobenzyl carbonochloridate
[0838] To a stirred yellow solution of
3-chloro-5-(hydroxymethylbenzonitrile (25 g, 145 mmol) in THF (200
mL) at 10.degree. C. was added dropwise phosgene in toluene (152
mL, 289 mmol) over 45 mins and the reaction mixture was allowed to
warm to RT over 24 hrs. The resulting mixture was concentrated
under reduced pressure and azeotroped with toluene. Purification
was carried out by chromatography on silica to afford the title
product;
Step 2: 3-Chloro-5-cyanobenzyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate
[0839] To a stirred suspension of
(4-(4-oxo-4-(piperidin-4-ylamino)butyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (Example 37, step 5) (550 mg, 1.418 mmol) and
3-chloro-5-cyanobenzyl carbonochloridate (359 mg, 1.560 mmol) in
DCM (10 mL) was added a saturated solution of sodium bicarbonate
(1.418 mL, 14.18 mmol). The reaction mixture was allowed to stir at
RT for 2 hours and then diluted with DCM. The organic portion was
dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. Purification was carried out on silica eluting with 1-10%
MeOH in DCM to afford the title product;
[0840] LC-MS: Rt 1.28 mins; MS m/z 545.4, 547.4 [M+H]+; Method
2minLowpHv03.
Step 3: 3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0841] To a stirred solution of 3-chloro-5-cyanobenzyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate (150 mg, 0.275 mmol) in MeOH (1 mL) at RT was added
1M NaOH (0.165 mL, 0.165 mmol). The reaction mixture was allowed to
stir at RT for 30 mins. An equivalent of 1M HCl (0.165 ml) was
added to neutralise the mixture and EtOAc and water were added. The
organic portion was dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. Purification was carried out
on silica eluting with 0-10% MeOH in DCM to afford the title
product;
[0842] LC-MS: Rt 1.04 mins; MS m/z 431.3, 433.3 [M+H]+; Method
2minLowpHv03
Example 45
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate
##STR00098##
[0843] Step 1: Tert-butyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate
[0844] A reaction mixture comprising of tert-butyl
3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (250 mg, 1.105
mmol), 4-(1H-1,2,3-triazol-4-yl)butanoic acid (Example 17, step 4)
(171 mg, 1.105 mmol), T3P.RTM. 50% DMF (1.29 ml, 2.209 mmol) and
TEA (462 .mu.l, 3.31 mmol) in DMF (3.6 ml) was stirred for 4 hours.
The reaction mixture was concentrated under reduced pressure. The
resulting oil was diluted with DCM and washed with water. The
organic portion was dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The material was taken crude
to the next step.
[0845] LCMS; Rt 0.89 mins MS m/z 364.5, 365.5 Method
2minLowpHv03
Step 2.
N-(8-Azabicyclo[3.2.1]octan-3-yl)-4-(1H-1,2,3-triazol-4-yl)butanam-
ide
[0846] A reaction mixture comprising of tert-butyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate (401 mg, 1.103 mmol) in dioxane (5 ml) was treated with 4M
HCl in dioxane (0.827 ml, 3.31 mmol) and stirred at room
temperature for 3 hours. The reaction mixture was concentrated
under reduced pressure to afford the title compound. The material
was taken on to the next step without further purification.
[0847] LC-MS: Rt 0.59 mins; MS m/z 263 [M+H]+; Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)-8-azabicyclo[3.2.1]octane-8-carbo-
xylate
[0848] A reaction mixture comprising of
N-(8-azabicyclo[3.2.1]octan-3-yl)-4-(1H-1,2,3-triazol-4-yl)butanamide
(294 mg, 1.116 mmol), 3,5-dichlorobenzyl carbonochloridate (267 mg,
1.116 mmol) and sodium hydroxide (5.58 ml, 112 mmol) in DCM (3.7
ml) was stirred at room temperature for 18 hours. The reaction
mixture was separated and the organic portion was dried over
MgSO.sub.4, filtered and concentrated under reduced pressure.
Further purification was carried out using preparative LC-MS and
the resulting product fractions were concentrated under reduced
pressure to give aqueous solutions which were extracted with ethyl
acetate. The organic extracts were dried over MgSO.sub.4, filtered
and concentrated under reduced pressure to afford the title
compound.
[0849] LC-MS: Rt 1.31 mins; MS m/z 466.5 and 468.5 [M+H]+; Method
2minLowpHv01
Example 46
3,5-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)azepane-1-carboxylate
##STR00099##
[0851] The title compound was prepared from
4-(1H-1,2,3-triazol-4-yl)butanoic acid (Example 17, step 4) and
tert-butyl 4-aminoazepane-1-carboxylate analogously to Example 45
step 3; LC-MS: Rt 1.20 mins; MS m/z 454.4 and 456.4 [M+H]+; Method
2minLowpHv0
Example 47
3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl)butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carb-
amate
##STR00100##
[0852] Step 1: Tert-butyl
3-((((3,5-dichlorobenzyl)oxy)carbonyl)amino)-8-azabicyclo[3.2.1]octane-8--
carboxylate
[0853] A reaction mixture comprising of tert-butyl
3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (210 mg, 0.928
mmol), 3,5-dichlorobenzyl carbonochloridate (222 mg, 0.928 mmol),
and sodium hydroxide (4.64 ml, 93 mmol) in DCM (3.1 ml) was stirred
at room temperature for 4 hours. The reaction mixture separated and
the organic portion dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. No further purification was
carried out and the material was taken on crude to the next
step.
[0854] LC-MS: Rt 1.63 mins; MS m/z 329 [M+H]+; Method
2minLowpHv01
Step 2: 3,5-Dichlorobenzyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate
hydrochloride
[0855] A reaction mixture comprising of tert-butyl
3-((((3,5-dichlorobenzyl)oxy)carbonyl)amino)-8-azabicyclo[3.2.1]octane-8--
carboxylate (388.3 mg, 0.904 mmol) in dioxane (5 mL) was treated
with 4M HCl in dioxane (0.678 mL, 2.71 mmol) and stirred at room
temperature for 3 hours. The resulting mixture concentrated under
reduced pressure. No further purification was carried out and the
material was taken on crude to the next step.
[0856] LC-MS: Rt 0.79 mins; MS m/z 329 [M+H]+; Method
2minLowpHv01
Step 3: 3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl)butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carb-
amate
[0857] A reaction mixture comprising 3,5-dichlorobenzyl
8-azabicyclo[3.2.1]octan-3-ylcarbamate hydrochloride (118 mg, 0.322
mmol), 4-(1H-1,2,3-triazol-4-yl)butanoic acid (Example 17, step 4)
(50 mg, 0.322 mmol), TEA (135 .mu.l, 0.967 mmol) and T3P.RTM. (376
.mu.l, 0.645 mmol) in DMF (1.0 ml) was stirred at room temperature
overnight. The reaction mixture was diluted with water and
extracted with DCM. The organic portion was concentrated under
reduced pressure. Purification was carried out using preparative
LC-MS method (Prep Run 30-70% Gradient low pH 9.5 min). The
resulting product fractions were concentrated under reduced
pressure to give aqueous solutions which were extracted with ethyl
acetate. The organic extracts were dried over MgSO.sub.4, filtered
and concentrated under reduced pressure to afford the title
compound.
[0858] LC-MS; Rt 3.96 mins; MS m/z 466.0 and 469.6 [M+H]+; Method
8minLowpHv01
Example 48
3,5-Dichlorobenzyl
(1-(4-(1H-1,2,3-triazol-4-yl)butanoyl)azepan-4-yl)carbamate
##STR00101##
[0860] The title compound was prepared from tert-butyl
4-aminoazepane-1-carboxylate and 3,5-dichlorobenzyl
carbonochloridate analogously to Example 47 steps 1-3; LC-MS: Rt
1.22 mins; MS m/z 454 [M+H]+; Method 2minLowpHv01
Example 49
Racemic 3,5-dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
##STR00102##
[0861] Step 1: 3,5-Dichlorobenzyl
3-((tert-butoxycarbonyl)amino)pyrrolidine-1-carboxylate
[0862] A mixture comprising of 3-(boc-amino)pyrrolidine (1 g, 5.37
mmol) and saturated sodium bicarbonate (9 mL, 5.37 mmol) in DCM
(17.90 mL) was stirred at room temperature for 5 minutes. The
resulting mixture was treated with 3,5-dichlorobenzyl
carbonochloridate (1.286 g, 5.37 mmol) and stirred at room
temperature for one hour. The reaction mixture was concentrated
under reduced pressure, diluted with water and extracted with DCM.
The organic portion was separated and dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to afford the
title compound;
[0863] LC-MS: Rt: 1.49 mins; MS m/z 389 [M+H]+; Method
2minLowpHv01.
Step 2: 3,5-Dichlorobenzyl 3-aminopyrrolidine-1-carboxylate
[0864] A mixture comprising of 3,5-dichlorobenzyl
3-((tert-butoxycarbonyl)amino)pyrrolidine-1-carboxylate (1.8143 g,
4.66 mmol) and trifluoroacetic acid (14.36 ml, 186 mmol) in DCM
(15.54 ml) was stirred at RT for 2 hours. The reaction mixture was
concentrated under reduced pressure, diluted with DCM and washed
with water. The organic portion was separated, dried over
MgSO.sub.4, filtered and concentrated under reduced pressure to
form an orange oil which was used in the next step without further
purification;
[0865] LC-MS: Rt: 0.72 mins; MS m/z 289 [M+H]+; Method
2minLowpHv01.
Step 3: Racemic 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
[0866] A mixture comprising of 3,5-dichlorobenzyl
3-aminopyrrolidine-1-carboxylate (1 equiv),
4-(1H-1,2,3-triazol-4-yl)butanoic acid (1 equiv.), HATU (1.5
equiv.) and triethylamine (5 equiv.) in dimethylformamide was
stirred at RT for 18 hours. Another 1 equivalent of
4-(1H-1,2,3-triazol-4-yl)butanoic acid was added to the reaction
mixture and stirring continued for a further 2 hours. The reaction
mixture was concentrated under reduced pressure, diluted with water
and extracted with DCM. The organic portion was separated, dried
over MgSO.sub.4, filtered and concentrated under reduced pressure.
The crude product was dry loaded using silica onto a 12 g ISCO
column, eluting with 0-15% MeOH in DCM. The product fractions were
combined and concentrated under reduced pressure. Further
purification was carried our using preparative LC-MS. The product
fractions were concentrated under reduced pressure to give an
aqueous solution and extracted with EtOAc to afford the title
compound;
[0867] 1H NMR (400 MHz, CDCl3) .delta. 7.50 (1H, d), 7.15 (3H, t),
6.25 (1H, s), 5.00 (2H, d), 4.45 (1H, s), 3.60 (1H, d), 3.45 (2H,
s), 3.30 (1H, s), 2.75 (2H, s), 2.15 (3H, d), 1.95 (2H, s), 1.20
(1H, t).
[0868] LC-MS: Rt: 1.14 mins; MS m/z 426 [M+H]+; Method
2minLowpHv01
Example 49a
(S)- or (R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
and Example 49b: (S)- or (R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
##STR00103##
[0870] Chiral separation of 3,5-dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
(racemate; Example 49) using Supercritical Fluid Chromatography
afforded the individual enantiomers (Example 49a and 49b).
Method Details:
Column: Phenomenex LUX-A2, 250.times.10 mm, 5 .mu.m
[0871] Mobile phase: 50% isopropanol/50% CO.sub.2 Flow: 10
ml/min
Detection: UV @ 220 nm
System: Berger Minigram SFC1
Example 49a
First Eluted Peak
[0872] (S)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate or
(R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
[0873] SFC Retention Time=2.720 min.
[0874] 1H NMR (400 MHz, MeOD). .delta. 7.50 (1H, d), 7.15 (3H, t),
6.25 (1H, s), 5.00 (2H, d), 4.45 (1H, s), 3.60 (1H, d), 3.45 (2H,
s), 3.30 (1H, s), 2.75 (2H, s), 2.15 (3H, d), 1.95 (2H, s), 1.20
(1H, t).
Example 49b
Second Eluted Peak
[0875] (S)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate or
(R)-3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)pyrrolidine-1-carboxylate
[0876] SFC Retention Time==4.163 min.
[0877] 1H NMR (400 MHz, MeOD). .delta. 7.50 (1H, d), 7.15 (3H, t),
6.25 (1H, s), 5.00 (2H, d), 4.45 (1H, s), 3.60 (1H, d), 3.45 (2H,
s), 3.30 (1H, s), 2.75 (2H, s), 2.15 (3H, d), 1.95 (2H, s), 1.20
(1H, t).
Example 50
3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl)butanamido)azetidine-1-carboxylate
##STR00104##
[0879] The title compound was prepared from commercially available
3-N-Boc-amino-azetidine and 3,5-dichlorobenzyl carbonochloridate
(prepared according to Bioorganic & Medicinal Chemistry
Letters, 21(21), 6608-6612; 2011, Intermediate 33) analogously to
Example 49 steps 1-3;
[0880] LC-MS: Rt: 1.12 mins; MS m/z 412 [M+H]+; Method
2minLowpHv01
Example 51
3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00105##
[0881] Step 1:4-(1H-1,2,3-Triazol-4-yl)butanoyl chloride
[0882] To a stirred solution/suspension of
4-(1H-1,2,3-triazol-4-yl)butanoic acid (150 mg, 0.967 mmol) in dry
DCM (10 mL) was added thionyl chloride (0.847 mL, 11.60 mmol) at
RT. After 30 mins some solid still remained so a further 0.4 ml
thionyl chloride was added and the reaction mixture allowed to stir
at RT for 2 hrs. The reaction mixture was concentrated under
reduced pressure to afford the title product which was used in the
next step without further purification.
Step 2: 3,5-Dimethylbenzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate
[0883] To a stirred solution of (3,5-dimethylphenyl)methanol (1.020
g, 7.49 mmol) in DMF (5 mL) at RT was added CDI (1.214 g, 7.49
mmol). The reaction mixture was heated at 50.degree. C. for 20 hrs.
Tert-butyl piperidin-4-ylcarbamate (1.5 g, 7.49 mmol) was added and
the reaction mixture stirred at 50.degree. C. for 4 hrs. The
mixture was diluted with EtOAc and washed with a saturated solution
of sodium bicarbonate, brine, dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. Purification was carried out
by chromatography on silica using 0-100% EtOAc in hexanes as eluent
to afford the title product.
[0884] LC-M: Rt 1.47 mins; MS m/z 263.3, 264.2; [M-Boc]+; Method
2minLowpHv03
Step 3: 3,5-Dimethylbenzyl 4-aminopiperidine-1-carboxylate
[0885] To a solution of 3,5-dimethylbenzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate (1.1 g, 3.03
mmol) in DCM (5 ml) at RT was added 4M HCl in dioxane (7.59 ml,
30.3 mmol). The reaction mixture was allowed to stir for 2 hrs,
concentrated under reduced pressure redissolved in DCM and
concentrated under reduced pressure to afford the crude title
compound as the HCl salt;
[0886] LC-MS: Rt 0.74 mins; MS m/z 263.2, 264.2; [M+H]+; Method
2minLowpHv03
Step 4: 3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0887] To a stirred solution of 4-(1H-1,2,3-triazol-4-yl)butanoic
acid chloride in DCM (5 ml) at RT (168 mg, 0.967 mmol) was added
3,5-dimethylbenzyl 4-aminopiperidine-1-carboxylate (318 mg, 1.064
mmol) and Huenig's Base (0.338 mL, 1.934 mmol) and the reaction
mixture was allowed to stir for 3 hrs. The reaction mixture was
diluted with DCM and washed with a saturated solution of brine. The
layers were separated and the organic portion dried over
MgSO.sub.4, filtered and concentrated under reduced pressure.
Purification was carried out by chromatography on silica using
0-10% MeOH in DCM as eluent to afford the title product;
[0888] LC-MS: Rt 1.12 mins; MS m/z 400.4, 401.4 [M+H]+; Method
2minLowpHv03
Example 52
3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4-yl)pentanoyl)piperidin-4-yl)carbamate
##STR00106##
[0889] Step 1: Tert-butyl
4-((((3,5-dichlorobenzyl)oxy)carbonyl)amino)piperidine-1-carboxylate
[0890] A reaction mixture comprising tert-butyl
4-aminopiperidine-1-carboxylate (1 g, 4.99 mmol),
3,5-dichlorobenzyl carbonochloridate (1.196 g, 4.99 mmol) and
sodium hydroxide (250 ml, mmol) in DCM (16.64 ml) was stirred at
room temperature for 18 hours. The reaction mixture separated and
the organic portion dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. No further purification was
carried out and the material was taken crude to the next step.
[0891] LC-MS; Rt 1.63 mins; MS m/z 329 [M+H]+; Method
2minLowpHv01
Step 2: 3,5-Dichlorobenzyl piperidin-4-ylcarbamate
[0892] A reaction mixture comprising tert-butyl
4-((((3,5-dichlorobenzyl)oxy)carbonyl)amino)
piperidine-1-carboxylate (2.01 g, 4.98 mmol) and 4M HCl in dioxane
(1.246 ml, 4.98 mmol) in dioxane (16.61 ml) was stirred at room
temperature for 1 hour. The resulting mixture was concentrated
under reduced pressure. No further purification under taken and the
material was dried and taken on to the next step.
[0893] LC-MS; Rt 1.63 mins; MS m/z 329 [M+H]+; Method
2minLowpHv01
Step 3: 5-(1-Benzyl-1H-1,2,3-triazol-4-yl)pentanoic acid
[0894] A reaction mixture comprising (azidomethyl) benzene (950 mg,
7.13 mmol) in tert-BuOH (100 mL) and Water (100 mL), hept-6-ynoic
acid (900 mg, 7.13 mmol) copper (II) acetate (130 mg, 0.713 mmol)
and sodium L-ascorbate (283 mg, 1.427 mmol) was stirred at room
temperature for 18 hours. The reaction mixture was acidified using
6M HCl to pH1. The mixture was saturated with NaCl and concentrated
under pressure to a give a green slurry. The mixture was then
diluted with ethyl acetate. The organics were separated and dried
over MgSO.sub.4, filtered and solvent concentrated under reduced
pressure to give the title compound; LC-MS; Rt 0.94 mins; MS m/z
259 [M+H]+; Method 2minLowpHv01
Step 4: 5-(1H-1,2,3-Triazol-4-yl)pentanoic acid
[0895] A reaction mixture comprising
5-(1-benzyl-1H-1,2,3-triazol-4-yl)pentanoic acid (1 g, 3.86 mmol)
in ethanol (77 ml) to give a green solution. The reaction solution
was passed through a continuous flow H cube system for 3 hours at
30 bar pressure and 70.degree. C. The reaction mixture was
concentrated under reduced pressure to afford the title
compound;
[0896] LC-MS: Rt 0.55 mins; MS m/z 168 [M+H]+; Method
2minLowpHv01
Step 5: 3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4-yl)pentanoyl)piperidin-4-yl)carbamate
[0897] A reaction mixture comprising
5-(1H-1,2,3-triazol-4-yl)pentanoic acid (55.8 mg, 0.330 mmol),
3,5-dichlorobenzyl piperidin-4-ylcarbamate (100 mg, 0.330 mmol),
TEA (138 .mu.l, 0.989 mmol) and T3P.RTM. (385 .mu.l, 0.660 mmol) in
DMF (1.1 ml) was stirred at room temperature for 18 hours. The
reaction mixture was concentrated under reduced pressure.
Purification was carried out using preparative LC-MS (low pH over
9.5 mins). The resulting product fractions were concentrated under
reduced pressure to give aqueous solutions which were extracted
with ethyl acetate. The organic extracts were dried over
MgSO.sub.4, filtered and concentrated under reduced pressure to
afford the title compound;
[0898] LC-MS: Rt 3.49 mins; MS m/z 455 [M+H]+; Method
8minHighpHv01
Example 53
4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00107##
[0900] The title compound was prepared from commercially available
(4-(trifluoromethyl) phenyl)methanol and tert-butyl
piperidin-4-ylcarbamate analogously to Example 51 steps 2-4;
[0901] LC-MS: Rt 1.12 mins; MS m/z 440.4 [M+H]+; Method
2minLowpHv03
Example 54
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl)phenyl)propanoyl)pip-
eridin-4-yl)butanamide
##STR00108##
[0902] Step 1: 3-(4-(Trifluoromethyl)phenyl)propanoyl chloride
[0903] A stirred solution of 3-(4-(trifluoromethyl)phenyl)propanoic
acid (500 mg, 2.292 mmol) in thionyl chloride was allowed to reflux
for 2 hours and concentrated under reduced pressure to afford the
crude title product.
Step 2:
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl)phenyl)propa-
noyl)piperidin-4-yl)butanamide
[0904] The title compound was prepared from
3-(4-(trifluoromethyl)phenyl)propanoyl chloride (step 1) and
commercially available tert-butyl piperidin-4-ylcarbamate
analogously to Example 51;
[0905] LC-MS: Rt 1.05 mins; MS m/z 438.4 [M+H]+; Method
2minLowpHv03
Example 55
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4-yl)-4-(1H-1,2,3-triazol-4--
yl)butanamide
##STR00109##
[0906] Step 1: Tert-butyl
(1-(2-(3,5-dichlorophenoxy)acetyl)piperidin-4-yl)carbamate
[0907] To a stirred solution of tert-butyl piperidin-4-ylcarbamate
(300 mg, 1.498 mmol) and 2-(3,5-dichlorophenoxy)acetic acid 331 mg,
1.498 mmol) in DMF (5 mL) at RT was added NMM (0.329 mL, 3.00 mmol)
and EDC.HCl (287 mg, 1.498 mmol). The reaction mixture was stirred
for 5 hours, diluted with DCM and washed with a saturated solution
of sodium bicarbonate, brine, dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. Purification was carried out
by chromatography on silica using 0-50% EtOAc in hexanes to afford
the title product.
[0908] LC-MS: Rt: 1.44 mins; MS m/z 347.3, 349.3 [M-tBu]+; Method
2minLowpHv03
Step 2.
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4-yl)-4-(1H-1,2,3-tr-
iazol-4-yl)butanamide
[0909] The title compound was prepared from tert-butyl
(1-(2-(3,5-dichlorophenoxy)acetyl)piperidin-4-yl)carbamate (step 1)
analogously to Example 51 steps 3 and 4;
[0910] LC-MS: Rt 1.10 mins; MS m/z 440.3, 442.3 [M+H]+; Method
2minLowpHv03
Example 56
3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00110##
[0911] Step 1: (3-Chloro-5-methylphenyl)methanol
[0912] To a stirred solution/suspension of 3-chloro-5-methylbenzoic
acid (800 mg, 4.69 mmol) in THF (5 ml) at 00.degree. C. under
nitrogen was added dropwise borane tetrahydrofuran complex (1M in
THF, 23.45 ml, 23.45 mmol) over 30 mins maintaining the temperature
around 00.degree. C. The reaction mixture was then allowed to warm
to RT over 20 hrs. On cooling in an ice/water bath the reaction
mixture was quenched dropwise with water and after a few minutes
the THF was removed under reduced pressure. Water was added to the
residue and on cooling a few drops of 1M HCl were added until
effervescence ceased. The mixture was diluted with water and
extracted into EtOAc, the organic portion dried over MgSO.sub.4,
filtered and concentrated under reduced pressure. Purification was
carried out by chromatography on silica using 0-50% EtOAc in
hexanes as eluent and azeotroping with toluene to afford the title
product.
Step 2: 3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0913] The title compound was prepared from commercially available
tert-butyl piperidin-4-ylcarbamate and
(3-chloro-5-methylphenyl)methanol (step 1) analogously to Example
51 steps 2-4;
[0914] LC-MS: Rt 1.15 mins; MS m/z 420.3, 422.3 [M+H]+; Method
2minLowpHv03
Example 57
3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5-yl)propanamido)methyl)piperidine-1-carboxylate
##STR00111##
[0915] Step 1: 3-(1H-1,2,3-Triazol-4-yl)propanoic acid
[0916] The title compound was prepared from (azidomethyl)benzene
and pent-4-ynoic acid analogously to Example 17, steps 3 and 4;
[0917] 1H NMR (400 MHz, MeOD) 14.8 (1H, s), 12.2 (1H, s), 7.6 (1H,
s), 2.9 (2H, t), 2.6 (2H, t),
Step 2: 3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5-yl)propanamido)methyl)piperidine-1-carboxylate
[0918] The title compound was prepared from 3,5-dichlorobenzyl
4-(aminomethyl)piperidine-1-carboxylate hydrochloride (Example 41,
step 2) and 3-(1H-1,2,3-triazol-4-yl)propanoic acid (step 1)
analogously to Example 41 step 3;
[0919] LC-MS; Rt 0.86 mins; MS m/z 440 [M+H]+; Method
2minLowpHv01
Example 58
2,4-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00112##
[0920] Step 1: 2,4-Dichlorobenzyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)
piperidine-1-carboxylate
[0921] To a stirred solution of commercially available
(2,4-dichlorophenyl)methanol (137 mg, 0.774 mmol) in DMF (2 mL) at
RT was added CDI (125 mg, 0.774 mmol). The reaction mixture was
allowed to heat at 50.degree. C. for 20 hrs.
(4-(4-Oxo-4-(piperidin-4-ylamino)butyl)-1H-1,2,3-triazol-1-yl)methyl
pivalate (Example 37, step 5)(272 mg, 0.774 mmol) was added and the
reaction mixture was stirred at 50.degree. C. for 10 hrs. The
reaction mixture was diluted with EtOAc and washed with a saturated
solution of sodium bicarbonate and brine, dried over MgSO.sub.4,
filtered and concentrated under reduced pressure. Purification was
carried out by chromatography on silica eluting with 0-100% EtOAc
in iso-hexane to afford the title product;
[0922] LC-MS: Rt 1.41 mins; MS m/z 554.6, 556.6 [M+H]+; Method
2minLowpHv03.
Step 2: 2,4-Dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0923] To a stirred solution of 2,4-dichlorobenzyl
4-(4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)butanamido)piperidine-
-1-carboxylate (100 mg, 0.180 mmol) in MeOH (1 mL) at RT was added
1M NaOH (0.397 mL, 0.397 mmol). The reaction mixture was allowed to
stir for 1 hr. An equivalent of 1M HCl (0.4 ml) was added to
neutralise the reaction mixture and the MeOH removed under reduced
pressure. The reaction mixture was diluted with EtOAc and water and
the organic portion was separated, dried over MgSO.sub.4, filtered
and concentrated under reduced pressure. Trituration with diethyl
ether afforded the title product;
[0924] LC-MS: Rt 1.17 mins; MS m/z 440.3, 442.3 [M+H]+; Method
2minLowpHv03
Example 59
3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00113##
[0926] The title compound was prepared from commercially available
tert-butyl piperidin-4-ylcarbamate and
2-(3,5-dichlorophenyl)ethanol analogously to Example 51 steps
2-4;
[0927] LC-MS: Rt 1.24 mins; MS m/z 454.3, 456.3 [M+H]+; Method
2minLowpHv03
Example 60
3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate
##STR00114##
[0928] Step 1: Tert-butyl prop-2-yn-1-ylcarbamate
[0929] A reaction mixture comprising of prop-2-yn-1-amine (100 mg,
1.816 mmol), di-tert-butyl dicarbonate (396 mg, 1.816 mmol), and
triethylamine (380 .mu.l, 2.72 mmol) in THF (6.1 ml was stirred at
room temperature for 18 hours. The reaction mixture was diluted
with a small amount of water and the solvent removed in vacuo. The
water was then extracted with ethyl acetate. The organics were
dried over MgSO4, filtered and concentrated under reduced pressure
to afford the title compound.
[0930] LC-MS: Rt 1.01 mins; MS m/z 170 [M+H]+; Method
2minLowpH_v01
Step 2: (1-benzyl-1H-1,2,3-triazol-4-yl)methanamine
[0931] A reaction mixture comprising of tert-butyl
prop-2-yn-1-ylcarbamate (219 mg, 1.411 mmol), (azidomethyl)benzene
(188 mg, 1.411 mmol), copper (II) acetate (25.6 mg, 0.141 mmol) and
sodium L-ascorbate (55.9 mg, 0.282 mmol) in tert-butanol (20
ml)/water (20 ml) was stirred for 18 hours at room temperature. The
reaction mixture was acidified to pH1 using 6M HCl, then saturated
with solid NaCl. The reaction mixture was concentrated under
pressure to yield a green aqueous solution. The mixture was diluted
with ethyl acetate and the organics were removed and dried (MgSO4).
Concentration under reduced pressure afforded an orange oil. The
oil was loaded on to a 10 g SCX2 cartridge, and this was washed
with water and methanol. The product was then eluted with 2M
ammonia in methanol. The solution was then concentrated to afford
the title compound.
[0932] LC-MS: Rt 1.10 mins; MS m/z 189 [M+H].sup.+; Method
2minLowpH_v01
Step 3:
3-(1-(((3,5-dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)propanoic
acid
[0933] To 3-piperidin-4-yl-propionic acid (1 g, 6.36 mmol) in DCM
(20 ml) was added 2M NaOH (9.54 ml, 19.08 mmol) to give a colorless
biphasic solution. 3,5-Dichlorobenzyl carbono-chloridate (1.523 g,
6.36 mmol) was added to the reaction mixture and this was stirred
at RT for 2 hrs. The mixture was extracted with DCM (2.times.50
ml), and the organics were dried (MgSO4) and concentrated to give
the product as a white solid.
[0934] LC-MS: Rt: 1.39 mins; MS m/z 360 [M+H]+; Method
2minLowpH_v01
Step 4: 3,5-dichlorobenzyl
4-(3-(((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidi-
ne-1-carboxylate
[0935] A reaction mixture comprising of
(1-benzyl-1H-1,2,3-triazol-4-yl)methanamine (46.2 mg, 0.245 mmol),
3-(1-(((3,5-dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)propanoic
acid (88 mg, 0.245 mmol), HATU (187 mg, 0.491 mmol) and TEA (103
.mu.l, 0.736 mmol) in DMF (0.8 ml) was stirred for 2 hours at room
temperature. The reaction mixture was diluted with water and ethyl
acetate. The organic layer was separated and dried over MgSO4,
filtered and concentrated under reduced pressure. Further
purification was carried out using preparative LC-MS. The resulting
product fractions were concentrated under reduced pressure to give
aqueous solutions which were extracted with ethyl acetate. The
organic extracts were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to afford the title
compound.
[0936] LC-MS: Rt 1.36 mins; MS m/z 530 [M+H]+; Method
2minLowpH_v01
Step 5: 3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carb-
oxylate
[0937] 3,5-dichlorobenzyl
4-(3-(((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)
piperidine-1-carboxylate (51 mg, 0.096 mmol) was dissolved in
ethanol (4 ml). The solution was then submitted to continuous flow
hydrogenation using H-cube hydrogenation apparatus, at 70.degree.
C. and 30 bar hydrogen pressure. After 90 mins the solution was
concentrated and the residue purified using preparative LC-MS.
Product fractions were collected, concentrated under reduced
pressure, diluted with ethyl acetate, and extracted with water. The
organics were separated, dried over MgSO4, filtered, and
concentrated under reduced pressure to give the title compound.
[0938] 1H NMR (400 MHz, MeOD) .delta. 7.65 (1H, s), 7.40 (1H, s),
7.35 (2H, s), 5.10 (2H, s), 3.45 (2H, s), 4.10 (2H, d), 2.80 (2H,
m), 2.25 (2H, m), 1.75 (2H, m), 1.60 (2H, m), 1.45 (1H, m), 1.10
(2H, m).
[0939] LC-MS: Rt: 3.87 mins; MS m/z 440 [M+H]+; Method
8minLowpHv01
Example 61
3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidine-1-carb-
oxylate
##STR00115##
[0940] Step 1: Tert-butyl but-3-yn-1-ylcarbamate
[0941] A reaction mixture comprising of but-3-yn-1-amine (130 mg,
1.881 mmol), di-tert-butyl dicarbonate (411 mg, 1.881 mmol), and
triethylamine (393 .mu.l, 2.82 mmol) in THF (6.2 ml) was stirred
for 18 hours at room temperature. A small amount of water was added
to the reaction mixture and the resultant mixture was concentrated
under reduced pressure. The aqueous solution was extracted with
ethyl acetate. The organics were dried over MgSO4, filtered and
concentrated under reduced pressure to afford the title
compound.
[0942] 1H NMR (400 MHz, DMSO-d6) .delta. 6.9 (1H, s), 3 (2H, q),
2.25 (2H, q), 1.4 (9H, s)
Step 2: 2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethanamine
[0943] A reaction mixture comprising tert-butyl
but-3-yn-1-ylcarbamate (306 mg, 1.808 mmol), (azidomethyl)benzene
(241 mg, 1.808 mmol), copper (II) acetate (32.8 mg, 0.181 mmol) and
Sodium L-ascorbate (71.6 mg, 0.362 mmol) in tert-butanol (25
ml)/water (25 ml) was stirred for 18 hours at room temperature. The
reaction mixture was acidified to pH1 using 6M HCl and then
saturated with solid NaCl. The reaction mixture was concentrated
under reduced pressure. The remaining mixture was diluted with
ethyl acetate. The organics were separated and dried over MgSO4,
filtered, and the solvent concentrated under reduced pressure to
afford an orange oil. The oil was loaded on to a 10 g SCX2
cartridge. The cartridge was washed with water and methanol.
Product was then eluted with 2M ammonia in methanol. The solution
was then concentrated under pressure to afford the title
compound.
[0944] LC-MS: Rt 1.11 mins; MS m/z 203 [M+H]+; Method
2minLowpH_v01
Step 3:
2-(1-(((3,5-dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)acetic
acid
[0945] To 2-(piperidin-4-yl)acetic acid (1 g, 6.98 mmol) in DCM (23
ml) was added 2M NaOH (10.48 ml, 20.95 mmol) and 3,5-dichlorobenzyl
carbono-chloridate (1.673 g, 6.98 mmol) to give a white biphasic
mixture. After vigorous stirring at RT for 1 hr the reaction
mixture was acidified with HCl (6M, 3.49 ml) and then extracted
with DCM. The organics were dried with MgSO4, filtered and
concentrated under pressure to give the title compound as a
colourless oil.
[0946] LC-MS: Rt: 1.34 mins; MS m/z 346 [M+H]+; Method
2minLowpH_v01
Step 4: 3,5-dichlorobenzyl
4-(2-((2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidi-
ne-1-carboxylate
[0947] A reaction mixture comprising of
2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethanamine (59.1 mg, 0.292 mmol),
2-(1-(((3,5-dichlorobenzyl)oxy)carbonyl)piperidin-4-yl)acetic acid
(101 mg, 0.292 mmol), HATU (222 mg, 0.584 mmol) and TEA (122 .mu.l,
0.877 mmol) in DMF (0.97 ml) was stirred for 3 hours at room
temperature. The reaction mixture was diluted with water and ethyl
acetate. The organic layer was removed and dried over MgSO4,
filtered and concentrated under reduced pressure. Further
purification was carried out using preparative LC-MS. The resulting
product fractions were concentrated under reduced pressure to give
aqueous solutions which were extracted with ethyl acetate. The
organic extracts were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to afford the title
compound.
[0948] LC-MS: Rt 1.36 mins; MS m/z 530 [M+H]+; Method
2minLowpH_v01
Step 5: 3,5-dichlorobenzyl
4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidine-1-carb-
oxylate
[0949] 3,5-dichlorobenzyl
4-(2-((2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidi-
ne-1-carboxylate (81.5 mg, 0.154 mmol) was dissolved in ethanol (4
ml). The solution was then submitted to continuous flow
hydrogenation using H-cube hydrogenation apparatus, at 70.degree.
C. and 30 bar hydrogen pressure for 2 hours. The resultant solution
was concentrated under reduced pressure. Purification was carried
out using preparative LC-MS. Product fractions were collected,
concentrated under reduced pressure, diluted with ethyl acetate,
and washed with water. The organic portion was separated, dried
over MgSO4, filtered, and concentrated under reduced pressure to
give the title compound.
[0950] 1H NMR (400 MHz, MeOD) .delta. 7.60 (1H, s), 7.40 (1H, s),
7.35 (2H, s), 5.10 (2H, s), 4.10 (2H, d), 3.50 (2H, m), 2.90, (4H,
m), 2.10 (2H, m), 1.90 (1H, m), 1.65 (2H, m), 1.15 (2H, m).
[0951] LC-MS: Rt: 3.68 mins; MS m/z 440 [M+H]+; Method
8minLowpHv01
Example 62
3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00116##
[0952] Step 1:4-(1H-1,2,3-triazol-4-yl)butanoyl chloride
[0953] To a stirred suspension of 4-(1H-1,2,3-triazol-4-yl)butanoic
acid (Example 17, step 4) (0.088 g, 0.57 mmol) in DCM (5 mL) at RT
under nitrogen was added thionyl chloride (0.499 mL, 6.84 mmol) and
the reaction mixture stirred at RT for 2 hours. The reaction
mixture was concentrated under reduced pressure to afford the crude
title product.
Step 2: (3-methyl-5-(trifluoromethyl)phenyl)methanol
[0954] To a stirred suspension of
3-methyl-5-(trifluoromethyl)benzoic acid (1 g, 4.90 mmol) in THF (5
ml) at -78.degree. C. under nitrogen was added dropwise over 10
mins borane tetrahydrofuran complex 1M in THF (24.49 ml, 24.49
mmol). The reaction mixture was then allowed to warm to RT over 20
hours. On cooling in an ice/water bath the reaction mixture was
quenched dropwise with MeOH (10 ml) and then 1M HCl until
effervescence ceased. Water was added and the reaction mixture
stirred at RT for 30 mins and the THF was removed under reduced
pressure. EtOAc was added and the organic portion dried over
MgSO.sub.4, filtered and concentrated under reduced pressure.
Purification was carried out by chromatography on silica using
0-50% EtOAc in Hexanes as eluent to afford the title product;
[0955] LC-MS: Rt 1.21 mins; MS m/z 214.1 [M+Na]+; Method
2minLowPHv03
Step 3: 3-methyl-5-(trifluoromethyl)benzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate
[0956] To a stirred solution of
(3-methyl-5-(trifluoromethyl)phenyl)methanol (250 mg, 1.315 mmol)
in DMF (5 mL) at RT under nitrogen was added CDI (213 mg, 1.315
mmol). The reaction mixture was allowed to heat at 50.degree. C.
for 20 hours. Tert-butyl piperidin-4yl carbamate (263 mg, 1.315
mmol) was added and the reaction mixture stirred at 50.degree. C.
for 3 hours. On cooling to RT the reaction mixture was diluted with
DCM and washed with a saturated solution of sodium bicarbonate, a
saturated solution of brine, then was dried (MgSO.sub.4), filtered
and concentrated under reduced pressure. Purification was carried
out by chromatography on silica using 0-100% EtOAc in Hexanes as
eluent to afford the title product;
[0957] LC-MS: Rt 1.53 mins; MS m/z 317.2 [M-Boc]+; Method
2minLowPHv03
Step 4: 3-methyl-5-(trifluoromethyl)benzyl
4-aminopiperidine-1-carboxylate
[0958] To a stirred solution of 3-methyl-5-(trifluoromethyl)benzyl
4-((tert-butoxycarbonyl)amino) piperidine-1-carboxylate (237 mg,
0.569 mmol) in DCM (5 ml) at RT under nitrogen was added 4M HCl in
Dioxane (1.423 ml, 5.69 mmol) and the reaction mixture stirred at
RT for 3 hours. The reaction mixture was concentrated under reduced
pressure to afford the title product as the hydrochloride salt;
[0959] LC-MS: Rt: 0.85 mins; MS m/z 316.9 M+H]+; Method
2minLowPHv03
Step 5: 3-methyl-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0960] To a stirred suspension of
3-methyl-5-(trifluoromethyl)benzyl 4-aminopiperidine-1-carboxylate
hydrochloride salt (201 mg, 0.570 mmol) in DCM (5 mL) at RT under
nitrogen was added Huenig's Base (0.199 mL, 1.140 mmol).
4-(1H-1,2,3,-triazol-4-yl)butanoyl chloride (99 mg, 0.570 mmol) in
DCM (2 mL) was added and the reaction mixture stirred at RT for 2
hours. The reaction mixture was diluted with DCM and washed with a
10% solution of citric acid, and saturated brine solution, before
the organic portion was dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. Purification was carried out
by chromatography on silica using 0-10% MeOH in DCM as eluent to
afford the title product;
[0961] LC-MS: Rt 1.18 mins; MS m/z 454.7, 455.4 [M+H]+; Method
2minLowPHv03
Example 63
3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00117##
[0962] Step 1: (3-bromo-5-(trifluoromethyl)phenyl)methanol
[0963] To a stirred solution of 3-bromo-5-(trifluoromethyl)benzoic
acid (1 g, 3.72 mmol) in THF (5 ml) at -78.degree. C. with stirring
under nitrogen was added dropwise over 10 mins borane
tetrahydrofuran complex 1M in THF (18.59 ml, 18.59 mmol) and then
the reaction mixture was warmed to RT over 20 hours. The reaction
mixture was cooled in an ice/water bath and quenched dropwise with
MeOH (10 ml) followed by 1M HCl until effervescence ceased. Water
was added and stirred at RT for 30 mins. THF was removed under
reduced pressure, and the compound extracted into EtOAc. The
organic portion was dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. Purification was carried out
by chromatography on silica using 0-50% EtOAc in Hexanes as eluent
to afford the title product.
[0964] 1H NMR (400 MHz, d6-DMSO): .delta. 7.83 (s, 1H), 7.83 (s,
1H) 7.69 (s, 1H), 5.54-5.51 (t, 1H), 4.60-4.59 (d, 2H)
Step 2: 3-bromo-5-(trifluoromethyl)benzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate
[0965] To a stirred solution of
(3-bromo-5-(trifluoromethyl)phenyl)methanol (567 mg, 2.223 mmol) in
DMF (5 mL) at RT under nitrogen was added CDI (360 mg, 2.223 mmol)
and the reaction mixture heated at 50.degree. C. for 20 hours.
Tert-butyl piperidin-4-yl carbamate (445 mg, 2.223 mmol) was added
and the reaction mixture stirred at 50.degree. C. for 3 hours. On
cooling to RT the mixture was diluted with DCM and washed with a
saturated solution of sodium bicarbonate, a saturated solution of
brine, and the organic portion was dried over MgSO.sub.4, filtered
and concentrated under reduced pressure. Purification was carried
out by chromatography on silica using 0-100% EtOAc in Hexanes as
eluent to afford the title product;
[0966] LC-MS: Rt 1.59 mins; MS m/z 427.2 [M-tBu]+; Method
2minLowPHv03
Step 3: 3-bromo-5-(trifluoromethyl)benzyl
4-aminopiperidine-1-carboxylate
[0967] To a stirred solution of 3-bromo-5-(trifluoromethyl)benzyl
4-(tertbutoxycarbonyl)amino) piperidine-1-carboxylate (100 mg,
0.208 mmol) in DCM (5 ml) at RT under nitrogen was added 4M HCl in
Dioxane (0.519 ml, 2.078 mmol) and the reaction mixture stirred at
rt for 1 hour. The reaction mixture was concentrated under reduced
pressure to afford the title product as the hydrochloride salt;
[0968] LC-MS: Rt: 0.86 mins; MS m/z 383.2 [M+H]+; Method
2minLowPHv03
Step 4: 3-bromo-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0969] To a stirred suspension of 3-bromo-5-(trifluoromethyl)benzyl
4-aminopiperidine-1-carboxylate hydrochloride salt (92 mg, 0.220
mmol) in DCM (5 mL) at RT under nitrogen was added Huenig's Base
(0.077 mL, 0.441 mmol). 4-(1H-1,2,3-triazol-4-yl)butanoyl chloride
(38.2 mg, 0.220 mmol) in DCM (2 mL) was added and the reaction
mixture stirred for 2 hours. The reaction mixture was diluted with
DCM and washed with a 10% solution of citric acid, a saturated
solution of brine, and the organic portion was then dried over
MgSO.sub.4, filtered and concentrated under reduced pressure.
Purification was carried out by chromatography on silica using
0-10% MeOH/DCM as eluent to afford the title compound;
[0970] LC-MS: Rt 1.25 mins; MS m/z 520.2 [M+H]+; Method
2minLowPHv03
Example 64
3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate
##STR00118##
[0971] Step 1:5-(1H-1,2,3-triazol-4-yl)pentanoyl chloride
[0972] To a suspension of 5-(1H-1,2,3-triazol-4-yl)pentanoic acid
(Example 20, step 3) (100 mg, 0.591 mmol) in DCM (5 mL) at RT under
nitrogen was added thionyl chloride (0.518 mL, 7.09 mmol). The
reaction mixture was stirred at rt for 2 hours and concentrated
under reduced pressure to afford the title product.
Step 2: 3-chloro-5-cyanobenzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate
[0973] To a solution of tert-butyl piperidin-4-ylcarbamate (1.045
g, 5.22 mmol) in DCM (25 mL) at RT was added a saturated solution
of sodium bicarbonate (5.6 ml). 3-Chloro-5-cyanobenzyl
carbonochloridate (Example 36, step 4) (1.2 g, 5.22 mmol) was then
added in DCM (2 ml) and the reaction mixture stirred at RT for 2
hours. The layers were separated and the organic portion was washed
with a saturated solution of brine, dried over MgSO.sub.4, filtered
and concentrated under reduced pressure to afford the title
product;
[0974] LC-MS: Rt 1.38 mins; MS m/z 294.2 [M-Boc]+H+; Method
2minLowPHv03
Step 3: 3-chloro-5-cyanobenzyl 4-aminopiperidine-1-carboxylate
[0975] To a solution of 3-chloro-5-cyanobenzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate (1.846 g,
4.69 mmol) in EtOAc (30 ml) at RT under nitrogen was added 4M HCl
in Dioxane (11.72 ml, 46.9 mmol) and the suspension stirred for 20
hours. After 3 hours a further 5 ml of 4M HCl in Dioxan was added.
The solid was filtered off and dried to afford the title product as
the hydrochloride salt;
[0976] LC-MS: Rt 0.69 mins; MS m/z 294.2, 296.2 [M+H]+; Method
2minLowPHv03
Step 4: 3-chloro-5-cyanobenzyl
4-(5-(1H-1,2,3-triazol-4-yl)pentanamido)piperidine-1-carboxylate
[0977] To a suspension of 3-chloro-5-cyanobenzyl
4-aminopiperidine-1-carboxylate hydrochloride salt (195 mg, 0.591
mmol) in DCM (5 mL) at RT under nitrogen was added Huenig's Base
(0.206 mL, 1.182 mmol). 5-(1H-1,2,3-Triazol-4-yl)pentanoyl chloride
(111 mg, 0.591 mmol) in DCM (2 mL) was then added and the reaction
mixture stirred for 20 hours. The reaction mixture was diluted with
DCM and washed with a 10% solution of citric acid, a saturated
solution of brine and the organic portion was then dried over
MgSO.sub.4, filtered and concentrated under reduced pressure.
Purification was carried out by chromatography on silica using
0-10% MeOH in DCM to afford the title product.
[0978] LC-MS: Rt 1.1 mins; MS m/z 445.3, 447.3 [M+H]+; Method
2minLowPHv03
Example 65
3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate
##STR00119##
[0979] Step 1: 3-(1H-1,2,3-triazol-4-yl)propanoyl chloride
[0980] To a solution of 3-(1H-1,2,3-triazol-4-yl)propanoic acid
(Example 19, step 2) (100 mg, 0.709 mmol) in DCM (5 mL) at RT under
nitrogen was added thionyl chloride (0.621 mL, 8.50 mmol) and the
reaction mixture stirred for 2 hours. The reaction mixture was
concentrated under reduced pressure to afford the title
product.
Step 2: 3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate
[0981] To a suspension of 3-chloro-5-cyanobenzyl
4-aminopiperidine-1-carboxylate HCl salt (Example 64, step 3) (234
mg, 0.709 mmol) in DCM (5 mL) at RT under nitrogen was added
Huenig's Base (0.248 mL, 1.418 mmol).
3-(1H-1,2,3-Triazol-4-yl)propanoyl chloride (113 mg, 0.709 mmol) in
DCM (2 mL) was then added and the mixture stirred for 1 hour. The
reaction mixture was diluted with DCM and washed with a 10%
solution of citric acid, a saturated solution of brine and then the
organic portion was dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. Purification was carried out
by chromatography on silica using 0-10% MeOH in DCM as eluent to
afford the title product;
[0982] LC-MS: Rt 1.01 mins; MS m/z 417.2, 419.1 [M+H]+; Method
2minLowPHv03
Example 66
3-cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
##STR00120##
[0983] Step 1: 3-cyano-5-(trifluoromethyl)benzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate
[0984] 3-Bromo-5-(trifluoromethyl)benzyl
4-((tert-butoxycarbonyl)amino) piperidine-1-carboxylate (Example
63, step 2) (214 mg, 0.445 mmol), zinc cyanide (26.1 mg, 0.222
mmol) and Pd(PPh.sub.3).sub.4 (20.5 mg, 0.018 mmol) were dissolved
in DMF (4 ml) and the vial flushed with nitrogen. The mixture was
heated in the microwave at 150.degree. C. for 10 mins, then cooled
and diluted with EtOAc (30 ml). This was washed with a saturated
solution of brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by chromatography on a 4 g
silica column using 0-50% EtOAC/hexanes as eluent gave the title
compound.
[0985] LC-MS: Rt 1.42 mins; MS m/z 328.2 [M-BOC+H]+; Method
2minLowPHv03
Step 2: 3-cyano-5-(trifluoromethyl)benzyl
4-aminopiperidine-1-carboxylate
[0986] 3-Cyano-5-(trifluoromethyl)benzyl
4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate (119 mg,
0.278 mmol) was dissolved in DCM (5 ml) and 4M HCl in Dioxane
(0.696 ml, 2.78 mmol) was added with stirring at RT under nitrogen.
After 3 hrs, the mixture was concentrated in vacuo to give the
title compound as the hydrochloride salt.
[0987] LC-MS: Rt 0.73 mins; MS m/z 328.2 [M+H]+; Method
2minLowPHv03
Step 3: 3-Cyano-5-(trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate
[0988] 3-Cyano-5-(trifluoromethyl)benzyl
4-aminopiperidine-1-carboxylate hydrochloride (50 mg, 0.137 mmol)
and 4-(1H-1,2,3-triazol-4-yl)butanoic acid (25.6 mg, 0.165 mmol)
were suspended in EtOAc (5 mL) and triethylamine (0.067 mL, 0.481
mmol) was added. After 5 mins at RT, T3P, 50% in EtOAC (0.164 mL,
0.275 mmol) was added and the mixture allowed to stir at RT for 20
hours. EtOAc (30 ml) was added and the mixture washed with a 10%
solution of citric acid and a saturated solution of brine. The
organics were dried over MgSO4, filtered and concentrated in vacuo.
Purification via silica chromatography eluting with 0-10% MeOH/DCM
gave the title compound.
[0989] LC-MS: Rt 1.09 mins; MS m/z 465.2 [M+H]+; Method
2minLowPHv03
Example 67
3,5-dichlorobenzyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate
##STR00121##
[0990] Step 1: 6-(1-benzyl-1H-1,2,3-triazol-4-yl)hexan-1-ol
[0991] Oct-7-yn-1-ol (0.948 g, 7.51 mmol) was dissolved in tBuOH
(100 mL) and water (100 mL) to give a colourless solution.
(Azidomethyl)benzene (1 g, 7.51 mmol), copper (II) acetate (0.136
g, 0.751 mmol) and sodium L-ascorbate (0.298 g, 1.502 mmol) were
added. The reaction was left to stir overnight at room temperature,
then was acidified to pH1 using 6M HCl. The mixture was saturated
with solid NaCl and concentrated under pressure to give a green
slurry. This was extracted with EtOAc, and the organics were
separated, dried over MgSO4, and concentrated under reduced
pressure. The resulting oil was dissolved in methanol and stirred
with celite/charcoal. The mixture was filtered and the filtrate
concentrated under reduced pressure to give the title compound.
[0992] 1H NMR (400 MHz, DMSO-d6) .delta. 7.9 (1H, s) 7.35 5H, m).
5.5 (2H, s), 4.4 (1H, t), 4.1 (4H, m), 3.5 (2H, t), 2.6 (2H, t),
1.6 2H, t), 1.4 (2H, t)
Step 2: 6-(1-benzyl-1H-1,2,3-triazol-4-yl)hexanoic acid
[0993] 6-(1-Benzyl-1H-1,2,3-triazol-4-yl)hexan-1-ol (100 mg, 0.386
mmol), sodium periodate (330 mg, 1.542 mmol), and ruthenium
trichloride (1.6 mg, 7.7 .mu.mol) were taken up in water (640
.mu.l), ethyl acetate (320 .mu.l) and acetonitrile (320 .mu.l) to
give a brown suspension. The reaction was stirred overnight at room
temperature under nitrogen. The mixture was diluted with ethyl
acetate and water and the black precipitate formed was removed by
filtration. The organics were dried with MgSO4, filtered and
concentrated under reduced pressure to give the crude title
product.
[0994] 1H NMR (400 MHz, DMSO-d6) .delta. 12.0 (1H, s), 7.9 (1H, s),
7.4 (5H, m), 5.5 (2H, s), 3.4 (2H, bs), 2.6 (2H, t), 2.2 (2H, t),
1.55 (4H, m)
Step 3: Tert-butyl
4-(6-(1-benzyl-1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate
[0995] 6-(1-Benzyl-1H-1,2,3-triazol-4-yl)hexanoic acid (100 mg,
0.366 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (81 mg,
0.402 mmol), HATU (278 mg, 0.732 mmol) and triethylamine (153
.mu.l, 1.098 mmol) were dissolved in DMF (1220 .mu.l) to give an
orange solution. The reaction mixture was stirred at RT for 72 hrs,
then concentrated under reduced pressure to yield a slurry. This
was diluted with water and ethyl acetate. The organics were
separated and washed with water, then concentrated under reduced
pressure to yield the title compound.
[0996] LC-MS: Rt 1.24 mins; MS m/z 456 [M+H]+; 2minLowpHv03
Step 4: Tert-butyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate
[0997] Tert-butyl
4-(6-(1-benzyl-1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate
(187 mg, 0.410 mmol) was dissolved in ethanol (10 ml) to give a
yellow solution. The solution was then submitted to continuous flow
hydrogenation using H-cube hydrogenation apparatus, at 70.degree.
C. and 30 bar hydrogen pressure for 2 hours. The resultant solution
was concentrated under reduced pressure to yield the title
compound.
[0998] LC-MS: Rt 0.96 mins; MS m/z 366.4 [M+H]+; Method
2minLowpHv03
Step 5. N-(Piperidin-4-yl)-6-(1H-1,2,3-triazol-4-yl)hexanamide
[0999] Tert-butyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate
(135 mg, 0.369 mmol) in 1,4-dioxane (1.2 ml) was treated with 4M
HCl in dioxane (1.8 ml, 7.39 mmol). The reaction mixture was
allowed to stir at RT for 3 hours. Concentration yielded the title
compound as a hydrochloride salt.
[1000] LC-MS: Rt 0.3 mins; MS m/z 265 [M+H]+; Method
2minLowpHv03
Step 6: 3,5-Dichlorobenzyl
4-(6-(1H-1,2,3-triazol-4-yl)hexanamido)piperidine-1-carboxylate
[1001] N-(Piperidin-4-yl)-6-(1H-1,2,3-triazol-4-yl)hexanamide (135
mg, 0.509 mmol) in DCM (50 ml) was treated with 3,5-dichlorobenzyl
carbonochloridate (134 mg, 0.560 mmol) and 2M sodium hydroxide (25
ml, 50 mmol). The reaction mixture was stirred at room temperature
for 5 hrs. The organics were removed, dried over MgSO4, filtered
and concentrated under reduced pressure. The residue was purified
by mass directed preparative LC to give the title compound, after
concentration of the relevant fractions.
[1002] LC-MS: Rt 1.24 mins; MS m/z 468.2 [M+H]+; Method
2minLowpHv03
Biological Data:
[1003] The compounds of the invention are suitable as ATX
inhibitors and may be tested in the following assays.
[1004] Reagents--
[1005] LPC (oleoyl (18:1)) was purchased from Avanti Polar Lipids
(Alabaster, Ala.) and solubilized in methanol to 20 mM. Amplex Red
was obtained from Invitrogen Life Technologies (Paisley, UK) and
dissolved in DMSO to 10 mM. Choline oxidase and horseradish
peroxidase (HRP) were obtained from Sigma Aldrich (Dorset, UK) and
dissolved in HBSS to 20 U/ml and 200 U/ml respectively. All
reagents were stored at -20.degree. C. in single use aliquots. All
experimental measurements were performed in assay buffer made up
immediately prior to use (HBSS, 0.01% BSA essentially fatty acid
free).
[1006] Protein--
[1007] Recombinant human ATX was prepared at Novartis (Basel, CH)
in a human embryonic kidney (HEK) cell preparation, and stored in
single use aliquots of 26 mg/ml (26 .mu.M) stocks stored at
-80.degree. C.
[1008] Method--
[1009] All experimental measurements were performed in black 384
well polystyrene (low volume, round bottom, Corning (3676)) plates.
PerkinElmer EnVision (Fluorescence Intensity/Absorbance
Monochromator) or Tecan Infinite 200 PRO series plate reader was
used to detect change in fluorescent intensity.
[1010] Assessing ATX Inhibition--
[1011] ATX activity was determined by measurement of released
choline in reactions containing ATX (10 nM), choline oxidase (0.1
U/ml), HRP (100 U/ml), amplex red (50 .mu.M) and LPC 18:1 (10
.mu.M). Compounds of the invention were prepared as 10 point serial
dilutions from 1 .mu.M in duplicate and pre-incubated with ATX at
37.degree. C. for 20 minutes prior to the addition of remaining
reagents. The liberated choline was measured from changes in
fluorescence intensity (.lamda.ex 530 nm, .lamda.em 590 nm) of the
product resurofin at 37.degree. C. every 2 minutes over a 40-minute
period. ATX activity was measured as a slope of the linear portion
of the progress curve, typically between 14 to 24 minutes.
[1012] Data Analysis--
[1013] Slope data was exported to Graphpad prism (Graphpad
software, San Diego, Calif.) where data was fitted to equation
1.
Y=Bottom+(Top-Bottom)/(1+10 ((Log IC50-X)*HillSlope)) Equation
1:
[1014] IC.sub.50 values are determined from the concentration of
compound that reduced the total activity by 50% and represent the
mean of n.gtoreq.2.
[1015] Table 1: The following table gives the IC.sub.50 values for
the exemplified compounds as measured in the above assay
TABLE-US-00001 TABLE 1 Example no. Compound IC.sub.50 (.mu.M) 1
3,5-dichlorobenzyl 4-(2-(3-hydroxy-N-methylisoxazole- 0.644
5-carboxamido)ethyl) piperidine-1-carboxylate; 2 3,5-dichlorobenzyl
4-(2-((2-methoxy-3,4-dioxocyclobut- 0.248
1-en-1-yl)(methyl)amino)ethyl)piperidine-1-carboxylate; 3
3,5-dichlorobenzyl 4-(2-((2-ethoxy-3,4-dioxocyclobut- 0.445
1-en-1-yl)amino)ethyl)piperidine-1-carboxylate; 4
3,5-dichlorobenzyl 4-(2-((2-hydroxy-3,4-dioxocyclobut- 0.728
1-en-1-yl)amino)ethyl)piperidine-1-carboxylate; 5
3,5-dichlorobenzyl 4-((3-(3-hydroxyisoxazol-5-yl) 0.313
propanamido)methyl)-2-methylpiperidine-1-carboxylate; 6
3,5-dichlorobenzyl 4-(2-(N-methyl-2-(1H-1,2,3- 0.062
triazol-4-yl)acetamido)ethyl)piperidine-1-carboxylate; 7
3,5-dichlorobenzyl 4-(2-(2-(1H-1,2,3-triazol-4- 0.028
yl)acetamido)ethyl)piperidine-1-carboxylate; 8 3,5-dichlorobenzyl
4-(2-(N,5-dimethyl-2-oxo-2,3- 0.36
dihydrooxazole-4-carboxamido)ethyl)piperidine-1- carboxylate; 9
(E)-3,5-dichlorobenzyl 4-(3-(1H-imidazol-4- 0.109
yl)acrylamido)piperidine-1-carboxylate; 10
6-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin-4- 0.543
yl)amino)-6-oxohexanoic acid; 11 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut- 0.051
1-en-1-yl)amino)ethyl)morpholine-4-carboxylate; 12
3,5-dichlorobenzyl 2-(2-(2-oxo-2,3-dihydrooxazole-5- 0.52
carboxamido)ethyl)morpholine-4-carboxylate; 13 3,5-dichlorobenzyl
2-(2-(N-methyl-2-oxo-2,3- 0.828 dihydrooxazole-5-carboxamido)
ethyl)morpholine-4- carboxylate; 14 3,5-dichlorobenzyl
2-(2-((2-ethoxy-3,4-dioxocyclobut- 0.54
1-en-1-yl)(methyl)amino)ethyl)morpholine-4-carboxylate; 15
3,5-dichlorobenzyl 4-(2-(N-methyl-2-oxo-2,3- 0.029
dihydrothiazole-5-carboxamido)ethyl)piperidine-1- carboxylate; 16
3,5-dichlorobenzyl 4-(2-(2H-tetrazole-5- 0.596
carboxamido)ethyl)piperidine-1-carboxylate; 17 3,5-dichlorobenzyl
4-(4-(1H-1,2,3-triazol-4- 0.002
yl)butanamido)piperidine-1-carboxylate; 18 3,5-dichlorobenzyl
4-(N-methyl-4-(1H-1,2,3-triazol-4- 0.094
yl)butanamido)piperidine-1-carboxylate; 19 3,5-dichlorobenzyl
4-(3-(1H-1,2,3-triazol-4- 0.003
yl)propanamido)piperidine-1-carboxylate; 20 3,5-dichlorobenzyl
4-(5-(1H-1,2,3-triazol-4- 0.004
yl)pentanamido)piperidine-1-carboxylate; 21 3,5-dichlorobenzyl
4-(2-(2-oxo-2,3-dihydrooxazole-5- 0.106
carboxamido)ethyl)piperidine-1-carboxylate; 22 3,5-dichlorobenzyl
4-(2-(3-(3-hydroxyisoxazol-5- 0.586
yl)propanamido)ethyl)piperidine-1-carboxylate; 23
3,5-dichlorobenzyl 4-(3-(3-hydroxyisoxazol-5- 0.396
yl)propanamido)piperidine-1-carboxylate; 24 3,5-dichlorobenzyl
4-(2-(N-methyl-2-oxo-2,3- 0.624
dihydrooxazole-4-carboxamido)ethyl)piperidine-1- carboxylate; 25
3,5-dichlorobenzyl 4-(2-(5-hydroxy-N-methyl-1H- 0.52
pyrazole-3-carboxamido)ethyl)piperidine-1-carboxylate; 26
3,5-dichlorobenzyl 4-(3-(N-methyl-2-oxo-2,3- 0.156
dihydrooxazole-5-carboxamido)propyl)piperazine-1- carboxylate; 27
3,5-dichlorobenzyl 4-(2-(2-oxo-2,3-dihydrooxazole-5- 0.375
carboxamido)ethyl)piperazine-1-carboxylate; 28 3,5-dichlorobenzyl
4-(2-(N-methyl-5-oxo-4,5-dihydro- 0.786
1,2,4-oxadiazole-3-carboxamido)ethyl)piperidine-1- carboxylate; 29
3,5-dichlorobenzyl 4-(2-(N-methyl-2H-tetrazole-5- 0.541
carboxamido)ethyl)piperidine-1-carboxylate; 30
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin- 0.274
4-yl)ethyl)-N-methyl-2-oxo-2,3-dihydrooxazole-5- carboxamide; 31
(E)-N-(2-(1-(3-(3,5-dichlorophenyl)acryloyl)piperidin- 0.387
4-yl)ethyl)-2-oxo-2,3-dihydrooxazole-5-carboxamide; 32
3,5-dichlorobenzyl 4-(2-(N-methyl-2-oxo-2,3- 0.068
dihydrooxazole-5-carboxamido)ethyl)piperidine-1- carboxylate; 33
3,5-dichlorobenzyl 4-((3-(3-hydroxyisoxazol-5- 0.131
yl)propanamido)methyl)piperidine-1-carboxylate; 34
3,5-dichlorobenzyl 4-(3-(1H-1,2,3-triazole-4- 0.282
carboxamido)propyl)piperazine-1-carboxylate; 35 3,5-dichlorobenzyl
4-(2-(N-methyl-1H-1,2,3-triazole- 0.175
4-carboxamido)ethyl)piperidine-1-carboxylate; 36
3-Chloro-5-cyanobenzyl 4-(2-(N-methyl-1H-1,2,3- 1.0
triazole-4-carboxamido)ethyl) piperidine-1-carboxylate; 37
3-Chloro-5-fluorobenzyl 4-(4-(1H-1,2,3-triazol-4- 0.055
yl)butanamido)piperidine-1-carboxylate, 38
(E)-N-(1-(3-(3,5-Dichlorophenyl)acryloyl)piperidin- 0.021
4-yl)-4-(1H-1,2,3-triazol-4-yl)butanamide, 39
(E)-N-(1-(3-(2,4-Dichlorophenyl)acryloyl)piperidin- 0.077
4-yl)-4-(1H-1,2,3-triazol-4-yl)butanamide, 40
8-((1-(((3,5-Dichlorobenzyl)oxy)carbonyl)piperidin- 0.135
4-yl)amino)-8-oxooctanoic acid; 41 3,5-Dichlorobenzyl
4-((4-(1H-1,2,3-triazol-5- 0.018
yl)butanamido)methyl)piperidine-1-carboxylate, 42
N-(1-(3-(3,5-Dichlorophenyl)propanoyl)piperidin-4- 0.119
yl)-4-(1H-1,2,3-triazol-4-yl)butanamide, 43
N-(1-(3-(2,4-Dichlorophenyl)propanoyl)piperidin-4- 0.113
yl)-4-(1H-1,2,3-triazol-4-yl)butanamide, 44 3-Chloro-5-cyanobenzyl
4-(4-(1H-1,2,3-triazol-4- 0.008
yl)butanamido)piperidine-1-carboxylate, 45 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4-yl) 0.555
butanamido)-8-azabicyclo[3.2.1]octane-8-carboxylate; 46
3,5-Dichlorobenzyl 4-(4-(1H-1,2,3-triazol-4- 0.731
yl)butanamido)azepane-1-carboxylate, 47 3,5-Dichlorobenzyl
(8-(4-(1H-1,2,3-triazol-4-yl) 3.161
butanoyl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate; 48
3,5-Dichlorobenzyl (1-(4-(1H-1,2,3-triazol-4- 0.791
yl)butanoyl)azepan-4-yl)carbamate; 49 3,5-Dichlorobenzyl
3-(4-(1H-1,2,3-triazol-4- 0.048
yl)butanamido)pyrrolidine-1-carboxylate; 49a (S)-or
(R)-3,5-Dichlorobenzyl 3-(4-(1H-1,2,3- >1
triazol-4-yl)butanamido)pyrrolidine-1-carboxylate, 49b (S)-or
(R)-3,5-Dichlorobenzyl 3-(4-(1H-1,2,3- 0.263
triazol-4-yl)butanamido)pyrrolidine-1-carboxylate, 50
3,5-Dichlorobenzyl 3-(4-(1H-1,2,3-triazol-4- 0.012
yl)butanamido)azetidine-1-carboxylate, 51 3,5-Dimethylbenzyl
4-(4-(1H-1,2,3-triazol-4- 0.006
yl)butanamido)piperidine-1-carboxylate, 52 3,5-Dichlorobenzyl
(1-(5-(1H-1,2,3-triazol-4- 0.042
yl)pentanoyl)piperidin-4-yl)carbamate, 53 4-(Trifluoromethyl)benzyl
4-(4-(1H-1,2,3-triazol-4- 0.04
yl)butanamido)piperidine-1-carboxylate, 54
4-(1H-1,2,3-Triazol-4-yl)-N-(1-(3-(4-(trifluoromethyl) 0.087
phenyl)propanoyl)piperidin-4-yl)butanamide; 55
N-(1-(2-(3,5-Dichlorophenoxy)acetyl)piperidin-4- 0.154
yl)-4-(1H-1,2,3-triazo1-4-yl)butanamide, 56 3-Chloro-5-methylbenzyl
4-(4-(1H-1,2,3-triazol-4- 0.01
yl)butanamido)piperidine-1-carboxylate, 57 3,5-Dichlorobenzyl
4-((3-(1H-1,2,3-triazol-5- 0.017
yl)propanamido)methyl)piperidine-1-carboxylate, 58
2,4-Dichlorobenzyl 4-(4-(1H-1,2,3-triazol-4- 0.206
yl)butanamido)piperidine-1-carboxylate, 59 3,5-Dichlorophenethyl
4-(4-(1H-1,2,3-triazol-4- 0.024
yl)butanamido)piperidine-1-carboxylate, 60 3,5-dichlorobenzyl
4-(3-(((1H-1,2,3-triazol-4- 0.007
yl)methyl)amino)-3-oxopropyl)piperidine-1-carboxylate; 61
3,5-dichlorobenzyl 4-(2-((2-(1H-1,2,3-triazol-4- 0.015
yl)ethyl)amino)-2-oxoethyl)piperidine-1-carboxylate; 62
3-methyl-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3- 0.005
triazo1-4-yl)butanamido)piperidine-1-carboxylate, 63
3-bromo-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3- 0.003
triazo1-4-yl)butanamido)piperidine-1-carboxylate, 64
3-chloro-5-cyanobenzyl 4-(5-(1H-1,2,3-triazol-4- 0.008
yl)pentanamido)piperidine-1-carboxylate, 65 3-chloro-5-cyanobenzyl
4-(3-(1H-1,2,3-triazol-4- 0.026
yl)propanamido)piperidine-1-carboxylate, 66
3-cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3- 0.004
triazol-4-yl)butanamido)piperidine-1-carboxylate 67
3,5-dichlorobenzyl 4-(6-(1H-1,2,3-triazol-4- 0.004
yl)hexanamido)piperidine-1-carboxylate
* * * * *